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Abstract  
 
Men who have sex with men (MSM) remain the group with the highest incidence of 
HIV in the UK, with a high concentration of infections in London. 
 
Multi-site safety and efficacy trials have demonstrated significant reductions in HIV 
acquisition among MSM when prescribed a daily pre-exposure prophylaxis (PrEP). 
Success translating these scientific developments into effective prevention interventions 
requires an understanding of how acceptable they are to individuals at risk of HIV 
acquisition. 
 
This thesis reports on the findings of twenty in-depth semi-structured qualitative 
interviews with MSM in London. To participate, men must have had at least one 
episode of sex without condoms with a known sero-discordant partner or a partner of 
unknown HIV status in the twelve months prior to interview. 
 
The acceptability of a range of PrEP methods were explored, including daily and 
intermittent oral; topical; and injectable formulations of PrEP and the potential impact 
of PrEP use upon men’s perceptions of risk and behaviours. 
 
Dimensions of acceptability draw on the personal (such as side effects; increased or 
diminished HIV vulnerability; adherence to drug/medical regimes); the inter-personal 
(such as negotiation of sex; stigma or discrimination); and community or social 
concepts of acceptability (such as financial burden and concepts of increased 
‘community risk’). 
 
The thesis provides a framework for understanding PrEP acceptability, showing that 
concepts of acceptability are complex and that the different dimensions of acceptability 
are inter-related.  
 
The thesis concludes with recommendations for future policy and service delivery of 
PrEP to at-risk groups in the UK. 
  
2 
 
Contents 
 
Acknowledgments .................................................................................................... 5 
Glossary ................................................................................................................... 7 
Integrating Statement ............................................................................................... 8 
Chapter 1: Introduction .......................................................................................... 12 
1.1 HIV infection among men who have sex with men – a public health concern ............. 12 
1.2 Preventing HIV transmission .................................................................................... 13 
1.3 Biomedical prevention: the emergence of PrEP ........................................................ 14 
1.4 Aims of the research ................................................................................................ 15 
1.5 Structure of the thesis ............................................................................................. 16 
Chapter 2: Reviewing the evidence ......................................................................... 18 
2.1 Pre-exposure prophylaxis – the evidence base ......................................................... 18 
2.1.1 Topical PrEP ............................................................................................................... 18 
2.1.2 Oral PrEP .................................................................................................................... 19 
2.1.3 Injectable PrEP .......................................................................................................... 21 
2.2 PrEP: Implementation issues to consider .................................................................. 22 
2.3 Existing evidence on PrEP acceptability .................................................................... 24 
2.4 Conceptualising ‘acceptability’ ................................................................................. 27 
2.5 Developing an acceptability framework ................................................................... 31 
2.6 An emerging and fast moving environment .............................................................. 33 
2.7 Chapter Summary .................................................................................................... 33 
Chapter 3: Methodology ......................................................................................... 35 
3.1 Research approach .................................................................................................. 35 
3.2 Sampling ................................................................................................................. 36 
3.3 Recruitment ............................................................................................................ 37 
3.3.1 Recruiting to the Sigma Panel ................................................................................... 37 
3.3.2 Recruiting to the PrEP acceptability study from the Sigma Panel ............................ 38 
3.4 Sample description .................................................................................................. 40 
3.5 The research process ............................................................................................... 41 
3.6 Interview schedule .................................................................................................. 42 
3.6.1 Developing an interview schedule ............................................................................ 43 
3.6.2 How men meet for sex .............................................................................................. 43 
3.6.3 History of HIV testing and sexual risk behaviour ...................................................... 44 
3.6.4 Use of PEP ................................................................................................................. 44 
3.6.5 Knowledge of PrEP .................................................................................................... 45 
3.6.6 Potential oral daily PrEP use ..................................................................................... 45 
3.6.7 Potential other PrEP method use .............................................................................. 45 
3.6.8 Inter-personal acceptability of PrEP .......................................................................... 47 
3.6.9 Societal and community acceptability ...................................................................... 47 
3.7 Data analysis ........................................................................................................... 48 
3.8 Quality, rigour and reflexivity .................................................................................. 50 
3.9 Limitations of the study ........................................................................................... 51 
3.10 Ethical considerations ............................................................................................ 53 
3.11 My subjective position within the thesis ................................................................. 54 
3.12 Summary ............................................................................................................... 55 
Chapter 4: Results - How men manage their sex lives .............................................. 56 
3 
 
4.1 Settings where men encounter sex and planning for sex ........................................... 56 
4.2 HIV Testing: frequency and rationales ...................................................................... 59 
4.3 Men’s explanations and accounts of sex without condoms ....................................... 60 
4.3.1 Control, consent and pressure .................................................................................. 61 
4.3.2. Psychological rationales and personal values .......................................................... 62 
4.4 Reducing risk – strategies and complexities .............................................................. 64 
4.4.1 Post exposure prophylaxis (PEP) ............................................................................... 68 
4.4.2 The potential impact of PrEP on risk reduction strategies........................................ 69 
4.5. Chapter summary ................................................................................................... 70 
Chapter 5: Results - Positioning PrEP in men’s lives ................................................. 71 
5.1 Knowledge and initial reactions to PrEP ................................................................... 71 
5.1.1 Knowledge of PrEP .................................................................................................... 71 
5.1.2 Potential PrEP use ..................................................................................................... 72 
5.2 Perceived impact and utility of PrEP ......................................................................... 74 
5.2.1 Sex and risk ................................................................................................................ 74 
5.2.2 Intimacy, opportunity and pleasure .......................................................................... 78 
5.3 Perceived practicalities of PrEP use .......................................................................... 80 
5.3.1 Considering the clinical interaction ........................................................................... 80 
5.3.2 Regimens and resistance ........................................................................................... 82 
5.3.3 Concerns relating to side-effects of PrEP medication ............................................... 85 
5.4 Body, lifestyle and routine ....................................................................................... 86 
5.4.1 Pre-planning of sex .................................................................................................... 87 
5.4.2 The practicality of using topical PrEP ........................................................................ 89 
5.4.3 Noticeability and pain ............................................................................................... 90 
5.5 PrEP efficacy ............................................................................................................ 91 
5.6 Negotiation and navigation ...................................................................................... 94 
5.6.1 Men’s own potential PrEP disclosure to sexual partners .......................................... 94 
5.6.2 Perceptions of other men’s use of PrEP .................................................................... 97 
5.6.3 Other men’s PrEP disclosure and sexual risk ............................................................ 98 
5.7 Section Summary ................................................................................................... 100 
Chapter 6: Results - Community and societal acceptability of PrEP ........................ 102 
6.1 Discussion and disclosure of PrEP among social peers ............................................. 103 
6.1.1 Social divisions and permissive discourse ............................................................... 103 
6.1.2 Disclosure of PrEP use with social peers ................................................................. 105 
6.2 Societal and community influences on PrEP acceptability ....................................... 107 
6.2.1 Stigmatisation of risk and risk-taking ...................................................................... 107 
6.2.2 Mis-information, norm setting and agenda setting ................................................ 109 
6.3 Summary ............................................................................................................... 110 
Chapter 7: Naivety, certainty and ambivalence: four case studies .......................... 112 
of PrEP acceptability ............................................................................................. 112 
7.1 Simon: the naïve risk taker ..................................................................................... 113 
7.2 Martin: the definitely wants to use PrEP ................................................................ 114 
7.3 Alex: the ambivalent ............................................................................................. 115 
7.4 Ed: the would not use PrEP .................................................................................... 117 
7.5 Summary ............................................................................................................... 118 
Chapter 8: Discussion ............................................................................................ 119 
Introduction ................................................................................................................ 119 
8.1 Key findings of the research ................................................................................... 120 
8.2 Willingness to use PrEP: contributors and barriers .................................................. 122 
4 
 
8.2.1 Risk perception and naïve risk taking ...................................................................... 123 
8.2.2 Holistic dimensions of health and well-being ......................................................... 124 
8.2.3 PrEP use and stigma ................................................................................................ 126 
8.2.4 Incorporating PrEP into current risk reduction strategies ...................................... 127 
8.3 The relative acceptability of different PrEP methods .............................................. 129 
8.3.1 Daily oral PrEP ......................................................................................................... 129 
8.3.2 Intermittent oral PrEP ............................................................................................. 129 
8.3.3 Topical PrEP ............................................................................................................. 132 
8.3.4 Injectable PrEP ........................................................................................................ 133 
8.3.5 Summary ................................................................................................................. 134 
8.4 Developing a PrEP acceptability framework ............................................................ 134 
8.5 Contributing to the evidence-base on PrEP and its acceptability ............................. 137 
Chapter 9: Conclusion ........................................................................................... 139 
9.1 Recommendations for future research ................................................................... 140 
9.2 Recommendations for development of policy and lobbying .................................... 141 
9.3 Recommendations for commissioning of PrEP services ........................................... 142 
9.4 Recommendations for PrEP service delivery ........................................................... 143 
References ........................................................................................................... 147 
Appendix 1 ........................................................................................................... 156 
Appendix 2 ........................................................................................................... 157 
Appendix 3 ........................................................................................................... 160 
Appendix 4 ........................................................................................................... 162 
Appendix 5 ........................................................................................................... 163 
Appendix 6 ........................................................................................................... 165 
Appendix 7 ........................................................................................................... 168 
 
 
 
  
5 
 
Acknowledgments 
  
This thesis and the completion of my DrPH could not have been possible without the 
support and love of very many people. 
 
I want to thank Anne-Marie Sue-Patt and Susan Quarrell for guiding me through the 
administrative hurdles of completing a doctorate, and Catherine McGowan for helping 
me navigate technologies. 
 
For many years I have benefitted from the knowledge and integrity of Sigma Research, 
who have become colleagues since commencing this thesis. I want to thank Gary 
Hammond for administrative and activism support; David Reid provided assistance in 
navigating the complexities of setting up an online survey; Ford Hickson supported me 
in understanding the Sigma Panel; and Peter Weatherburn fine-tuned my thinking and 
analysis and reminded me of my adequacies. I want to acknowledge Catherine Dodds as 
an advisory group member, and for helping me to own my work; Charlie Witzel for 
being my most recent and inspiring partner-in-crime; and, Adam Bourne, for being the 
most patient and supportive supervisor and mentor I could have ever hoped for. 
 
Chris Bonell provided support and encouragement as my initial supervisor when I 
started considering undertaking a doctorate, as well as being part of my advisory group 
and Wendy Macdowall first encouraged me to follow the DrPH programme. 
 
I have benefitted from a handful of secret writing places and want to especially 
acknowledge Susan and the staff and volunteers at the Stuart Hall Library for providing 
a sanctuary.   
 
The fieldwork for my OPA would not have been possible without the generosity of 
Alexandra Bizani who quite literally provided me with hearth and home; Karen Elkins 
Cohen, whose love made me less homesick than I would otherwise have been; Pere 
Ramirez Caceres and Jos Gibson; the kinship of Mike Anton, Kevin Deniz, Mike 
Discepola, Justin Hall, Jamal McCrainey, Israel Nieves-Rivera and Guillermo 
Rodriguez. At San Francisco Aids Foundation I am grateful for the support given to me 
6 
 
by Judy Auerbach, Mark Cloutier, Steve Gibson, Barbara Kimport, James Loduca, Eric 
Saddick and other staff at the Foundation for welcoming me into their bosom. 
 
This thesis would not have been possible without the generosity of the twenty men who 
took part. I offer them my gratitude for allowing me to probe them about some of the 
most personal aspects of their lives. My thanks to Alex, Brad, Colin, Duncan, Ed, 
Francis, Javi, Jos, Jovan, Louis, Marc, Marco, Martin, Mattie, Max, Nate, Philip, Roy, 
Simon, and to Yan (not their real names). 
 
I want to acknowledge the many people who have mentored and guided me in my 
thinking and work in human rights, queer health and activism and whose inspiration has 
contributed to this work: Brent Allan, Yusef Azad, Chris Bartlett, Edwin Bernard, Roy 
Butler, Sarah Caldwell, Liza Cragg, Michael Crosby, Will Devlin, Nicholas Feustel, 
Mitzy Gafos, Lee Gale, Robert Goodwin, Pippa Grenfell, Luis Guerra, Hunter 
Hargreaves, Michael Hurley, Ajamu Ikwe-Tyehimba, Peter Keogh, Paul Kidd, 
Sebastian Kola-Bankole, Jay McNeil, Rick Marchand, Simon Nelson, Jim Pickett, 
Carole Reilly, Eric Rofes, Michelle Ross, Marc Thompson, Terry Trussler, Rola 
Yasmine, Ingrid Young, and Colin Dixon, Robin Gorna, Nick Partridge and Lisa Power. 
 
Bobby Petty and Bruno Romanelli have provided continued friendship and 
encouragement. 
 
Finally, Aaron Balick and Richard Kahwagi, who have been my moon, my stars, my 
sun. 
 
For Daphne Nutland, Alison Hunt, Rowena Hall. For cultivating my love of nature; my 
love of life; my love of love. 
 
  
7 
 
Glossary 
 
 
ART Anti-retroviral therapies 
CAPRISA 004 South African based study assessing the effectiveness and the 
safety of a vaginal gel  
DrPH Doctor of Public Health 
ECDC European Centre for Disease Control 
FDA Federal Drug Administration (USA) 
Ipergay Intervention Prophylactique pour Et avec les Gays. The first study 
to explore the efficacy of non-daily oral PrEP 
iPREX Multi-national Phase III trial exploring efficacy of daily oral PrEP 
in MSM and transgender women 
iPREX OLE Open label extension of iPREX 
MSM Men who have sex with men. A behavioural definition that 
encompasses all men who are or have had sex with men, 
regardless of their sexual identity or orientation 
OPA Organisational Policy Analysis  
PEP Post exposure prophylaxis 
PrEP Pre exposure prophylaxis 
PROUD England based study exploring the effectiveness of daily oral 
PrEP in MSM and transgender women 
STI Sexually transmitted infection 
SWC Sex without condoms 
Topical PrEP In the context of this thesis topical PrEP is taken to mean any 
foam, gel or non-solid substance that is inserted into or applied to 
the body for the purpose of preventing HIV 
Transgender Someone whose gender identity is not that assigned to them at 
birth 
TasP Treatment as Prevention – the concept that HIV drugs used to 
treat HIV infection can also prevent onward transmission of HIV 
from someone with HIV 
WHO World Health Organisation 
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Integrating Statement  
 
LSHTM’s Doctor of Public Health programme seeks to equip and skill leaders or future 
leaders in the public health field. As a previous leader within the field of HIV 
prevention in the UK, and unlike many of my contemporaries on the programme, I had 
the sense that I already had a proven track record of leadership and management within 
this particular public health discipline, but lacked the academic and intellectual 
robustness to break through the glass-ceiling of the career pathways of that field. For 
many other students, especially those who had followed the traditional trajectory from 
undergraduate, to Masters and then doctoral level studies, there was a sense that it was 
leadership experience in public health that was lacking, rather than academic rigour.  
 
At the time of my enrolment, students took two five week modules in Evidence Based 
Public Health Practice (EBPHP), and one five week module in Leadership and 
Management and Personal Development (LMPD) - a requirement that had shifted to 
two five week modules by the time I started that course, in my second year - followed 
by a selection of courses from the School’s MSc programme. 
 
EBPHP furnished me with a raft of knowledge and skills that stretched my thinking and 
challenged my (then) practice as a public health practitioner. Training in undertaking 
systematic reviews and debates around the use of evidence challenged my notions and 
belief in the foundations of the practice I was undertaking at the time and, in part, 
contributed to a decision to move on from that practice. Undertaking the systematic 
review assignment, was one of my most intellectually challenging academic 
experiences, and set a high bar for my expectations for the rest of the programme. 
Conversely, the modules of the course that addressed public health policy and its use in 
practice reassured me of the skills I was already putting to use – and I sailed through the 
assignment on developing policy and applying policy in public health practice. On 
reflection, the sessions on how the media interpret and use evidence, and how to talk to 
journalists, seem to be a crucial element of how a modern public health leader operates.  
 
LMPD offered a more reflexive and ‘softer’ but no less challenging accompaniment to 
EBPHP.  The theoretical concepts of (change) management and leadership provided an 
essential grounding for the work to follow in the Organisational and Policy Analysis 
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(OPA). The modules providing techniques and tools for management and leadership 
within work settings accompanied and complimented the on-the-job leadership training 
and experience I had been exposed to within my work place. Aside from the theoretical 
and practical approaches, having the time and opportunity to reflect, debate, explore and 
nurture some of the opportunities and challenges of leadership provided a valuable 
learning and development opportunity.  Going through a ten-week process of personal 
development and reflection, alongside my peers, was both a privilege (when else do we 
have the time out for such opportunities?) and an honour.  This opportunity can only 
happen when individuals involved make the commitment to participate – both through 
time and willingness – and when the interaction happens face-to-face. Despite debates 
as to whether some elements of the programme could happen through Distance 
Learning, I can categorically say that the benefits of this course can only be attained 
through knowing and trusting your peer group directly, rather than virtually. 
 
The (at the time) compulsory Masters modules gave me insight in to the School’s 
teaching programme and methods of assessing students. Arguably, opting for more 
skills based courses, such as qualitative research skills, rather than subject based 
courses, might have increased my learning and development, but the courses were 
‘Masters level’ and my two major reflections on those modules were i/ that they 
reflected how exceptionally well taught and ‘top level’ the dedicated DrPH taught 
modules were (i.e. the difference between the standard of DrPH and Masters courses 
were stark) and ii/ they provided me with an in-road to teaching on a range of in-house 
Masters modules and module organising on Distance Learning Masters courses: an 
unforeseen but very welcome career development outcome of being a student on those 
courses.  
 
A further unplanned and unforeseen benefit of being a self-funded student within the 
School was the opportunity to place myself within research projects and studies that 
honed and refined my research skills. An early opportunity to work alongside Professor 
Kaye Wellings on a study of attitudes to blood donation in men who have sex with men 
in the UK provided me with on-the-job development and training in qualitative field 
work, navigating ethics approval and publication, as second author, in my first peer-
reviewed journal article. Furthermore, it gave me the opportunity to bring my previous 
experience of engaging with stakeholder organisations in research dissemination, into 
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that research team. I would strongly recommend that future DrPH students are made 
aware of and know the development benefits of being ingrained in the teaching and 
research opportunities within the School, especially when those opportunities assist in 
preparation for research skills that will be needed in the final thesis. 
 
That qualitative fieldwork experience allowed for a fairly smooth transition into 
developing a research protocol, and undertaking field work, using a broad range of 
qualitative methods for the OPA undertaken at San Francisco Aids Foundation. 
Preparation for the OPA raised the particular challenges of being a part-time student, 
not least because the compulsory DrPH modules running concurrently in the autumn 
term mean that part-time students, having completed one module, had to wait for a 
further nine months before completing the further module that fully equips them to 
undertake the OPA. In retrospect, taking the taught modules full-time for one term 
would have been a more efficient path to follow and one that I would strongly 
recommend to future students. 
 
The opportunities and challenges of undertaking the OPA are partially addressed in the 
OPA report itself and have been reviewed on a number of occasions with the DrPH 
Course Director since then. In addition to that commentary, arriving in an organisation 
and in a City during a period of such fundamental change (the resignation of the CEO, 
the introduction of a new public health strategy respectively) was fortuitous, even if it 
muddied the focus of my original research questions. The OPA gave me the opportunity 
to fine-tune my qualitative research skills and to get in to the rhythm of academic 
writing.  Most importantly, learning to balance the fine line between being an observer 
and a participant, and where to draw those boundaries, was the biggest asset that I took 
from the experience.  
 
The final thesis has been the moment when my previous practitioner experience and the 
time spent on the DrPH programme have aligned most starkly. Having previously 
commissioned research, recruited to research projects, been the recipient of research (as 
a practitioner) and been a research participant, I have been more cognisant of my 
research participants as both end-users of that research and as true participants, rather 
than research subjects. Attempting to ‘bring along’ a number of participants, and other 
key stake holders – such as commissioners and providers who might benefit from the 
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results of the research – has brought challenges about when to ‘release’ findings, as has 
the challenge of studying within an institution that tends to be more driven by academic 
journal outputs rather than the iterative release and discussion of findings with 
practitioner colleagues. The final stages of the programme have been enthralling, 
experiencing the elements of the programme come together and observing the potential 
for driving that learning further.  
 
A more general reflection on the programme surrounds the position it holds within the 
School. On-going attempts by students, course coordinators and administrators to 
enhance the kudos, awareness of, and interest in the DrPH programme have been 
undertaken, yet it still seems that the DrPH programme is viewed as a ‘poor relation’ to 
a PhD within the School. Recent attempts – driven by students – to shift that focus 
appear to have had limited progress and, to draw on the theoretical learning of 
organisational change from LMPD, could benefit from more transformational, rather 
than transactional, leadership approaches from within the School’s hierarchy.  
 
Finally, from a broader developmental perspective for research degree students across 
the School, there is a current emphasis on development opportunities for early-career 
researchers. Yet far less emphasis is given for those of us, especially mature students, 
who have already developed or had a career and are looking for directions that do not 
follow a traditional academic pathway.  
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Chapter 1: Introduction 
 
This thesis sets out to explore how acceptable pre-exposure HIV prophylaxis (PrEP) 
might be to men who have sex with men (MSM) in London who are at risk of HIV 
acquisition. It explores personal dimensions of PrEP acceptability, and how those 
personal dimensions are influenced and impacted by inter-personal and community or 
societal acceptability of PrEP. It provides a comparative analysis of PrEP acceptability 
by different PrEP methods, and considers how future HIV prevention policy, research 
and health promotion interventions should develop to incorporate PrEP. 
 
PrEP is an HIV prevention technology that makes use of existing antiretroviral therapy 
to prevent HIV acquisition in uninfected individuals. This introductory chapter outlines 
the evidence of why MSM in London can be considered a priority population for PrEP 
provision in the UK, drawing on contemporary data from national HIV surveillance 
systems. It describes the HIV prevention successes of the last decade and highlights 
how current HIV prevention approaches, on their own, will likely fail to stem the 
onward transmission of HIV among MSM, before introducing the concept of how 
antiretroviral therapy has the potential to play a key role in future HIV prevention 
approaches. The chapter establishes the aim and objectives of this thesis and then sets 
out the structure of the subsequent chapters. 
 
1.1 HIV infection among men who have sex with men – a public health concern 
HIV infection resulting from sex between men accounts for the majority of UK-
acquired HIV diagnoses (Yin et al., 2014). HIV diagnoses among MSM have risen 
steadily each year since 2001 and, despite a leveling-off during 2007-09, increased in 
2010, accounting for 45% of total infections diagnosed - but not necessarily acquired – 
in the UK. Around one quarter of those infections are thought to have been recently 
acquired, with men under 35 accounting for one-third of those newly diagnosed who 
were recently infected (Health Protection Agency, 2011). In 2013, more than half of the 
UK’s diagnosed HIV infections were amongst MSM with an estimated 43,500 MSM 
living with HIV in the UK (Yin et al., 2014). Public Health England estimates that 
around 7,000 MSM, or 16% of MSM with HIV, had not had their infection diagnosed 
(Yin et al., 2014). HIV prevalence in MSM in the UK is estimated to be 59 per 1,000 
population compared with an estimated UK general population prevalence of 2.8 per 
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1,000. It is higher still in MSM in London where 1 in 8 MSM have HIV, compared with 
1 in 26 MSM outside of London (Yin et al., 2014). Of key significance to this thesis are 
the large geographical variations, and the fact that HIV prevalence among MSM is 
London is more than three times higher than outside of London (1 in 8 vs. 1 in 26). 
 
With early diagnosis of HIV infection and significant improvements in HIV anti-
retroviral treatments, HIV infection in the UK is thought to have an insignificant impact 
on longevity of life. Mathematical models suggest that a non-smoking, 30-year old gay 
man who receives a prompt diagnosis after infection, has a life expectancy of 78 years, 
compared to a life expectancy of 82 for a man who does not have HIV (Nakagawa, 
2011). However, the long-term impacts of HIV infection and HIV medication are 
uncertain; stigma and discrimination against people with HIV – in personal and sexual 
relationships, in medical settings, and from wider society – exist and can impact on the 
mental, sexual and physical health of a person with HIV (Bourne et al., 2009; Smit et 
al., 2012); and the costs of HIV medication, treatment and care have a significant 
impact on the National Health Service, with the lifetime costs of HIV treatments alone 
estimated to be between £280,000 and £360,000 per person (Select Committee on HIV 
and AIDS in the United Kingdom, 2011). As such, measures to prevent primary HIV 
infection remain essential, with a particular need to prioritise the prevention of HIV 
infection amongst MSM. 
 
1.2 Preventing HIV transmission  
Over the last three decades, significant activity has been undertaken to reduce HIV 
infection in the UK. Strategies for reducing HIV acquisition amongst MSM in England 
have focused on the concept of ‘best sex with least harm’ and have included raising 
awareness of HIV status and diagnosis of HIV; raising awareness, diagnosis and 
treatment of STIs; interventions that increase MSM’s knowledge of HIV, as well as its 
prevention and treatment; interventions that increase men’s skills to negotiate and have 
the sex they want; and interventions that facilitate increased awareness or risk reduction 
in environments where men meet for sex – such as the provision of information or 
condoms and lubricant (CHAPS Partnership, 2011). 
 
There have been notable successes in HIV prevention activity (Sullivan et al., 2012); 
not least those that have been connected to increased levels of HIV testing (Yin, 2014).  
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Systematic reviews have identified evidence of behavioural interventions – including 
interpersonal skills training, multi-method interventions, and multiple interventions over 
durations of a minimum of 3 weeks - that have been shown to impact on HIV risk on an 
individual, group or community level (Herbst et al., 2005, Herbst et al., 2007, Johnson 
et al., 2002, Johnson et al., 2005). Yet, these interventions are costly to implement on a 
population level and resources to adequately scale-up these interventions have not been 
forthcoming. Indeed, structural impediments to implementing behavioural interventions, 
including opposition to school-based sex education and complex re-organisation of 
health service have further impacted upon behavioural implementation (Select 
Committee on HIV and AIDS in the United Kingdom, 2011). Additionally, 
behavioural-only interventions have been shown to be less acceptable, appropriate or 
feasible with many MSM, with international bodies, such as UNAIDS, making a strong 
case for combination prevention: prevention that combines behavioural, bio-medical 
and structural interventions (Buchbinder & Lui, 2011; Tatoud, 2011; UNAIDS, 2010). 
 
1.3 Biomedical prevention: the emergence of PrEP 
The last decade has witnessed significant scientific developments with regards to 
preventing HIV transmission using medical technologies. Anti-retroviral therapy, once 
thought of only in terms of maintaining the well-being of those already infected with 
HIV, is now emerging as a central component of HIV prevention efforts.  Early 
treatment of people with HIV with anti-retrovirals has been found to lower the infected 
individual’s HIV viral load (a measure of the amount of HIV in an individual’s body 
fluids), and reduce onward transmission of HIV by up to 97% (Cohen et al., 2011) thus 
rendering them effectively uninfectious. This has led to a reconstruction of anti-
retroviral therapy as ‘treatment as prevention’ (Das Douglas et al., 2010; Lima et al., 
2008; UNAIDS, 2011). 
 
In addition to the use of anti-retroviral therapy to reduce viral load of those already 
infected, the same medication has been utilised to reduce the likelihood of HIV 
transmission to uninfected individuals who are exposed to HIV. This ‘post exposure 
prophylaxis’ (PEP) for individuals exposed to HIV has been utilised in medical settings 
following needle-stick and surgical injuries with protocols on occupational use 
developed internationally (Rey et al., 2000). Guidelines for the prescription of PEP for 
individuals who have been sexually exposed to HIV were introduced in England in 
15 
 
2006 (Fisher et al., 2006), along with a raft of health promotion interventions to increase 
knowledge and access to PEP amongst at-risk MSM (Terrence Higgins Trust, 2006). 
 
Further to the notion of ‘treatment as prevention’ and PEP, there has been significant 
development of antiretroviral medication that can be used prior to HIV exposure that 
might prevent an HIV negative individual becoming infected. Termed ‘pre-exposure 
prophylaxis’ (PrEP), this is a biomedical technology that allows HIV uninfected 
individuals to control their susceptibility to HIV prior to exposure. Current scientific 
research is being undertaken that explores the safety and efficacy of PrEP in men in 
three different formats - 
 
Oral PrEP - taken as a tablet either daily or intermittently  
PrEP in a topical gel format - inserted vaginally or rectally (often termed 
‘microbicides’) 
PrEP in an injectable format 
 
In addition, and not touched upon in this research, PrEP is also being explored in other 
formats such as cervical ring formats, for use by women during sex with men (Chen et 
al., 2014). For the purpose of this research, “PrEP” is used as a term to encompass all of 
the above formats.  
 
1.4 Aims of the research 
PrEP has demonstrated considerable promise in clinical trials as a means of preventing 
HIV infection among those most at risk of acquisition (Grant et al., 2010). If this 
technology is to be successfully integrated into existing HIV practice, it is imperative to 
better understand acceptability of PrEP among those to whom it will be targeted. As 
such, the aim of this research is:  
 
To assess the acceptability of HIV pre-exposure prophylaxis (PrEP) amongst men who 
have sex with men (MSM) in London. 
 
Objectives: 
 
 To assess MSM’s knowledge and views of PrEP; 
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 To assess MSM’s willingness to consider using PrEP, the factors contributing to 
willingness to use PrEP and barriers to using PrEP; 
 To assess the relative acceptability of different PrEP delivery methods to MSM; 
 To make recommendations for PrEP provision and for PrEP health promotion 
interventions that target MSM. 
 
1.5 Structure of the thesis 
Chapter 2 summarises the current evidence on the efficacy and effectiveness of PrEP 
from clinical trials, before moving on to establish some of the key social, economic and 
political constraints to the provision of PrEP. The chapter describes and discusses the 
central importance of acceptability of new HIV prevention technologies, if they are to 
be used by key at-risk populations, and summarises existing evidence on the 
acceptability of PrEP. The concept of acceptability is examined, within theoretical 
frameworks of risk, before an acceptability framework is proposed, that forms the basis 
of this thesis. The chapter concludes with a brief overview of how the fast-moving 
evidence base on PrEP is impacting on policy and practice, especially with regard to the 
timeframe in which fieldwork for this thesis was collected. 
 
Chapter 3 sets out the methodology used in the study, with an explanation of why the 
research approach that was employed was deemed to be the most appropriate. The 
chapter explains the sampling method and describes the demographic profile of the men 
in the study, and how they were recruited. Ethical considerations and limitations of the 
study are also considered. 
 
Chapter 4, the first results chapter, explores how men manage their sex lives. This 
context setting chapter explores how men ‘do’ sex and how they manage risk in the 
current absence of access to PrEP. 
 
Chapter 5 explores the possible positioning of PrEP in men’s lives – with a particular 
(and obvious) focus on men’s sex lives. The chapter explores men’s immediate 
willingness to use PrEP personally, including the dimensions of personal acceptability 
of daily oral PrEP, and then a comparative analysis by other PrEP methods.  
 
Chapter 6 addresses perceived community and societal dimensions of PrEP and if and 
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how these perceptions impact on the extent to which men consider it personally 
acceptable. The chapter provides a focus on the impact of stigmatisation of risk and 
risk-taking and the resulting impact on PrEP acceptability.  
 
Chapter 7 provides four case studies of individual men’s perceptions of PrEP and the 
potential impact of PrEP use on their (sex) lives. The case studies highlight the dynamic 
nature of individual’s PrEP beliefs, including their own inconsistencies in how PrEP 
might be used or considered.  
 
Chapter 8 draws out and further discusses the key findings of this research, and how the 
thesis makes a unique contribution to the evidence on potential PrEP uptake and use 
among MSM. This discussion chapter focuses on the major findings from the research 
and concludes with a proposed model of PrEP acceptability. 
 
The final chapter provides an overview of the key recommendations of this thesis and, 
given the applied nature of the doctorate in public health, the implications of these 
findings for future research, policy makers and HIV health promoters. 
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Chapter 2: Reviewing the evidence  
 
In the chapter that follows I review the existing literature relevant to this research study. 
The chapter starts by reviewing the literature on PrEP itself, focusing on three different 
PrEP methods. Then follows a review of contemporary issues relating to the 
implementation of PrEP, establishing some of the key social, economic and political 
constraints to the provision of PrEP. The chapter continues by describing and discussing 
the central importance of acceptability of new HIV prevention technologies, if they are 
to be used by key at-risk populations, and to summarise existing evidence on the 
acceptability of PrEP. The concept of acceptability is examined, within theoretical 
frameworks of risk, before an acceptability framework is proposed that forms the basis 
of this thesis. The chapter concludes with a brief overview of how the fast-moving 
evidence base on PrEP is impacting on policy and practice, especially with regard to the 
timeframe in which fieldwork for this thesis was conducted. 
 
2.1 Pre-exposure prophylaxis – the evidence base 
 
2.1.1 Topical PrEP 
Much of the early clinical research relating to PrEP focuses on topical application in the 
vagina. Conceptually, topical PrEP might act in a number of ways to prevent HIV (and 
other pathogen) infection, including providing a physical barrier to prevent pathogens 
reaching target cells; preventing replication of a virus once it has entered a cell; killing 
or disabling the pathogen; or enhancing the natural defences of the vagina, such as 
maintaining an acidic ph. While many early studies failed to demonstrate significant 
effectiveness in preventing HIV transmission from an infected male to an uninfected 
female (Van Damme, 2007), July 2010 saw publication of results from the CAPRISA 
004 trial (Abdool Karim and Abdool Karim, 2010). This large, double blind randomised 
controlled trial explored the effectiveness and safety of tenofovir (a specific form of 
antiretroviral medication) as a vaginal microbicide and showed a reduction in HIV 
incidence of around a half among women consistently and correctly using the gel, with 
no evidence of HIV drug resistance. 
 
Whilst the CAPRISA trial results show promise for future use as one HIV prevention 
method for women having vaginal intercourse, evidence for the use of topical PrEP to 
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prevent HIV during anal intercourse is less developed. In January 2012, recruitment 
commenced to the MTN 017 rectal microbicide trial – the first Phase II safety and 
acceptability trial of tenofovir gel reformulated for rectal use (Microbicide Trial 
Network, 2015). MTN 017 evaluated drug absorption, participant acceptability and 
safety of the reformulated tenofovir gel used daily, used before and after sex amongst 
216 HIV negative MSM. To gauge acceptability of the gel, participants were asked 
about any side effects experienced, their preference for using the gel on a daily or 
intermittent basis, and whether they would consider using the gel in future to reduce 
HIV acquisition. Results from MTN 017 are expected at the start of 2016.  
 
In addition, in 2014 the John Hopkins Institute announced US National Institute of 
Health funding to develop an antimicrobial solution, in a single dose rectal enema or 
douche format, for use prior to anal intercourse (John Hopkins Medicine, 2014). Further 
research has been undertaken to better understand preferences between rectal 
applicators among MSM, when used to apply placebo or tenofovir gel (Carballo-
Dieguez et al., 2014). Furthermore, “Project Gel” is a multi-stage trial exploring rectal 
microbicide acceptability, safety and adherence in young MSM in the USA (Project 
Gel, 2014). While evidence for the efficacy of topical PrEP is still not forthcoming, 
significantly more progress has been observed with oral PrEP. 
 
2.1.2 Oral PrEP 
Clinical progress in relation to the development of oral PrEP has been far more 
pronounced. Early safety trials on the effectiveness of using tenofovir in a pill form 
among HIV negative gay men at high risk of acquiring HIV suggested no safety 
concerns in prescribing anti-retroviral drugs to HIV uninfected men (Grohskopf, 2010). 
In this randomised control trial of 400 men in the USA, none of the men in the tenofovir 
arm became infected, whilst seven men on the placebo arm acquired HIV during the 
period of the trial. 
 
In November 2010, results of the Pre-Exposure Prophylaxis Initiative (iPrEX) – a 
multinational, randomised, double-blind, placebo controlled, Phase III trial - found that 
a daily oral dose of Truvada (a combination of tenofovir and emtricitabine) reduced 
HIV acquisition by 44% and, in those who took the drugs as directed, by approximately 
90% (Grant et al., 2010). This first large scale PrEP study in MSM explored safety and 
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efficacy of a daily dose of ART in just under 2,500 MSM and transgender women in 
eleven countries. The medication caused no major side effects and none of the 
participants developed resistance to the drug.  
 
In 2012 an open-label extension of iPREX for MSM and transgender women who have 
sex with men (iPREX OLE, 2012) commenced with 1225 participants from the iPREX 
study being given the option of continuing to take daily oral Truvada. Of these, 847 
opted to continue to take PrEP. To date, the trial has found no HIV infections in people 
taking four or more doses of Truvada a week, with evidence that those at greatest HIV 
risk are taking more PrEP, and are adhering better than those at lower risk (Grant, 
2014). 
 
Two European based studies have further reported on PrEP efficacy and effectiveness 
amongst MSM since the start of 2015. The PROUD study, conducted among 545 MSM 
and transgender women at sites in England, randomised participants into either an active 
arm, that took daily oral Truvada, or a deferred arm, that was given oral PrEP after 12 
months following enrolment. In October 2014, PROUD was un-randomised, with all 
participants being offered PrEP, when the trial’s independent Data and Safety 
Monitoring Committee recommended that the randomisation be halted, given the 
significant differences in HIV infection between the two arms. In February 2015, 
evidence was presented from PROUD that daily oral PrEP was 86% effective at 
preventing HIV. The trial found adherence to be high, side effects to be low and mostly 
tolerable when they did occur. No significant difference was found in sexually 
transmitted infection (STI) incidence between participants in the active and deferred 
arms, with preliminary data suggesting that there was only negligible difference in 
condom use between participants in each arm, although further analysis on this is 
expected (McCormack, 2015). Further qualitative data on experience of using PrEP and 
other factors, including disclosure of PrEP use and sexual negotiation is expected later 
in 2016.  
 
Following the un-randomisation of the PROUD study, the French and Canadian 
Intervention Prophylactique pour et avec les Gays (Ipergay) study (Agency Nationale de 
recherches sur le SIDA et les Hepatites virales, 2012), was also un-randomised in 
November 2014, when its Data and Safety Monitoring Board reviewed HIV incidence 
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and found oral PrEP to be highly effective. Ipergay is the only study to report on the 
effectiveness of intermittent or event based oral PrEP. 350 participants were randomised 
to take two Truvada pills, or a placebo, between one day to two hours before they 
planned to have penetrative intercourse and then, if intercourse took place, to take 
another pill 24 hours after sex, and then a fourth pill 48 hours after intercourse. 
Investigators on Ipergay were keen to explore if adherence using intermittent dosing 
would be better than daily oral PrEP. Like the PROUD study, Ipergay reported that 
PrEP was 86% effective at preventing HIV (Molina, 2015). 
 
Both PROUD and Ipergay continue as un-randomised studies.  
 
It is worth noting that at the time of fieldwork for this thesis research, iPREX OLE had 
reported no findings. Recruitment for PROUD and Ipergay only commenced at the end 
of the fieldwork and no findings of these two studies had yet been released during the 
fieldwork.  
 
2.1.3 Injectable PrEP 
Finally, the first human trials of a once-a-month injectable formulation of PrEP reported 
in March 2012 that drug levels in participants were maintained at a high enough rate to 
offer sufficient protection against HIV infection. The London-based trial of 27 women 
and six men found few side-effects when a single injection of rilpivirine was 
administered to HIV uninfected participants (Jackson, 2012). 
 
Since fieldwork for this thesis was completed, further and substantial progress has been 
made with injectable PrEP. Both Johnson and Johnson, and Glaxo-Smith-Klein have 
undertaken safety studies of monthly injectable PrEP (HIVPlusMag, 2013). A study of 
GSK1265744 (commonly referred to as GSK744), found that monthly injections offered 
100% protection to monkeys against SHIV, and suggested that injections given on a 
three-monthly basis might be similarly protective (Andrew et al., 2013). The same drug, 
trialed on 47 individuals, was found to reach drug levels expected to be therapeutic 
within 3 days, with concentrations remaining high for a prolonged period, and declining 
slowly, offering a level of ‘forgiveness’ if a dose is delayed (Spreen et al., 2013; 
Highleyman, 2013). Phase 2 trials of GSK744 (in a trial named HPTN077) are 
progressing, and, although it is now known that GSK744 remains active in the body for 
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about 12 weeks, it is still not clear how effective it is at preventing HIV in humans 
(Newman, 2015). HPTN077 is likely to complete in mid-2017, with a degree of 
anticipation that injectable PrEP might be an option sooner than anticipated (Heitz, 
2015), especially if the drug can be demonstrated to be as safe and better than existing 
oral PrEP methods (Cohen, 2014). 
 
These studies add further weight to the body of evidence regarding PrEP efficacy and 
effectiveness and that prescription of PrEP to MSM at risk of HIV infection in the UK 
might be considered in the very near future. However, prior to such prescription 
occurring, there are a number of practical and economic issues that need addressing, and 
behavioural and social questions that need to be explored in order to support the 
addition of this promising medical technology to the toolbox of existing HIV prevention 
interventions in the UK.  
 
2.2 PrEP: Implementation issues to consider 
Having reviewed the existing literature on PrEP, there are a number of key areas worthy 
of consideration with regard to the implementation of PrEP. Studies and opinion pieces 
have raised questions about the ethics, cost-effectiveness and behavourial risk 
implications of PrEP (Cairns, 2014a; Cohen and Baden, 2012; Desai, 2008; Grant, 
2006; Tuller, 2013). Some have queried the extent to which PrEP should be made 
widely available with others suggesting that countries with focused epidemics should 
target specific ‘at-risk’ groups (Livoti, 2012; Paxton et al., 2007; Peterson et al., 2006). 
The possible impact of PrEP on individual men’s condom use via behavioural dis-
inhibition (PrEP being used as a substitute for condoms in men wanting unprotected 
sex) and risk compensation has been highlighted (Evans, 2012; Golub, 2010; Yeung, 
2012). A further area of debate and concern has been the implications of widespread 
PrEP prescription on future availability of anti-retrovirals for HIV treatment, should 
drug resistance develop if anti-retrovirals for prevention are used sub-optimally (Gibbs, 
2011; Mellors, 2010). Further discussions have focused on the potential cost of PrEP 
(Gomez et al., 2012), particularly in resource-poor settings where those with diagnosed 
HIV are unable to access ARTs (Gibbs, 2011). 
 
However, consideration of all of these is beyond the scope of a DrPH thesis and I have 
necessarily focused on one particular pressing issue for consideration. Despite the 
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growing data on the efficacy of PrEP to prevent HIV, the success of translating these 
scientific developments into effective scaled-up HIV prevention interventions in a 
diversity of settings requires an understanding of how acceptable they are to individuals 
at risk of HIV exposure. Understanding the acceptability of an intervention or 
programme is an essential element of its success. As Ayala and Elder (2011) identify, 
interventions developed without an understanding of their acceptability risk being 
poorly implemented, unsustainable and without the trust of the target group. They can 
increase health inequalities if they are inappropriate to the target group (Cooper et al., 
2002). Without an understanding of how target populations perceive an intervention, 
how they envisage it might form part of their decision making in their sexual lives and, 
ultimately, how acceptable PrEP might be to men who may be offered it, we are 
uncertain of if, how, and when it will be utilised. This is even more pronounced given 
the potential side effects associated with PrEP (see below) and the stigma associated 
with HIV and sex between men.  
 
Existing models of intervention effectiveness in sexual health promotion provide 
frameworks under which to better understand the importance of acceptability in 
intervention design and evaluation. Kirby’s review of effective interventions to reduce 
teenage pregnancy identifies seventeen characteristics of interventions that can be 
applied to other interventions (Kirby, 2007). Similarly, the England-wide planning 
framework to reduce HIV during sex between men (CHAPS Partnership, 2011) 
articulates seven dimensions or qualities of an effective sexual health promotion 
intervention of which acceptability is one key quality. That is: how does the target 
regard the objectives of the intervention, particularly in that setting? 
 
Prior UK studies of HIV medication adherence can help us to better understand why 
acceptability is an important component of future PrEP delivery. Among people with 
HIV on treatments who experienced problems using HIV drugs regularly, participants 
raised issues including side-effects of drugs; difficulties fitting treatment-taking into 
daily routines; and concerns surrounding loss of confidentiality when carrying or using 
treatments in public or in family-settings (Weatherburn et al., 2002, Weatherburn et al., 
2009). Understanding similar issues regarding potential PrEP prescription assists in our 
understanding of the acceptability of those risks and concerns versus the benefits of 
PrEP to individuals, their sexual partners and communities. 
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2.3 Existing evidence on PrEP acceptability 
Several studies have already briefly addressed certain aspects of PrEP knowledge and 
acceptability in the population of MSM in the UK, although the concept in general, in 
relation to PrEP, remains poorly defined (a point explored in more detail in section 2.6) 
and has thus been constructed differently by the studies described in this section. It is 
important to be mindful of how research undertaken outside of the UK might not be 
transferable to UK settings – not least for that conducted in lower or middle income 
settings, or those, such as the USA with health insurance systems. 
 
Findings of a 2011 online survey of 1259 MSM in England (Sigma Research, 2011) 
provide initial data on the acceptability of PrEP among this group. Awareness of PrEP 
was generally low, with 80% of respondents having previously been unaware of PrEP. 
When asked to consider how they might use PrEP were it available in England, around 
half of men who had not tested HIV positive (52.4%) would consider using PrEP if they 
were offered it at a sexual health clinic; and more than half of men (54.9%) would 
prefer taking a daily pill to intermittent dosing (27.4%). Men with casual partners were 
slightly more likely to consider using PrEP and men with a regular partner with 
diagnosed HIV were no more likely to consider PrEP than other men.  
 
In open-text response boxes to explain their position, respondents saw PrEP as being 
acceptable for those who were cognisant of their risk taking. However, they did not see 
PrEP as influencing their current sexual behaviour; rather, that PrEP offered a way of 
reducing the risks of and concerns about their current known risk taking. In other men, 
PrEP might offer them the chance to engage in sex that they currently deemed too risky. 
Others failed to see the benefit of PrEP either because of consistent condom use or 
because they were of the belief that they did not have unprotected sex with men with 
HIV.  
 
However, this was an online survey with a self-selecting sample and, as a result, the 
potential of respondents to be more amenable to responding to HIV health promotion 
surveys introduces a potential selection bias. The survey offers respondents a limited 
capacity to report and respond to their attitudes to PrEP and, although it provides a 
useful initial insight in to the views of MSM in England about PrEP, it lacks the depth 
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of fuller qualitative research in to acceptability.  
 
Findings from a cross-sectional survey of 842 HIV-negative men recruited in gay 
venues across London undertaken in 2011 suggest that around half of men would 
consider taking PrEP (Aghaizu, 2012), whilst a survey of 121 HIV-negative MSM 
attending a Manchester sexual health clinic undertaken in 2011-2012 found that over a 
third would be “very willing” to take PrEP (Thng et al., 2012). As with the Sigma 
Research survey, these surveys offer a limited capacity to report PrEP acceptability, and 
the settings in which they are undertaken capture the views of a limited cross-section of 
men. Also, their focus only on willingness to use PrEP represents only one possible 
dimension of acceptability.  
 
Since fieldwork for this thesis was completed, further research on PrEP acceptability 
has been conducted in Scotland. In a cross-sectional survey of 17 gay commercial 
venues in Edinburgh and Glasgow (Young et al., 2013) around half of the 1393 men 
included in the analysis reported that they would consider taking PrEP on a daily basis. 
Those who would not consider taking PrEP tended to report that they did not consider 
their risk to be sufficient to warrant taking a daily pill, or they highlighted concerns with 
using medication to prevent HIV.  
 
Frankis et al’s (2014) mixed method study on understanding PrEP acceptability from a 
range of sites in Scotland found that almost half of 929 MSM in a cross-sectional survey 
would be likely to use PrEP should it be available, with a further quarter of men being 
unsure, and just over a quarter saying that they would be unlikely to use PrEP. Focus 
groups of men diagnosed with HIV found concerns about the potential costs of PrEP to 
the NHS, along with concerns about side effects and adherence. Men with HIV also 
voiced fears about HIV negative men using condoms less frequently when using PrEP. 
HIV negative or untested men in focus groups shared concerns about major side effects. 
In semi-structured qualitative interviews, men who did not have HIV voiced cautious 
optimism about PrEP. The authors conclude that it is crucial to consider the social 
context and men’s existing risk reduction strategies and how these will impact upon 
men’s future PrEP uptake.  
 
Further Scottish research exploring barriers to uptake and use of PrEP (as indicators of 
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acceptability) was published in late 2014 (Young et al., 2014) and reported on findings 
from focus groups and in-depth interviews with MSM and Africans, including HIV 
positive, HIV negative and untested individuals. Understanding of PrEP’s effectiveness 
and the maintenance of adherence were viewed as barriers to PrEP uptake, and self-
perception of being at low-risk for HIV transmission meant that few participants saw 
themselves as benefitting from PrEP. Concern about other people’s condom use whilst 
using PrEP meant that many participants viewed PrEP unfavourably. The authors 
conclude that PrEP implementation needs to consider appropriate communication 
methods to take into account divergent HIV literacy, and to demonstrate how PrEP sits 
alongside and complements other strategies to manage HIV transmission.  
 
A small number of studies have been undertaken with MSM in sero-discordant 
relationships in the USA (Brooks et al., 2011; Mimiaga et al., 2009) that broadly find 
PrEP to be acceptable, although acceptability remains ill-defined in those studies. A 
2012 mixed-method study of males in sero-discordant and sero-concordant 
(positive/positive couples) in San Francisco found a relatively low acceptability in the 
sample of 164 couples (Saberi et al., 2012). Men in the study articulated concerns about 
possible risk-compensation and the authors noted that a quarter of men in the study 
confused PrEP with PEP. As with the other US based studies, acceptability was not 
clearly defined within this study. 
 
Young and McDaid’s (2014) review of research on acceptability of treatment as 
prevention (TasP) and PrEP explored 27 studies that examined acceptability of TasP 
and/or PrEP. They concluded that acceptability of PrEP within randomised control trials 
was usually measured by individual adherence rates and that few studies explored issues 
of risk. They found limited evidence of how individual choice and actions are limited or 
facilitated by broader cultural or social contexts. It should be noted however that this 
review had a primary focus on TasP (given the existing literature at the time of the 
review). 
 
Beyond the UK, a seven-country interview-administered and self-administered survey 
(Peru, Ukraine, India, Kenya, Botswana, Uganda and South Africa) of 1,750 potential 
PrEP users recruited in a wide range of locations found an overall willingness to adopt 
PrEP within key populations – including MSM – and this willingness extended to use 
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despite possible side-effects, the need for regular HIV tests and the possibility of having 
to pay for PrEP (Eisingerich et al., 2012). Most participants said they would use 
condoms in combination with PrEP and that the most preferred method of 
administration of PrEP would be through a bimonthly buttock injection, followed by a 
monthly injection in the arm. A daily pill and a pill before or after intercourse were the 
least preferred route of administration and – as many participants reported they might be 
likely to share their medication – the authors report that an injectable format of PrEP 
(administered by medical staff), if such an option becomes available, might be 
preferable to reduce medication sharing and to increase adherence.  
 
A study of 45 MSM, transgender women and female sex workers in Peru, published in 
May 2011, found that the low-cost of PrEP for individuals was the most significant 
determinant of its acceptability. Participants reported that they would be more likely to 
use PrEP if it was low cost, had efficiency of 95%, had no side effects and could be 
taken just prior to sex, rather than on a daily basis (Galea et al., 2011). Further concerns 
were raised by participants with regard to potential sexual risk dis-inhibition, stigma and 
discrimination associated with taking PrEP, and concerns with mistrust of health care 
professionals. 
 
A number of studies have explored the acceptability of oral and topical vaginal PrEP in 
Ghana (Guest et al., 2010), Uganda (Kamali et al., 2010) and USA amongst sexually 
active women (McGowan et al., 2011). Similarly to acceptability studies in MSM, a 
2003 – 2004 acceptability trial of vaginal microbicide gel amongst women in Ghana 
concluded that “women found gel use highly acceptable” (Guest et al., 2010) but fails to 
define ‘acceptability’. A US trial of sixty-one sexually active women exploring safety 
and acceptability of VivaGel (McGowan et al., 2011) restricted acceptability to side 
effects and usage issues of the gel – such as messiness and leakage.   
 
2.4 Conceptualising ‘acceptability’ 
Many of the studies in the previous section utilised the term ‘acceptability’ in their 
descriptions of results when exploring how people from HIV at-risk groups perceive 
PrEP and how they consider its use within the context of their sexual behaviour. 
However, few provide a clear definition of what they mean by ‘acceptability’, instead 
using measures including: financial cost to the individual; potential sexual risk 
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reductions or increases; side effects of PrEP medication; the burden of using PrEP 
including hospital or clinic visits and procedures – such as regular HIV testing; and the 
potential stigma and discrimination faced when using a biomedical HIV prevention 
technology. In general, and across all health behaviours, acceptability is a poorly 
defined concept. However, clarity on the issue is necessary for a focused exploration of 
acceptability, as proposed in this current DrPH research.  
 
It is useful to consider the literature on women’s reproductive and contraceptive health, 
particularly with regard to early acceptability studies of contraceptive spermicides and 
vaginal microbicides. Elias and Coggins remind us that attempting to understand the 
term ‘acceptability’ is mired in historical controversy. They note that “once upon a time, 
the acceptability of contraceptive technology was narrowly defined primarily in terms 
of method continuation rates” (p3) and that over recent years the term has broadened to 
encompass user perspectives of a technology and service delivery of new (reproductive) 
health technologies (Elias and Coggins, 2001). 
 
In Elias and Coggins’ exploration of the acceptability of female-controlled barrier 
methods to prevent heterosexual transmission of HIV, they define acceptability as: “for 
a product to be acceptable, a potential user must fully understand the potential benefits 
of using the product, its potential side effects, and alternate methods and be willing and 
able to consistently apply such knowledge to the use of technology in everyday life” 
(p3). They state that the provision of information and support, and concerns of cost and 
availability of any new technology are “implicit in this definition” and that “obviously, 
the physical and pharmacological characteristics of any given product will directly 
influence its acceptability” (p3). 
 
Gafos (2013) provides further insight into how acceptability of vaginal HIV 
microbicides has been framed. She argues that although there has been extensive 
research into (vaginal) microbicide acceptability, “research to date has focused 
predominantly on either hypothetical acceptability of a potential microbicide or the 
acceptability of specific product characteristics” (p 22) and that “acceptability research 
has focused on willingness to use a product and satisfaction with a particular product” 
(p22). Socio-cultural issues and conceptual gaps in our understanding of microbicides 
exist, and that attempts are being made to move “acceptability research … beyond 
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purely measuring acceptability of product characteristics, and now attempts to identify 
and measure the complex set of individual, relational, behavioural and socio-cultural 
factors that influence the acceptability of microbicides” (p 25). 
 
With most studies exploring acceptability of PrEP alongside efficacy and safety, 
understanding of acceptability has focused on concepts of usability, adherence and 
potential side effects, rather than attending to broader sociological or psychological 
conceptions of acceptability. This is notable given that a risk discourse, explored in 
detail by sociologists and psychologists alike, appears to pervade thinking about 
acceptability. This is evident in findings from the Sigma Panel study (Sigma Research, 
2011) by the manner in which participants voiced opinions regarding the management 
of sexual risk, and the Galea et al. (2011) study and concerns regarding sexual dis-
inhibition and risk-taking that may result from utilising PrEP. Consideration of risk(s) 
might inform many aspects of one’s sexual life, sexual health and engagement with 
clinical and prevention interventions and, as such, the literature on risk – in particular, 
on risk and health – helps to further define and interpret the possible elements of 
acceptability of PrEP for MSM in London. 
 
There are three dominant constructions of risk falling along disciplinary lines: the 
sociological, the psychological and the socio-cultural. 
 
Sociological concepts and experiences of risk can be broadly divided into three 
theoretical perspectives. Beck’s theory of the risk society (1992) articulates that, as 
modern society has moved away from an economy and way of life shaped by industrial 
processes, today’s “late modern period” has resulted in dangers and hazards that result 
from industrialisation, urbanisation and globalisation. Beck maintains that an 
individuals’ life is dominated by anxiety and discussions about risk and the prevention 
or avoidance of ‘bads’ have become central to the modern world with a reliance on 
experts to identify and calculate the dangers of those risks (Beck, 1992). Douglas adopts 
a more anthropological perspective on risk. She argues that concepts of risk are part of 
shared cultural understandings and practices, forged by social expectations and 
responsibilities; risk beliefs and behaviours maintain social control and cohesion and are 
ways of dealing with deviance (Douglas, 1969). Finally, interpretations of Foucault’s 
governmentality perspective of risk postulates that risk is a tool by which individuals 
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are self-regulated within society, with individuals voluntarily establishing practices that 
make us “good citizens” (Castel, 1991, Ewald, 1991). Citizens of modern society avoid 
risk as a moral enterprise to demonstrate control, knowledge and improvement, with 
those not willing or able to comply with risk avoidance facing hostility through 
stigmatisation or moral judgment. This suggests that these elements of control, 
knowledge and acceptability are ones we might wish to attend to when considering 
acceptability. 
 
Psychological perspectives of risk are additionally useful in understanding concepts of 
acceptability in relation to PrEP with MSM. The heuristics or psychometric paradigm 
approach to risk, developed by Slovic, articulates that ‘expert’ assessments are made of 
various technological risks that sit alongside ‘lay’ perceptions of their relative chance of 
the risks impacting upon them (Slovic, 2000). Emotions play a moderating role within 
risk assessment; with individuals making a judgment on the risk based upon the quality 
and intensity of negative feelings an individual has about a potential hazard. Finally, 
Joffe’s social representation approach to risk argues that we should not concentrate on 
risk approaches that focus on individuals as cognitively deficient or heuristically 
misguided but rather, explore how individuals explore the meaning of risk through the 
lens of social forces of moral solidarity and group norms (Joffe, 1999). Joffe 
understands that ‘managing risk’ does not succeed if it involves devising a correct 
formula of information but an individual’s perceptions of risk are rather understood as a 
reflection of their social identification, their moral codes and their trust with and to 
others. 
 
Men’s perception of risk is determined by social and cultural practice (Beck, 1992; 
Douglas, 1969) but is also determined by prior experience and meaning. For example, a 
man’s use of condoms is determined by awareness, by social norms relating to condom 
use, and his personal risk assessment.  
 
Given the pluralistic nature of public health as a discipline (and given that this is a 
DrPH thesis), valid and relevant theories across the social sciences are drawn upon. This 
is a deliberate strategy, to take into account a variety of perspectives, given public 
health’s wide encompassing embrace of disciplines. 
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2.5 Developing an acceptability framework 
None of these theories or concepts alone is sufficient to understand the meaning of 
acceptability for MSM considering PrEP in London. However, each contributes to our 
understanding of the various dimensions of acceptability, and this is furthered still by 
consideration of existing studies that explored acceptability in its various forms. 
Sociological perspectives, particularly those drawn from Foucault, suggest that risk is 
constructed at the social or societal level, and the appropriate, or acceptable, means of 
managing it help to determine whether we are "good citizens". Psychological 
perspectives highlight the importance of emotional factors and the personal meanings of 
risk in determining how individuals consider risk and what risks might be acceptable to 
take. Given this extant literature, it is proposed to frame an understanding of 
acceptability building on three broad dimensions of acceptability: the personal; the 
interpersonal; and the community or social dimensions. 
 
The ‘personal’ dimension of this framework, will consider the concepts of acceptability 
that are already primarily explored in existing acceptability studies – the (financial) cost 
to the individual (incorporating the ‘cost’ of regular clinic attendance); sides effects and 
usability acceptability issues (including leakage for topical PrEP or the localised pain of 
injectable PrEP); the acceptability of potential lowered HIV vulnerability and changes 
in risk taking behaviour, weighed up alongside potential increases in heightened 
vulnerability to other STIs; and the acceptability of adherence to PrEP medication 
regimes and medical procedures. The research has also been designed to be open and 
responsive to other possible dimensions of personally situated PrEP acceptability, 
should they arise. 
 
The second dimension moves on from an individual response to PrEP and explores the 
acceptability of PrEP through inter-personal dimensions. This could be seen to include 
the more complex negotiation of sex and (non) condom use with sexual partners; issues 
pertaining to disclosure of PrEP use and how sex might be negotiated with the added 
dimension of PrEP; the acceptability of risk to sexual partners and/or the risk from 
sexual partners who might be using PrEP; and the stigma or discrimination faced by 
PrEP users from sexual partners, from peers or from medical practitioners and health 
providers. 
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The third dimension explores acceptability from a community or social dimension. 
Contemporary commentators on new prevention technologies have included views that 
biomedical interventions such as PrEP draw resources away from an over-burdened 
health service, and that condoms are sufficient to prevent HIV infection (Leibowitz et 
al., 2011; Pink News, 2011), or that health service providers’ attitudes to PrEP may 
discourage people from seeking it (Boerner, 2014; Kirby and Thornber-Dunwell, 2014). 
Do such views impact on men’s broader understanding of the acceptability of PrEP and 
how acceptable are potential increased “community” (rather than individual or inter-
personal) risks, such as increased STIs, or more complex (safer) sex negotiations. 
Finally, this third dimension might explore how rationing or targeting of PrEP is viewed 
by potential users such as the acceptability of targeting PrEP based on applied 
epidemiological principles, or being prescribed on demand.  
 
However, it is important not to position the dimensions of this framework as being 
separate and unique. Rather, each dimension is strongly connected to the other: an 
individual’s perceived acceptability of PrEP is a consequence of his interaction with 
others, and of how he experiences and perceives community and societal acceptability 
of PrEP. Table 1 below summarises some of the dimensions of PrEP acceptability that 
may prove pertinent, although this is illustrative and not an exhaustive list. 
 
Table 1: Summary of possible PrEP acceptability dimensions 
  
Personal Individual financial costs 
Side effects 
HIV vulnerability/risk acceptability 
Adherence to PrEP regime and medical procedures 
Inter-personal Negotiation of sex/disclosure 
Risk to/from sex partners of PrEP users 
Stigma or discrimination related to use of PrEP 
Social/structural Financial costs to NHS 
“Community risk” 
Rationing/targeting of PrEP 
Medicalisation of HIV prevention and MSM 
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2.6 An emerging and fast moving environment 
The emergence of evidence and policy on PrEP has been fast moving. At the time that 
fieldwork for this study was undertaken, evidence on PrEP efficacy existed only from 
two large international trials and policy on PrEP prescription was patchy and cautious. 
As outlined above, three clinical trials (iPREX OLE, PROUD and Ipergay) have further 
added to the evidence on PrEP and MSM, including intermittent oral PrEP, and further 
Phase II trials on rectal topical PrEP and injectable PrEP are underway. 
 
Further, policy and practice guidelines have moved apace. The US Food and Drug 
Administration (FDA) issued guidance on PrEP prescription to key at risk groups in 
2012 (FDA, 2012); the World Health Organisation (WHO), having been cautious about 
PrEP in 2012 (WHO, 2012), moved to a robust policy of strongly recommending that 
MSM consider taking PrEP, alongside condoms (WHO, 2014); and the European 
Centre for Disease Control (ECDC), after making a policy statement in July 2014 about 
the need for more evidence on PrEP before making a recommendation (Cairns G, 
2014b), shifted position on PrEP, following the release of the PROUD and Ipergay 
findings (ECDC, 2015). On the basis of new evidence, ECDC recommends member 
states consider the integration of PrEP into existing HIV prevention programmes, and 
calls for a review of current regulatory approval of PrEP. 
 
Closer to home, a coalition of non-profit organisations have called for PrEP to be made 
available on the NHS (PrEP Access, 2014); the British Association of Sexual Health, 
and British HIV Association, having published guidance in 2012 stating that there was 
not enough compelling evidence to offer PrEP to patients on demand (McCormack et 
al., 2012), are consulting on new and more directive guidance on PrEP to its members; 
and processes are underway to review the evidence base to support PrEP provision on 
the NHS in England, through the HIV Clinical Reference Group (NHS England, 2015). 
These developments are highlighted to allow the reader to consider the research design, 
and its findings, within the current context. 
 
2.7 Chapter Summary 
This chapter reviewed the existing evidence relevant to this research and examined 
contemporary findings relating to three methods of PrEP. Research on acceptability of 
PrEP has been explored, along with discussion on the challenges of defining what 
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acceptability might mean. The chapter has outlined how, following a public health 
approach, multi-disciplinary theories of social science have been drawn upon to 
understand concepts of acceptability and, as a consequence, a framework for 
conceptualising PrEP acceptability has been presented, that captures personal, 
interpersonal and community or societal dimensions of acceptability. Despite recent 
developments, the fundamental questions posed in this thesis remain the same and 
remain largely unanswered by research undertaken since completion of fieldwork – how 
acceptable is PrEP to at risk MSM in London? 
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Chapter 3: Methodology 
 
This chapter explains the methodology used in this study. First, the research approach is 
explored, with a justification of why this approach was deemed the most appropriate. 
The chapter moves on to explore the sampling method and rationale, followed by the 
ways participants were recruited to the study, using a previous cohort of MSM. This is 
followed by a description of the key demographics of the men and a detailed account of 
the research process and a description of the methods of data analysis. The final section 
of the chapter considers the limitations of the approach, and ethical considerations that 
were taken into account when designing and undertaking the study.  
  
3.1 Research approach 
Given the multiple, discursive elements of acceptability, and the need to understand 
individual perceptions and considerations relating to PrEP, a qualitative methodology 
was deemed the most appropriate approach for this study. Although some have sought 
to understand PrEP acceptability through surveys and other quantitative measures 
(Frankis et al., 2014), these offer less opportunity to capture the richness of men’s 
thoughts and experiences. Surveys are limited in the extent to which they are can 
account for multiple motivating factors that change in different scenarios or over time. 
Qualitative research, on the other hand, seeks to capture and preserve the complexities, 
intricacies and idiosyncrasies of perception, perspective and experience (Buston et al., 
1998), which is essential when trying to understand how PrEP might, or might not, be 
acceptable to MSM and, crucially how interventions might be designed to support its 
use. One-on-one qualitative interviews provide an opportunity to explore acceptability 
and allow for the participant to situate their own perspective within broader social 
constructions of what is, or is not, acceptable. Interviews allow the researcher and 
participant to engage in meaningful dialogue where initial questions can be modified to 
meet individual need, and interesting avenues of arising discussion can be explored 
(Smith and Osborn, 2003). 
 
Consideration was given to a range of qualitative data collection methods other than 
one-on-one interviews when designing the study. Focus groups were initially proposed 
and considered as an additional data collection method. Although focus groups have a 
benefit of accessing cultural norms (Green and Thorogood, 2004), there was a concern 
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that the dynamics of a group format might silence views of some participants, especially 
given PrEP as an emerging technology, and considering the sensitivity of the subject 
area. Diaries were also considered as an option, especially with regard to recording 
men’s sexual risk taking but given the study was aiming to explore co-generation as 
well as individual views on PrEP, diaries were also rejected as a data collection method. 
In addition, as diaries are most suitable at examining experience over time – and this is 
not what I was seeking to achieve – they were further rejected for this reason. While 
each of these collection methods are valid, it was concluded that a semi-structured 
interview approach, in contrast to other approaches, would also create opportunities for 
MSM to bring in themes independently. 
 
3.2 Sampling 
In-depth, semi-structured qualitative interviews with twenty MSM were undertaken 
between September 2012 and January 2013. To be eligible to participate men had to be 
aged between 18 and 45 and resident in central London, or to have conducted the 
majority of their recent sexual and social lives in the capital. The study’s geographical 
boundaries were chosen to reflect the enhanced HIV incidence in London compared 
with the rest of the UK (in 2012, 1,450 of the UK’s 3,250 MSM HIV diagnosis were in 
London MSM (Aghaizu et al., 2013) and the age criteria reflects that the majority of 
HIV diagnoses – and as such, the likeliest age group to benefit from PrEP – are in adults 
under 45 (in 2012, the mean age of HIV diagnosis was 34) (Health Protection Agency, 
2011). The sample size of twenty men allowed for a considerable range of perspectives 
to be captured, while still remaining feasible given the confines of a DrPH research 
project. Twenty is deemed to be a sufficient number of interviews, especially when 
addressing a specific research question before saturation is reached (Green and 
Thorogood, 2004). This sample size also allowed for rigorous textual analysis utilising 
the principles of thematic content analysis (see section 3.7 below).  
 
Qualitative research seeks to understand and describe, in detail, the unique perspectives 
and experiences of a small number of people, rather than trying to make generalisations 
about the world. As such, it was not necessary or appropriate to recruit a sample that 
was representative of all MSM to this study. However, it was still considered beneficial 
to attend to demographic characteristics to get an indication of whether perspectives on 
the acceptability of PrEP may differ amongst MSM from sub-populations and whether 
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such differences could or should be explored in more detail in future studies. As such, I 
endeavoured to recruit participants from a broad range of ages and ethnic backgrounds.  
 
The original cohort of men from whom this study was drawn included transgender men. 
To ensure that there was no ambiguity as to whether transgender men were also 
included in this study, an explicit statement on the inclusion of transgender men was 
made in the recruitment materials and participation was welcomed from transgender 
men if they self-identified as a man who has sex with other men and they met the other 
eligibility criteria.  
 
In order that they were eligible to take part, men had to have received a negative HIV 
test result in the last 12 months prior to interview recruitment and have had at least one 
episode of known sero-discordant sex without condoms (SWC) or SWC with a partner 
whose HIV status was unknown or not discussed in the same period. An explicit 
definition of ‘anal intercourse’ was given in the recruitment material, which defined 
anal intercourse as penile to anal intercourse and excluded non-penile penetration such 
as dildos, sex toys, fists, and tongues. These eligibility criteria reflect a definite at-risk 
group who would be most likely to benefit from PrEP related interventions, given that 
penile anal intercourse is known to be the route by which most HIV transmission occurs 
during sex between men. 
 
3.3 Recruitment 
Respondents for the study were recruited through a mailing list of Sigma Research, a 
social research group based at the London School of Hygiene and Tropical Medicine 
with a history of undertaking HIV related research with MSM. Men on the mailing list 
were part of a previous cohort of MSM participating in monthly online sex and health 
surveys called ‘The Sigma Panel’, that ended in 2011, who had indicated they were 
willing to be contacted to take part in future research. In section 3.3.2 below, a 
description is given of how men were recruited to this panel and then goes on to 
describe how I sampled from among this group of men in the panel for my study. 
 
3.3.1 Recruiting to the Sigma Panel  
Men were recruited to this previous cohort by a variety of paid advertising on gay 
commercial websites (such as www.gaydar.com) and gay community or HIV 
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prevention organisations. Men living in England who had completed a European 
internet survey of MSM (EMIS) had been asked if they wished to provide an email 
address and be contacted to take part in future research. These men were emailed and 
invited to be part of The Sigma Panel. Of the 3,390 men who provided an email address 
and who were invited to take part in The Sigma Panel, 1,823 submitted a response to the 
first survey. Of these men, the mean age was 42.4 years; 35% lived in London; 82.6% 
were attracted to men only; almost half had a higher educational qualification; 82% 
were White British, 12.9% White other, 1.6% were Black; 2.4% were Asian, and 1.3% 
defined their ethnicity as Other.  
 
The 1,463 men who submitted a response to the final survey in February 2011 were 
asked if they were prepared to provide an email address to be contacted for future 
research and approximately 1,200 men responded to this request. It is these men who 
were contacted by email and were invited to participate in this PrEP acceptability study.  
 
3.3.2 Recruiting to the PrEP acceptability study from the Sigma Panel  
An email was compiled that stipulated the eligibility criteria for the study and that the 
study was seeking to explore men’s views on ‘using HIV medication to prevent HIV’ 
(Appendix 1). The email invited eligible men to participate in the study by visiting a 
secure Survey Monkey site (www.surveymonkey.com/prepacceptability) in order to 
complete a short questionnaire (Appendix 2).   
 
The list of men from the Sigma Panel that was shared with me for the purposes of 
recruitment contained only email addresses and no demographic information (such as 
geographical location, age, HIV status, HIV testing history nor sexual activity). As 
such, the majority of men approached by email were not eligible to participate, as they 
did not meet the criteria for the study (for example, they lived outside of London and/or 
had been diagnosed with HIV). Men who were not eligible to participate who raised 
questions or concerns about their non-eligibility were responded to individually by 
email and provided with further details about the study and clarification of the reasons 
for the eligibility criteria. 
 
One third of the panel mailing list was emailed at the start of the study and non-
responders were followed up with a reminder email several weeks later. No further 
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follow up was undertaken after this. Two further rounds of emails were sent out in 
October 2012 and then in December 2012 for the remaining two-thirds of addresses on 
the list, each followed up with reminder emails to non-responders several weeks later. 
In the final round of email recruitment, emphasis was placed on the desire to recruit 
men under 30 and non-white men in to the study, without discouraging other eligible 
participants. 
 
Men who visited the Survey Monkey web site were furnished with further information 
about the study and were reminded again of the eligibility criteria. The website 
reassured men that their details would remain confidential, that their ISP data would not 
be stored, and that the website was provided by a secure provider. Men were asked to 
complete a series of demographic questions to re-check their eligibility to participate 
and a number of questions relating to their HIV status, recent HIV testing history and 
episodes of unprotected anal intercourse in the previous 12 months. When men’s 
responses to any question indicated they were not suitable for participation, they were 
automatically directed to an end page thanking them for their interest in the study but 
informing them that they were not eligible to take part. Men who fully completed the 
survey, and who fully met the eligibility criteria, were invited to supply a contact name 
(a first name only) and a telephone number and/or an email address. Men were asked for 
consent again to be contacted by their chosen method and for permission for a voice 
mail message to be left, if a telephone number had been given. 
 
In the first recruitment round, all men who met the eligibility criteria, who provided 
contact details and who responded to interview requests were offered the opportunity to 
participate in a face to face in-depth interview. In the second and third rounds of 
interviews, three men were assigned to a ‘reserve list’ and were not followed up for 
interview. These men were older, of white ethnicity and possessed higher educational 
qualification: characteristics that were common in those men who had already been 
interviewed.  
 
Upon expressing an interest in participating in a face-to-face interview, men were 
provided with further information about the study and the interview process. This was 
provided either verbally through a telephone conversation or through an email. All men 
were informed that the interview was voluntary, that it was confidential, and that it 
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could take place at a date, time and venue of their choice, including at the participant’s 
home or in an office at LSHTM. When email details were provided, participants were 
furnished with a copy of the Information Sheet (Appendix 3) and Consent Form 
(Appendix 4) in advance, and paper copies of these were provided at the interview. 
 
In addition to the recruitment processes detailed above, one participant – the first – was 
recruited through my own social networks (but was previously unknown to me). This 
participant understood that his use of the Survey Monkey website was being seen as a 
pilot, to test the functionality and understanding of the web survey and that his 
interview was being used to pilot the interview topic guide. Given that no changes were 
made to the Survey Monkey website and so few changes were made to the interview 
schedule following this pilot, it was deemed that the pilot data was of suitable quality to 
include in the study. Post interview he gave full consent for his interview data to be 
included in the study. 
 
3.4 Sample description 
All participants had had a negative HIV test in the previous twelve months prior to 
interview and all men had had at least one instance of SWC with a known HIV positive 
partner, or a partner whose HIV status was unknown or not discussed, since that last 
HIV test. Seven of the men knew for certain that they had had unprotected anal 
intercourse with a known HIV positive partner, and five of the men were in primary 
relationships with HIV positive partners, although the sero-discordant SWC that 
determined their eligibility for the study was not necessarily within those primary 
partnerships.  
 
There was a wide variation in educational attainment. Two of the men identified their 
ethnicity as being Mixed and one as Black. Men’s ages ranged from 21 to 45, with a 
mean age of 34. One of the participants identified as a transgender man. The participant 
names included in the following table, and throughout the report, are pseudonyms.  
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Table 2 Age, ethnicity, and education of sample  
Name Age range Ethnicity Education Known s/d SWC 
Simon  25 + under White British Degree No 
Ed  25 + under White British To 16 No 
Max  26-30 Black Degree No 
Jos  26-30 White British To 16 No 
Philip  31-35 White British Degree Yes 
Louis  31-35 White British To 18 No 
Mattie  31-35 White British Degree Yes 
Marco  31-35 White Other Degree No 
Yan  31-35 White Other Degree No 
Alex  36-40 White British Degree No 
Brad  36-40 White Other Degree Yes 
Javi  36-40 Mixed Degree No 
Duncan  36-40 White British Degree No 
Francis  36-40 White British Degree No 
Martin  36-40 Mixed Degree Yes 
Colin  41-45 White British Degree No 
Roy  41-45 White British Degree Yes 
Nate  41-45 White Other Degree No 
Jovan  41-45 White Other Degree Yes 
Marc  41-45 White British Degree Yes 
 
(Note that in the table above, in the final column, ‘No’ relates to men who had SWC 
with a partner where sero-status was unknown or not discussed.) 
 
3.5 The research process 
Prior to commencement of interview, participants were again provided with an 
information sheet about the study (Appendix 3). This information sheet outlined: the 
nature of the study; the ways in which participants would be involved, including that the 
interview would be audio recorded; how a participant’s information and details would 
be kept confidential, including systems for storing, access to, and destroying audio 
recordings and transcriptions; and that participants could withdraw from the interview at 
any time, or ask for the interview to be stopped without giving a reason. Participants 
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were given the opportunity to discuss any elements of the information on the sheet and 
the processes around confidentiality were verbally reiterated (see section 3.9). 
Participants were reminded that the interview was not a test of their knowledge and that 
they should be as candid as they felt comfortable to be. 
 
Before interviews started I re-confirmed to participants the nature of my role as a 
researcher and described that I had previous experience in sexual health related social 
research. I reassured men that my previous research and professional experience meant 
that I was used to hearing about a broad range of social and sexual issues pertaining to 
MSM, and invited them to be as candid as they wanted to be, and as open as they felt 
comfortable being. Cornwall’s (1984) research on the contrasting ‘public’ accounts 
given by interviewees at first interview, compared with the ‘private’ accounts given 
during follow-up interviews, demonstrates how less ‘deviant’ and more ‘socially 
acceptable’ accounts are given when a participant sees the interviewer more as a 
researcher rather than a confidante. Given I only interviewed men once, and did not 
have the chance to build an on-going relationship with participants, and based upon 
previous research interview experience, I made a decision to disclose my own (homo) 
sexuality at the start of the interview. As well as establishing a rapport, I wanted men to 
understand my role as a ‘peer’ rather than a ‘medical professional’ and to encourage 
open discussion. Participants were comfortable with this disclosure and, in some 
instances, remarked during interviews that they would not have disclosed certain 
information had I not done so. 
 
Once participants had read the information sheet and had the opportunity to ask any 
questions, they were asked to read, sign and date a consent form (Appendix 4) and 
participants were verbally asked if they had any further questions before proceeding. All 
interviews were audio recorded. 
 
3.6 Interview schedule 
This section starts by describing the process of interview schedule development. This is 
followed by a description of the questions that were asked of men and the reasoning 
behind various aspects of the schedule. 
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3.6.1 Developing an interview schedule  
Guided by the dimensions of acceptability that were identified earlier, as well as prior 
research on PrEP acceptability, I drafted a schedule of interview questions to address 
the research objectives. These questions were also framed by representations of PrEP in 
the mainstream media and in the gay and MSM targeted media, including social media, 
web sites and blogs particularly in regard to exploring the third social/structural 
dimensions of acceptability including ‘community’ (Evans and van Gorder, 2014; 
Glazek, 2013; Stern, 2014a) responses to PrEP that participants may have encountered 
or been exposed to. Questions were open-ended to allow for broad articulation of 
acceptability by participants. Appropriate prompts and probes were devised to be used 
where natural dialogue was not forthcoming. The schedule of questions was reviewed 
and discussed, prior to interview, by members of the advisory committee and were 
informally piloted on a research degree student colleague. A pilot interview schedule 
was used with the first interviewee and the questions were found to be understandable, 
acceptable and appropriate. The same interview schedule was used for a further four 
interviews before being reviewed again. At this stage, I transcribed all five interviews 
and transcriptions were discussed with my supervisor. No further changes were made to 
the interview schedule (Appendix 5). However, three ‘prompt cards’ were devised and 
used for the remaining fifteen interviews. These cards contained bulleted key highlights 
of three research trials and were used during interviews to prompt discussion on 
attitudes to and acceptability of different PrEP formulations (Appendix 6). These cards 
were devised to ensure that interviewees were being exposed to consistent and concise 
information on these trials and to ensure that no elements of the trials were omitted or 
incorrectly articulated.   
 
3.6.2 How men meet for sex  
At the start of the interview men were asked to describe how and where they socialise 
with other men. The question was intended to introduce men gently into mechanisms 
for describing where they meet other men for sex and to encourage them to start 
describing their sexual networks, sexual relationships (including if they have a regular 
partner, are monogamous etc.) and their sexual practices. Men were prompted to 
describe the settings in which they socialise and/or meet other men for sex (including 
bars, clubs, sex venues, saunas, cruising grounds); their use of social media, social and 
sexual networking sites for meeting men; and their use of media technologies such as 
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mobile phones to meet other men. In addition, men were prompted to describe the 
extent to which they pre-planned their sex and/or the extent they looked for immediate 
or imminent sex.  
 
3.6.3 History of HIV testing and sexual risk behaviour 
Men were asked about their more recent HIV testing history and were asked to describe 
the circumstances behind their most recent test and the reasons for that test. Men were 
asked if they had a rationale or a pattern to their HIV testing – for example if they tested 
at regular frequency, regardless of previous sexual activity or risk, or if their testing was 
more ad hoc, or dependent on a recent risk. Given that an eligibility criteria was that all 
men had had SWC since their most recent test, and within the last 12 months, men were 
asked to describe the SWC they had had since their last test.  The circumstances behind 
that sex were explored, including whether it was with a regular or casual partner; 
whether it was known discordant intercourse; whether the unprotected sex was 
discussed before or pre-planned or ‘just happened’; and if HIV status was discussed 
before or after sex. Men were asked to describe any other unprotected intercourse they 
have had, including the frequency of it, whom it had happened with, and the 
circumstances behind that sex. 
 
If not already discussed, participants were asked if and how they have managed or 
thought about managing HIV risk during condomless sex. They were prompted to 
discuss modality, withdrawal, frequency and duration of unprotected intercourse; and if 
a known HIV positive partner was on treatments and had a known and undetectable 
viral load. 
 
3.6.4 Use of PEP  
Given that previous use of existing oral HIV prevention technologies might influence 
acceptability of PrEP in the future, men’s use of post exposure prophylaxis (PEP) was 
explored with men, and men were prompted to discuss their knowledge, use or 
experience of PEP to reduce HIV risk. Men were asked to describe what they knew 
about PEP and the sources of that information. They were asked if they had ever 
attempted to access PEP and, if not, what had been the barriers to accessing this post 
exposure medication. Men who had attempted to access PEP, and had taken it, were 
asked to describe their experience on PEP, and whether they had completed their 
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treatment and what had been barriers and impediments, or mechanisms of support, to 
completing the treatment.  
 
3.6.5 Knowledge of PrEP  
Participants were reminded that the purpose of the research was to explore views about 
the acceptability of using HIV drugs to prevent HIV infection in men who do not have 
HIV. They were told, if they had not already articulated such, that the drugs are 
commonly called pre-exposure prophylaxis or PrEP. Men were then asked if they had 
heard about PrEP, and to describe what they had heard about it. If men articulated 
knowledge of PrEP, they were asked about the source of that knowledge, and to say if 
they had used PrEP or had sought access to PrEP.  
 
3.6.6 Potential oral daily PrEP use  
All participants were furnished with the key headlines of the iPREX trial, which 
reported in 2010. The trial design was briefly explained and the headline results of the 
trial. It was clarified that adherence to Truvada, in the trial arm, had been key to its 
efficacy. It was confirmed that there had been no short-term side effects to trial 
participants. 
 
Men were given the opportunity to discuss any questions they had about the top-level 
trial findings and were then asked to describe their responses to the results of the iPREX 
trial.  Respondents were asked to recall if the results of the iPREX trial were familiar to 
them and where they had learnt about those results.  
 
Participants were also asked, if daily oral PrEP became widely available, would they 
consider taking it. Men were then asked about the kinds of issues they would consider 
in making that choice to take, or to not take, a daily oral dose of Truvada and in what 
circumstances they might consider taking it.  
 
3.6.7 Potential other PrEP method use  
Men were then told about four other possible formulations of PrEP that are either in trial 
development, in consideration or exploration, or have been explored in ‘pipeline’ 
development. For each, relevant available research data was presented to the 
participants where this was available. 
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For each method, men were then asked to describe their responses to the information on 
the prompt cards; to articulate if they would consider using such a formulation, should it 
become available in the UK; what issues they would consider before making a choice to 
take, or not take that formulation; and to articulate the pros and cons of that formulation 
methods over any of the other methods described. If this was not mentioned, men were 
prompted to discuss the impact of PrEP on their condom use and if and how PrEP might 
sit alongside their current risk reduction approaches. 
 
The four methods discussed were:  
 
Intermittent dosing of oral PrEP before pre-planned or pre-expected unprotected sex. 
It was noted that no current research findings were available on using PrEP in this 
format but that a current French study was exploring the use of intermittent dosing 
(Molina et al., 2015).  
 
Rectal topical PrEP. The key headlines from the CAPRISA trial (Abdool Karim and 
Abdool Karim, 2010) were presented to men on a ‘prompt card’ and participants were 
informed that the use of topical rectal PrEP was being explored in a number of safety 
trials and efficacy trials (Microbicide Trial Network, 2015). Men were informed that 
although women in the CAPRISA trial had inserted the gel vaginally no more than 12 
hours prior to intercourse, and no more than 12 hours after intercourse and that it was 
still unclear what the optimal pre and post insertion timings might be for such a gel.  
 
Once a month injectable PrEP. Men were presented with the key headlines of a safety 
trial from St Stephen’s Aids Trust (Jackson, 2012) on a ‘prompt card’ and were 
informed that these were the results of a safety trial only and that further research 
needed to be conducted.  
 
Longer term injectable PrEP. Men were asked to consider a concept of a longer- term 
injectable or implanted formulation of PrEP, similar to long-term contraceptive 
methods. Men were informed that no such method currently exists, although it has been 
discussed in the ‘pipeline’ as a potential slow release method of PrEP administration 
(Andrew et al., 2013).  
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Men were given the opportunity to clarify questions about any of the methods 
discussed. 
 
3.6.8 Inter-personal acceptability of PrEP  
Once all potential methods had been presented and discussed, and having gauged a 
broad sense of individual men’s responses to PrEP, participants were asked about inter-
personal dimensions of PrEP. First, men were asked to describe the response of their 
social peers to PrEP and to explore if men they know might consider using PrEP, and in 
what circumstances. Men were also asked to describe if they would disclose their own 
PrEP use to men in their peer group, and if they had a perception that PrEP use would 
hold any element of stigma, discrimination or taboo amongst their social peers. 
 
Second, men were asked to consider their potential PrEP use in relation to their sexual 
partners (who might also be their peers, above). Participants were asked if they thought 
they would disclose PrEP use to sexual partners and to consider if and how their 
potential PrEP use might impact upon negotiating the kind of sex they have with other 
men. Again, they were asked if PrEP use might hold any element of stigma, 
discrimination or taboo amongst their sexual peers. 
 
Third, participants were asked to think about their own sexual negotiation if they 
encountered another man using PrEP, when the participant was not using PrEP. Would 
knowing another man was on PrEP make a difference? 
 
3.6.9 Societal and community acceptability  
As a final stage participants were asked to consider wider societal responses to such an 
intervention. Apart from their social and sexual peers, men were asked if they had 
perceptions of how PrEP might be viewed by a broader community of MSM, outside of 
their direct peers and by the media, health professionals or ‘wider society’ and if any of 
these perceptions might impact on the man’s decision to access PrEP. 
 
To bring the interview to a close, men were asked to summarise what would make PrEP 
acceptable to them, and were given an opportunity to reflect on the discussions during 
the interview. 
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Post interview, participants were provided with an information sheet about PrEP 
(Appendix 7) and provided with the opportunity to address any of the information 
discussed during the interview. This is discussed further in section 3.9 on ethical 
considerations.  
 
My email details were provided, so that participants could opt in to receiving a 
summary of the final research. 
 
3.7 Data analysis 
There are numerous available methods of qualitative data analysis, which differ 
according to the assumptions they make about the nature of the world and what can be 
inferred from spoken language, but all seek to understand subjective perspective or 
experience, as well as meaning. For the purposes of this research study, I drew upon the 
principles of thematic analysis (Boyatzis, 1998) to understand the acceptability of PrEP 
amongst MSM. Thematic analysis provides a comparative process by which the content 
of the interviews are compared and classified in to recurrent themes. Braun and Clarke 
(2006) make a compelling case for drawing on thematic analysis in qualitative (health) 
research – arguing that its flexibility and accessibility also provides richness and 
complex accounts of data. Thematic analysis acknowledges the importance of both 
individual lived experience (‘the psychological’) and the nature of social processes (‘the 
sociological’). This stands in contrast to largely discipline specific analysis such as 
Interpretive Phenomenological Analysis (IPA) (i.e. psychology) (Smith, 2003) or 
Grounded Theory (i.e. sociological) (Charmaz, 2006; Glaser & Strauss, 1987). In 
seeking to understand the acceptability of PrEP it is crucial to understand both how 
participants respond to risk in the context of their sex lives and how they negotiate this 
with sexual partners in inherently social interactions.  
 
Further, Braun and Clarke (2006) highlight the strength of undertaking thematic 
analysis when research is being conducted that will be accessible to an audience other 
than academics. Such an analysis, drawing on subjective experience and thematising it 
through the process outlined below, humanises the material for the reader. Such a 
choice is further relevant and when producing analysis that aims to inform policy 
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development, making thematic analysis suitable for a DrPH thesis. Analysis of data 
broadly followed Braun and Clarke’s phases of thematic analysis, as outlined below. 
 
All interviews were audio-recorded and fully transcribed verbatim by myself. This 
included pauses, interruptions, laughter and other background noise. Any identifying 
information such as real names, place names and venue names were removed during 
transcription. Interviews lasted between 40 and 70 minutes. Self-transcription of the 
data, although time consuming, allowed for a far richer knowledge and understanding of 
the data (Riessman, 1993) and constituted part of the interpretation and analysis of the 
data itself (Lapadat and Lindsay, 1999). 
 
NVIVO7 was used as an analysis tool for the data. Each participant was assigned to a 
case, with attribute data for the case coded as a case node (Bazeley, 2007) including key 
demographics such as age, ethnicity and educational qualification. An initial coding 
scheme was developed following transcription of the first five interviews with initial 
tree nodes created. These nodes were both inductive and deductive: my own prior 
professional practice and reading of the PrEP literature ensured I was attentive to certain 
issues that I wanted to examine in more detail, however I remained entirely open to the 
possibility of new and interesting issues emerging (which indeed they did). In order to 
ensure complex and divergent data was not lost in the process of establishing the coding 
tree, a number of free nodes were created and used during this initial analysis for data 
that did not initially sit within the tree nodes. These tree nodes included men’s accounts 
of SWC; delivery method of PrEP – with each of the five potential methods as branch 
nodes; and risk reduction strategies. These themes were discussed with my supervisor 
and then verified with him following further transcriptions of interviews. These themes 
were discussed further with support of the advisory committee, and a framework was 
constructed to illustrate their connectivity.  
 
As the further fifteen interviews were coded, a small number of additional tree modes 
were created, and data from free nodes were merged into these. On completion of 
coding, each tree node was thematically analysed. Each node (and/or its branch) was 
printed and analysed for recurrent and common themes (Green and Thorogood, 2004). 
Interesting features, including justifications, narratives and metaphors were highlighted 
and interrogated for meaning. As suggested by Braun & Clarke (2006), at the 
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fundamental level, a theme represents a form of patterned response or meaning within 
the dataset. While not seeking to establish an arbitrary cut off for how often such a 
pattern emerges in the data before considering it a theme, I was carefully attentive to 
whether such patterns were replicated across transcripts or whether they emerged only 
within specific cases. As far as space allowed within this thesis, I tried to take account 
of variation as well as partial duplication in narrative and meaning expressed by 
participants.  
 
At this point a decision was made to include four case studies as part of the study’s 
results (Chapter 7). This decision hinged on two key factors. The first, given the process 
of deconstruction and reconstruction employed in thematic analysis, I wanted to present 
a more ‘holistic’ understanding of four different participant’s understanding and views 
on PrEP, not least to identify and illustrate the individual complexities and 
contradictions about PrEP acceptability. Second, given the applied nature of this 
research, I wanted to present over-arching narratives for non-academic readers that 
summarised four key ‘stories’ (but by no means all of the stories) pertaining to PrEP 
acceptability in a way that neatly captured the essence of the findings. 
 
These four men were selected as case studies as they provided the most distinct 
characterisations of PrEP acceptability and potential use: the naïve risk taker, for whom 
PrEP would not be deemed acceptable as the man could not recognise his HIV risk; the 
man who definitely would seek PrEP; the ambivalent man, for whom PrEP would be 
acceptable in certain circumstances but had a considered approach to determining PrEP 
use; and the man who would not use PrEP, broadly for whom HIV risk was deemed 
insufficient to warrant PrEP. 
 
3.8 Quality, rigour and reflexivity 
Qualitative research acknowledges that we bring something of ourselves and our beliefs 
into the research process, and that this necessitates a level of reflexivity and awareness 
of oneself within the process. Such reflexivity enhances the quality and credibility of 
the analysis (Green and Thorogood, 2004) and contributes to the rigour of the research. 
Guidelines exist for assessing and checking quality in quantitative research, such as 
those developed by Elliot et al (1999), including the extent to which one’s own 
perspective is owned.  
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Green and Thorogood establish four considerations to inform reflexivity, each of which 
informed my own research practice (and in turn the credibility and rigour of the research 
and the analysis): methodological openness (as outlined throughout Chapter 3); 
theoretical openness (as outlined in particular in section 3.7); awareness of the social 
setting of the research itself (which is, in part, discussed in section 3.9); and awareness 
of the wider social context (which is addressed and acknowledged throughout, not least 
in the Discussion and Conclusion chapters). My own subjective position within the 
research is further addressed in Section 3.11 below. 
 
3.9 Limitations of the study 
As with all research, there are a number of limitations with this study design of which 
the reader should be mindful of when considering the findings that follow. 
 
As outlined, participants were drawn from a cohort of men who had previously engaged 
in online sexual health research via the Sigma Panel. As such, participants of my study 
were likely to be drawn from groups of men who are more amenable to research 
participation. Men who signed up to participate in the original online research (from 
which my study participants were recruited), who then did not go on to participate in 
that research, were more likely to be less well educated, from a Black or minority ethnic 
group, and to be younger, than those men who participated in the research. Those same 
demographic groups of men were also more likely not to respond to a request for 
interview, or agree to be interviewed, for my study, meaning that the final group of 
study participants were more likely to have higher educational qualifications, to be 
older, and to be more likely to be White (both White British and White Other). As such, 
the study reflects the views of men who are more likely to be socially or economically 
privileged and their perspectives may differ from other sub-populations of MSM. 
 
In addition, given that the cohort had previously been asked questions relating to PrEP 
in a survey, in June 2011, some men would have been exposed to information 
pertaining to PrEP by participating in that survey. Not all men will have responded to 
the invitation to participate in that survey’s PrEP questions, nor necessarily opened the 
email inviting them to participate in those questions. As such, a potential limitation 
could be that men recruited to the study were already well versed about PrEP, with 
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PrEP knowledge, awareness and consideration well beyond that of most MSM. 
However, few of the participants identified that survey as their source of PrEP 
knowledge and those who did rarely had a robust knowledge and understanding of 
PrEP. Additionally, the research was not seeking to establish participant’s knowledge of 
PrEP, rather their attitudes about it and potential acceptability of PrEP. As such, 
although it might be the case that these men might have been better informed about 
PrEP than would otherwise have been the case, this is not seen as a limitation of this 
study. 
 
Taking these potential limitations into consideration, caution should be given into the 
transferability of the findings of this study to less-educated, more ethnically diverse, and 
younger populations of MSM. Further consideration of the limitations should be given 
when considering transferability outside of London, or other high HIV incidence and 
prevalence populations. Previous research has documented how a greater proximity to 
HIV (with regard to local prevalence and familiarity with those living with HIV) can 
influence and inform both a perception of personal risk and the strategies employed to 
manage it (Keogh, 2008). 
 
Finally, at the time of the commencement of the fieldwork, oral daily PrEP was not 
available in the UK, other than through self-importation from abroad. Although 
recruitment to the clinical PROUD trial (McCormack et al., 2012) started towards the 
end of the fieldwork, none of the participants had enrolled on that clinical trial at the 
point of interview. With the exception of the one participant who was buying PrEP 
himself online, none of the participants were using PrEP, and indeed PrEP knowledge 
was new to many men. As such, participants were being asked hypothetical questions 
about potential PrEP use for technologies available only in clinical trials or 
technologies in pipeline or concept development. A limitation of this study could be that 
the hypothetical nature of the potential PrEP use limits the depth and breadth of men’s 
knowledge of and desires to engage with acceptability of technologies that are not 
currently available. However, a benefit of undertaking field work prior to the 
commencement of enrolment to a large clinical trial is that it established acceptability to 
an HIV prevention technology prior to its wider implementation. Indeed, undertaking 
research about PrEP technologies when all of the technologies are unavailable gives a 
level of consistency to men’s consideration of their potential use (rather than comparing 
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in-use technologies with pipeline ones). Also, and as discussed, consideration of an 
intervention’s acceptability prior to its roll out can be seen as crucial to ensuring it 
meets the needs of the target population and scientific and clinical potential is realised 
in the real-world. 
 
3.10 Ethical considerations 
Ethical approval for the study was received from the Ethics Committee at LSHTM. 
As a prospective and theoretical exploration of a potential new technology, it was not 
envisaged that there were any significant ethical issues relating to this proposed 
research. However, given the research was asking participants about their sex lives and 
their potential exposure to HIV there was the potential that participation in the research 
might raise concerns. 
 
To mitigate against any potential harm from participation, a number of safeguards were 
put in place. These included: ensuring that men were appraised in advance of the 
interview about the issues that would be discussed; that informed consent to participate 
was obtained (including that men could withdraw at any time); and that a post-interview 
information sheet (Appendix 7) was provided and discussed with every participant post 
interview. This sheet contained: a lay-person’s summary of currently available 
information about PrEP; reiterated that PrEP is different from PEP – and provided 
information on where to access PEP; stated the importance of not sharing another 
person’s HIV medication; and reminded participants that PrEP does not protect against 
other sexually transmitted infection. The sheet included contact numbers of sexual 
health specialist services for men who had any further questions regarding the 
management of sexual risk and participants were made aware of, and sign posted to, 
appropriate information or services after the interview was complete, if and when 
necessary. Men were given the opportunity to discuss any further questions regarding 
PrEP prior to leaving.  
 
My previous experience as a sexual health promoter ensured that I was equipped to 
provide referrals and information to men post-interview and provide the opportunity for 
participants to check-out factual information about PrEP, HIV prevention and sexual 
health. I was also equipped with referral details of specialist sexual health counselling 
and psychosexual health services should men require the need of such services as a 
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result of issues raised during interview, although referrals were neither required nor 
requested as no participant expressed or demonstrated concerns about their emotional 
well-being during interviews. 
 
Considering that men were discussing and disclosing intimate and personal aspects of 
their (sex) lives, men were provided with additional reassurance around confidentiality. 
This included considerations around where interviews took place (interviews were 
conducted in places where men could not be overheard – often their homes); storage of 
audio files and documentation (all audio files were uploaded to password protected files 
and audio recordings were deleted after being transcribed); and how transcribing would 
be undertaken (by me), and how data would be anonymised (with all real names and 
geographical locations deleted and names replaced with pseudonyms).  
 
Given my previous career as a sexual health promoter, including some high-profile 
work, there was potential that I had previously interacted with participants on a 
professional basis. As a gay man frequenting social and online settings within the 
capital, and with a broad social network, there was also the potential that participants, or 
those interested in the study, would be known to me directly, or be directly connected 
with my professional or social networks. On the very few occasions when this occurred 
and was identified (either by me or by a potential participant), the participant was given 
the opportunity to withdraw. When interviews proceeded, additional reassurances 
regarding confidentiality and anonymity were provided. 
 
3.11 My subjective position within the thesis 
Throughout the process of undertaking this thesis, I have been cognisant of my 
subjective position within it, as a gay (queer) man; as someone with a former career as 
an HIV health promoter; and as an HIV prevention activist. While I make reference to 
both my former career (in the Integrating Statement) and my sexual orientation (in 
respect to the ethical approach I undertook), further consideration of my position, and 
the influence of that position on the research is worthy of acknowledgement and 
discussion. 
 
Given that background, my research area and my desire to produce research that 
influences policy and inspires change is inevitable. Despite Green and Thorogood’s 
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(2004) categorisation of such a research approach as being that of “the radical”, I started 
this research being broadly skeptical of bio-medical approaches to HIV prevention, even 
when they are so entwined with behavioural approaches. As long ago as 2003 I was 
“broadly supportive” of more research into PrEP (Allen, 2003) but held a healthy 
scepticism about PrEP long into the research process of this thesis. Indeed, undertaking 
this research heavily influenced my policy and practice analysis: scrutinising 
international research and talking in-depth to MSM about the potential for PrEP 
radically shaped my HIV prevention activism, rather than that activism shaping the 
research. 
 
3.12 Summary 
This research study explored the acceptability of PrEP with MSM in London. A 
qualitative approach using semi-structured in-depth interviews was used, with 
interviews being conducted with 20 MSM. Men were recruited from an existing cohort 
of men who had previously participated in online sexual health research. The 
methodology was appropriate for the study as it allowed exploration of PrEP 
acceptability and potential future PrEP use with a view to guiding development of 
policy and practice for PrEP awareness and prescription, in relation to other HIV 
prevention strategies and policies. 
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Chapter 4: Results - How men manage their sex lives 
 
In this first results chapter I address the ways in which men in the study described the 
management of their sex lives. The places where men meet for sex, and how men 
encounter sex, are important factors in establishing the circumstances in which PrEP 
might be acceptable, or not, as well as where PrEP education might meaningfully be 
delivered. Understanding men’s account and narratives of the circumstances in which, 
and why, they have sex with and without condoms assists in contextualising men’s 
PrEP acceptability. Finally, men’s decisions relating to HIV prevention is unlikely to be 
singular (i.e. it will not be PrEP verses no prevention at all) and, as such, it is important 
to understand the context and value that other risk-reduction strategies hold for men. 
This first chapter is essential in contextualizing narratives of how men ‘do’ sex and how 
they manage risk in the current absence of routine access to PrEP. 
 
4.1 Settings where men encounter sex and planning for sex  
 
Research on MSM provides compelling evidence that the settings in which men meet 
for sex, or where men encounter sex, has changed over the past decade and a half 
(EMIS, 2013; Frankis and Flowers, 2005; Frankis and Flowers, 2009; Keogh and 
Weatherburn, 2000; Weatherburn et al., 2003). As is explored subsequently, whether 
men pre-plan their sex, or instead encounter sex more spontaneously, has implications 
for the relative acceptability of different PrEP methods. As such, it is important to 
understand how men in this study plan for and encounter sexual partners. 
 
Given that men were recruited to the original Sigma Research cohort online (from 
which this study recruited), and in some instances, through recruitment adverts in online 
gay chat and sex sites, it is not surprising that the majority of men reported using the 
internet to find sexual partners. While a small number of men reported that their 
primary means of securing sex was through sex on premises venues (such as saunas or 
sex clubs that are favoured by some MSM for the immediacy of sexual contact that they 
facilitate), and fewer still used cruising grounds or public spaces to engage in sex with 
other men, almost all of these men also used the internet as a way of finding sex. Only 
Jovan indicated that he preferred what he termed a more ‘old fashioned’ way of finding 
sex. 
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 “That’s it! I pick up men in the old fashioned way! It’s so easy. Give someone 
the eye. Give them a double take. I am very direct and I go up to them and say, 
‘Hey! Let’s get naked and fuck!’ or something of that nature”. (Jovan) 
 
Using the commercial gay scene (i.e. clubs and bars) for meeting men was far less 
common than using the internet and participants over 40, in particular, reported that 
their patterns of setting use had changed in recent years, with a decline in the use of the 
commercial scene. Issues around ageing, including the inability to converse in settings 
with loud music, contributed to older men’s reduced use of bars, whilst other factors 
included: the cost of going out; the dislike of being around men under the influence of 
drink or drugs; discomfort with being associated with (other) gay men; and, in the case 
of migrant men, a feeling of not being welcome. For one such man, the struggle of 
understanding the ‘codes’ of communication and cruising in bars had turned him off the 
commercial scene. 
 
“When I moved to England I found it very, very disturbing because no-one was 
coming to talk to me and I thought, ‘what is wrong with me?’ because I’m [a] 
very free guy, fairly attractive and suddenly no-one talk to me. I was like, ‘Urgh! 
What happened?’ ” (Marco) 
 
Broadly, clubs and bars (rather than sex venues) were viewed as settings in which to 
socialise, where men would meet with friends, rather than a place to ‘pull’. If sex 
happened, it tended to be opportunistic, rather than a man having an intention to ‘go out 
on the pull’. In some instances sexual encounters in bars and clubs would be facilitated 
using smart phone apps. 
 
The fifth of men who did not currently use, or no longer used, the internet for sex were 
put off by experiences of men who misrepresented themselves online or did not follow-
through with meeting up or the inordinate amount of time spent chatting and swapping 
photos only for the encounter to be postponed. For others, there was a concern about 
meeting someone they had never met before, either from a safety perspective or because 
they were not comfortable with having sex with strangers. However, most men’s 
narratives concerned the opportunities that the internet provided; enabling some men to 
facilitate sex with others without having to mix with other gay men, or because they felt 
they did not ‘fit in’ with the gay scene, or because they found the gay scene unsavoury. 
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For a quarter of participants the internet offered a sense of flexibility or convenience, 
when work, travel or other commitments ruled out the chance of using clubs or bars. 
However, the biggest opportunity of the internet was the immediacy of encounters and 
the ability to be spontaneous: men did not have to wait until a bar opened if they were 
feeling sexually aroused but could log online.  
 
“It’s a lot easier to go online and have someone over within 15, 20 minutes, 
rather than spending 2 hours looking at someone out the corner of your eye!” 
(Martin) 
 
Smart phones have further enhanced this sense of immediacy, allowing men to secure 
sexual partners while in motion, travelling around the city, or simply in quiet periods 
throughout the day. Operating though ‘apps’, smart phones allow for users to create a 
profile, often with photographs, that describe the user’s sexual preferences and the 
activities they are seeking. Most are geo-specific, allowing users to connect with others 
in their immediate geographical vicinity. For Alex, a smart phone meant that he no 
longer sat in front of his computer ‘for hours. And hours. And hours’ as he could pick 
up men as he travelled around, using his phone. For Javi, being able to encounter men 
passing through his neighborhood, meant he no longer had to deal with the ‘time 
wasters’ who would chat online for hours, and then say it was too far to travel to meet. 
 
“They tend to happen more on the street, literally on the corner and we say 
‘come over’ and he says ‘yes’ and then he comes over. That is the way that most 
of that happens”. (Javi) 
 
The majority of men who used the internet to meet men for sex used it for immediate 
sex, driven by the convenience and immediacy, rather than to facilitate pre-planned sex 
in the future: to meet a need now rather than to fulfill a future need.  
 
“I was in my hotel room last night and somebody was 3 floors down and it was, 
‘am I coming to your room or are you coming to mine?’ and it’s ur ..,. it’s that 
easy!”  (Colin) 
 
When men did use the internet for planning sex ahead, they were more likely to do so 
with men who they had already established a connection with – that is, men they knew 
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or who they had previously hooked up with and who they trusted to follow-through on 
their agreement to meet for sex.  
 
In summary, this data confirm the findings of contemporary research amongst MSM on 
the use of settings to meet men for sex: that increasingly men find their sexual partners 
online, and men see that this as an opportunity. Along with this, many men’s sex is 
spontaneous rather than planned and, when it is planned, is frequently with men they 
have previously met or encountered. GPS based phone apps facilitate this spontaneous 
sex, allowing men to have unplanned encounters more frequently. As will be explored 
in the following chapters, the ability to increasingly have unplanned sex had 
implications for how acceptable men considered PrEP to be, and how this judgment 
varied according to the method of PrEP delivery. 
 
4.2 HIV Testing: frequency and rationales 
Having considered how men plan for and encounter sex, and the potential implications 
for PrEP acceptability, this section considers the role that HIV testing plays in men’s 
risk analysis. Not only did participants use HIV testing to inform future decisions about 
sex, but more often men use testing to reassure themselves of their HIV status following 
a particular sexual activity or risk period. Understanding how men test and their 
rationales for testing, are important considerations in PrEP acceptability: not least given 
the necessity of regular testing in PrEP regimes. 
 
Almost all the men had an established routine of testing, influenced by either number of 
partners, the type or amount of sex they had had since their last test, the duration of time 
since their last test, or a combination of these. A small number of men used birthdays, 
anniversaries or regular time-based events as reminder, with tests being undertaken at 
these milestones, regardless of the amount of sex, partners or risk that had occurred 
since the last test was taken. Others tested with greater regularity, such as every three to 
four months, but would test more frequently if there were cause to do so, such as 
symptoms of STIs, or there had been an incident that had concerned them.  
 
Around a third of men tested entirely outside of a frequent time-based routine but rather 
only did so following an episode of sex that occurred which they felt warranted a test, 
such as condom-less sex with a partner of unknown HIV status. In these instances, an 
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HIV test was retrospectively checking back on an incident that had occurred in the past 
- a desire to ‘be on the safer side’. 
 
“ [Unprotected sex] just ended up happening. And I thought … I’m probably 
OK but I just want to double check … um … I just want to make sure I’m OK … 
and that’s why.” (Philip) 
 
For a smaller number of men, taking an HIV test was (also) prospective and was used as 
part of the forward planning for (unprotected) sex.  This was used to inform decision-
making around sex in longer-term relationships to establish HIV sero-concordance with 
a partner, but also used to inform decisions about condom-less sex with some casual 
partners. 
 
“It wasn’t because I suspected anything bad, no. At that time I actually had a 
friend coming from [name of country] and he was going to stay for a month and 
he was saying ‘can we have sex? Can we go without condoms?’ and I was 
saying ‘OK but only if we do the tests right now’ … so yeah … that was part of 
the timing, why.” (Francis) 
 
A narrative reoccurring throughout the majority of men’s interviews was the sense that 
regular HIV testing was an important part of a man’s health. Testing was portrayed as 
the right thing to do, a sign of being responsible to maintain one’s own health and 
wellbeing, with testing being normative, and easy to do. Overall, however, men’s 
decisions to test were rational and pragmatic, based on frequency of sex, partners or risk 
or duration of time since the last test. Given recent drives to increase men’s frequency 
of HIV testing and knowledge of status (Yin et al,. 2014), these results highlight the 
centrality of HIV testing in contemporary HIV prevention, within key groups of MSM 
(Witzel et al., 2015). They also indicate the extent to which men use testing 
pragmatically, and sometimes imperfectly, to limit the likelihood of them acquiring 
HIV.  
 
4.3 Men’s explanations and accounts of sex without condoms  
In order to understand the potential impact of PrEP use on men’s perceived risk taking 
and sexual negotiation, it is important to frame PrEP within the context of men’s current 
risk taking and their accounts of SWC. Exploring how men contextualise risk-taking 
within their sexual lives assists in framing if and how PrEP might contribute to men’s 
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perceptions of, and response to, risk – for themselves and their sexual partners. Given 
the criteria of the study’s inclusion, all participants had had SWC on at least one 
occasion in the year prior to interview, and were asked to describe their most recent 
episodes of SWC. While for a few, sex without condoms was a simple matter of not 
being able to establish or maintain an erection while using them, for others complex 
psychological and inter-personal factors influenced their ability to utilise condoms 
effectively and consistently. Their narratives fall broadly into two categories: those of 
control, consent and pressure (forces external to the individual); and those that relate to 
perceived personal and psychological mechanisms, including that which men simply 
considered inexplicable.  
 
4.3.1 Control, consent and pressure 
A common theme related to men’s (in)ability to cease sex without condoms during 
moments of sexual arousal. This was especially the case when the other partner (rather 
than the man being interviewed) was instigating or suggesting the condom-less sex. 
Around a fifth of men spoke of being pressured into having SWC, including instances 
of condoms being removed prior to insertion, or during anal intercourse. 
 
“That struck me as a particular incident because I was saying ‘hey condoms’ 
and he was saying ‘hell no’ and in the past couple of years that has happened to 
me twice. There was one occasion when someone actually pulled the condom off 
and tried to shove it in me. Um … That really weirded me out too much.”  
(Francis) 
 
Building on the issue of control, four men recounted the role that drugs or alcohol 
played in their sexual decision making, often combined with being on holiday, or away 
from home for work of pleasure. In these circumstances, men described situations when 
drugs or alcohol adversely impacted upon their perceptions of risk, or their capacity to 
respond to and to be in control of risky situations. In two instances, men recounted how 
being away from their home environment provided a setting where more drugs and 
alcohol could be consumed than usual (in part because they did not have to be at work 
the next day) and where those drugs facilitated types of sex that they would not 
otherwise indulge in.  
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These notions of control were not restricted to any one group of men but were more 
common in younger rather than older participants. Situations when participants 
struggled to control their sexual safety most commonly occurred when sex took place 
with men that participants were unfamiliar with or when an agreement had not already 
been established about condom use. In these circumstances, the pressure exerted to have 
SWC was obvious. However, one participant, who occasionally sold sex, recounted how 
clients regularly attempted to pressurise or coerce him into having SWC in a more 
covert way. Despite agreements about condom use being established prior to meeting, 
he recounted the occasions when men would start with condoms, before removing them 
part way through sex, and, on some occasions, would then attempt to ‘bargain’ a higher 
payment for condom-less intercourse. 
 
4.3.2. Psychological rationales and personal values 
What might be termed ‘psychological’ explanations for SWC were provided by one-
third of the men, who felt that issues such as low self-esteem and depression had 
negatively impacted upon their ability to negotiate condom use in the manner they 
would prefer. For one man his (regular) condom-less sex was explained as ‘an element 
of self-destruction’ linked to challenges with depression and doubts regarding his self-
worth. Three men indicated that SWC was enticing for them because it was 
transgressive, or was about breaking the rules or was seen as taboo or, in Javi’s case, 
forbidden. 
 
“I don’t want to be infected and that sounds crazy because I really shouldn’t be 
exposing myself but I really get off on unprotected sex, probably because it’s 
forbidden. It’s so bizarre. It’s so fucked up.” (Javi) 
 
For two of the men, the calculated risks they took were informed by considered views 
on what it is like to be diagnosed with HIV in the twenty-first century. Both had had 
partners with HIV and both were well informed about the impact of an HIV positive 
diagnosis. For Marc, having lived through a history of HIV, his reasons for reducing 
condom use were based upon a framework of understanding risk that, for him, was clear 
and rational: 
 
“I guess at 45, I know a lot of people who are HIV positive and healthy, and the 
last thing I want to do is get HIV … I don’t know a single person aged 45 who 
has died of Aids … I’ve got friends who died in car crashes … from cancer … a 
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brain hemorrhage … do you know I don’t know a single person who has died of 
Aids and to be 45 and have been actively gay since my early 20s is … you know, 
I grew up in the eye of the storm. I was 17 and I remember thinking I knew I 
fancied guys but there’s no point pursuing it because I’ll start seeing other guys 
and I’ll get Aids and I’ll die … and then the whole 80s things and then the 90s 
… and to be honest with you I’m just bored of condoms too. It’s been twenty-five 
years. You know what I mean? It’s got to the point now when you think the risk 
is lower and that’s part of my thinking. I’m bored with condoms. I’m bored with 
the whole thing … the risks are lower.” (Marc) 
 
For Marc, the reality of HIV in the twenty-first century had shifted his perception of risk 
and the appropriate management strategies. With the passing of time, and decreases in 
HIV related morbidity, the attention paid to the risk of infection was subsumed by other 
more pressing personal factors, such as pleasure or desire. A few men could be frank 
about how concerns regarding pleasure consciously informed their risk management, 
while others talked of more implicit, subconscious processes that appeared to guide 
their behavior ‘in the heat of the moment’.  
 
“Yeah, I have [had unprotected sex]. More by accident than by design. I was in 
a sauna with a guy. Started pawing around… tries to shove me up his butt … um 
… and I was like ‘calm down’ and reached for [a condom] and he was like ‘you 
don’t need to’ and sat down … and there comes a point when you don’t want to 
stop.” (Francis) 
 
Over half of the men interviewed simply felt that the condomless sex they had ‘just 
happened’. It was not pre-planned or negotiated in advance, but took place in the ‘heat 
of the moment’ for reasons that could not be easily articulated but largely appeared to 
relate to a dominance of sexual desire over cognitive risk appraisal. In describing their 
risk encounters in such a way, men were drawing upon commonplace and widely 
accessible discourses of risk-taking that, they believed, did not require explanation.  
 
A number of men highlighted the conflicting nature of their sexual activity verses the 
types of men or sex they were seeking: men who were actively seeking unprotected sex 
were avoided; yet unprotected sex was (subconsciously) sought. This played out in a 
complex dance of ambiguity between desire and ambition: avoiding men seeking SWC 
but actively seeking, or hoping for, SWC. 
 
“It’s a very conflicted line because I’m finding that protected sex I don’t enjoy 
any more, if doesn’t turn me on, I can’t really perform. It’s not something I find 
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myself wanting to pursue and if I get talking to some relative stranger and they 
are like ‘hey, let’s bareback’ that turns me off because it tells me they are far too 
casual about it and if I get talking to someone who is like ‘I never bareback’ that 
turns me off because I know I’m never going to have a good time. So … there is 
no middle road between someone who never bare backs does and someone who 
does.” (Louis) 
 
For most of the men whose SWC with irregular partners was not pre-planned, the sex 
was regretted, and sometimes, but not usually followed by discussions about HIV status 
and concerns related to sero-conversion with the man the SWC had occurred with. 
 
In summary, in attempting to explain their experience of SWC men acknowledged that 
their reasons are complex, often not static and can change over time. Men’s 
explanations for SWC are just that: their own explanation (and sometimes justifications) 
for their sex, that are likely to be far more complex than summarized here or articulated 
in a relatively short interview. However, how men account for their SWC offers 
interesting implications for potential PrEP use and acceptability. Whilst the potential 
implications for those offering physiological explanations might be easier to 
comprehend (“PrEP might enable me to get an erection and ejaculate”) those offering 
psychological justifications offer more complexities: if a man’s rationalisation for SWC 
centers on a desire for risk (consciously or otherwise), or transgression, to what extent 
would PrEP offer any attraction?  
 
Having explored men’s explanations and accounts of SWC, the chapter moves on to 
explore how men manage their HIV risk in reality through a process of shifting and 
sometimes complex risk reduction strategies.  
 
4.4 Reducing risk – strategies and complexities  
To understand if and how PrEP might be used by men to manage the risk of acquiring 
HIV, it is important to understand men’s current strategies for reducing risk during sex: 
how they are successful; how they are challenging; and if or how PrEP might be 
integrated into the management of risk in their sexual lives. As might be expected, 
men’s strategies of risk management are complex, multi-faceted, and are often 
situational: with regard to the types of partners men are encountering; where sex is 
happening; and the type of sex that is taking place. 
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Two or three participants each mentioned one or more of the following strategies that 
they believed helped to reduce the risk of acquiring HIV: the age of their sexual partner 
(i.e. younger men were seen to be less likely to have HIV); avoiding sex altogether with 
known HIV positive men (i.e. ‘sero-sorting’ their sexual partners); taking into 
consideration the types of settings that other men use for sex (e.g. avoiding sex with 
men who use saunas or sex on premises venues – perceived as frequented by a higher 
proportion of HIV positive men); the duration of sex (shorter periods less likely to result 
in HIV exposure); and reducing the numbers of sexual partners, and thus the probability 
of having sex with a risk of HIV transmission. While these approaches may decrease the 
likelihood of acquiring HIV to a certain extent, these strategies tend not to be actively 
promoted as risk-reduction approaches for MSM within the field of sexual health 
promotion (although some community organisations have encouraged men to reflect on 
duration of intercourse and their turnover of sexual partners).  
 
However, more commonly mentioned strategies were: (1) considering the viral load of 
an HIV positive partner (as a HIV positive man who has an undetectable viral load is 
less likely to be infectious): 
 
“One guy in particular … I knew he was HIV positive … [and] he was really, 
really clued up on his treatments and … so him putting his cock inside me 
without cumming seemed that the risk was minimised and he seemed to know 
what he was talking about. So yeah, we had that conversation.” (Duncan) 
 
(2) Considering the modality of intercourse (an insertive partner is less likely to become 
infected); (3) withdrawal prior to ejaculation during anal intercourse;  
 
“To be honest if I’ve gone to the stage when I’m having anal sex with someone 
without a condom then I’d expect for them to cum in me … and I find it 
wonderful … and the only time when I’ve stopped it is when I hadn’t intended to 
have sex with someone without a condom … and we started and I’d pushed them 
to stop.” (Mattie) 
 
(4) Limiting sex without condoms to regular or known partners (whose HIV sero-
concordance they feel surer of); and (5) discussion of HIV status prior to intercourse (an 
active form of sero-sorting for both HIV negative and undetectable HIV positive men). 
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“If I’m talking to a guy online I’ll tell him I prefer bareback sex … I’m fairly 
relaxed about it to be honest … I’ll tend to say, what do you prefer sexually, I’m 
negative. If he’s negative and tested then I’ll have bareback sex with him … and 
if he’s positive and undetectable … that is generally the same … the same thing. 
If he doesn’t know that will go for me in the dangerous corner … I’d rather 
someone said he was positive. Doesn’t know is kind of the worst one for me 
because it means they don’t know. They don’t care.” (Marc) 
 
These strategies were not used by all men or at all times, but rather were determined by 
the unique factors within the sexual setting, including their desire for different sexual 
acts (such as being receptive or insertive during anal intercourse) or what they felt might 
be efficacious in terms of risk reduction with particular partners. For example, many 
men were distinctly uncomfortable with the notion of withdrawal prior to ejaculation 
with men known to be HIV positive:  
 
“I wouldn’t let a guy who said he is positive cum in me. I just wouldn’t do that. 
Um … because that is obviously the maximum level of risk and I just wouldn’t 
go that far.” (Duncan) 
 
Participants also frequently made a distinction between the kind of sex they might have, 
and the risk reduction strategies they might use, with romantic or otherwise regular 
partners compared to casual ones. Almost half of men discussed the type of sex they do 
or have had with regular or monogamous partners as a risk reduction strategy in and of 
itself. This included restricting all sex or SWC to one or a few regular partners; or being 
in a (sero-discordant) monogamous relationship. In some instances, men described a 
continuum of sex that started with a regular partner and lead to SWC, followed by a 
discussion about HIV, and going for an HIV test, once there was a realization that the 
relationship was steady. 
 
“We started off with oral sex but I wanted to take it a bit further. Basically I 
wanted to swallow. So that’s when I asked him, that I’d love to do it for you but I 
need to know that you are OK. And that’s how we discussed and actually had 
unprotected sex and I fancied him … fancied feeling him inside me … and that 
was before the HIV test.” (Yan) 
 
Discussion of HIV status also played a role in risk management for men not in regular 
sexual partnerships. Four men discussed how HIV status would usually be discussed 
prior to meeting, with mention of how websites facilitated such discussion, by enabling 
men to state HIV status in their profiles. However, disclosure of HIV status was not 
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always a determining factor in deciding whether to have SWC, again often with other 
risk reduction strategies coming in to play. Other men used post-hoc discussion of HIV 
status or discussion during sex either to reassure them that the sex was ‘safe’, and this 
might lead them to altering or ending a particular sexual activity. Almost all mentioned 
the fallibility of these approaches either because they thought that men could not be 
trusted to tell the truth, or because they understood the unreliability of men being 
uninfected after their last previous HIV test. 
 
“When you both have that discussion of ‘you are clean aren’t you?’ … um … 
and last time I was but there aren’t any guarantees and the same with him as 
well. I’m not stupid but it doesn’t stop me.” (Colin) 
 
Almost all participants had recognised that their sex was potentially exposing them to 
HIV. That is, that their risk taking was cognisant. Much has been written about how 
cognisant risk takers understand and manage their risk, albeit imperfectly (Henderson et 
al., 2001; Keogh, 2008; Grov et al., 2015). But for a man to manage HIV risk, he needs 
to be able to make an appraisal of that risk. For three participants, the shortcomings of 
risk appraisal, made it harder for them to employ sophisticated risk reduction strategies 
because they failed to understand that their SWC might be sero-discordant. Such naïve 
risk takers pose particular challenges for HIV prevention in general and PrEP health 
promotion in particular. This issue of naïve risk taking is discussed further in Chapter 8. 
 
Each of these post-hoc rationalisations of how men manage risk during SWC provides 
further understanding of why and how men might find PrEP acceptable. The continuum 
of risk strategies utilised by men, especially with regular or monogamous partners, 
provide particular opportunities for PrEP acceptability and use. Using PrEP at the start 
of a relationship potentially adds to that continuum (start with PrEP; test; negotiate; 
move to SWC) or, as seen with men in known sero-discordant relationships, adds to the 
continuum at a later stage (for example, start with sex with condoms; move to PrEP). 
Such patterns of PrEP use, alongside other risk reduction strategies, that shift according 
to relationship status, or other situational factors, including men starting, stopping and 
re-commencing PrEP use, is being reflected in PrEP demonstration projects (Grant et 
al., 2014; Liu et al., 2014). 
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It is telling how imperfect each of the strategies described by men is and the uncertainty 
that exists for each. In section 4.4.2 below, how men might use PrEP alongside these 
risk reduction strategies is explored, along with how PrEP might assist in removing that 
uncertainty. How participants have considered or utilized another bio-medical 
technology to reduce post-risk uncertainty is explored as a further HIV risk reduction 
strategy. 
 
4.4.1 Post exposure prophylaxis (PEP)  
PEP is the only existing bio-medical prevention technology currently available to 
reduce HIV transmission for uninfected individuals in the UK.  While most other risk 
reduction strategies in this section may be pre-determined (or at least used at post-facto 
rationales to suppress the association of risk), PEP is the only method that is usually 
only considered after an event of recognised risk taking. PEP is 28 day course of anti-
retroviral tablets taken within 72 hours of exposure to HIV and has been available on 
the NHS for over a decade. Although its use is relatively uncommon, increasing 
numbers of MSM have accessed it (EMIS, 2013), following sexual exposure to HIV (or 
assumed exposure). Men in this study were asked about their knowledge and use of 
PEP, not only with regard to a post-hoc risk reduction strategy, but how knowledge or 
attitudes to this existing technology might shape men’s views and attitudes to future 
technologies, including PrEP. 
 
Almost all participants had heard of PEP and their knowledge about PEP was generally 
high, with their opinions of it largely shaped by other men’s accounts of using it. When 
men had heard of PEP and considered using it, but not sought it (around half of 
participants), their reasons generally surrounded a perception that their risk had not been 
sufficient to warrant taking it, or they had been medically advised not to take it. A small 
number of men were also concerned about availability of access to PEP; raised concerns 
about its effectiveness, or side effects; were concerned about being judged for accessing 
it; or had decided that it was not the right time to take such medication. Five men had 
accessed PEP and taken it, three of those men described negative experiences of being 
on PEP, and two of these felt that the side effects reduced the likelihood that they would 
seek PEP again in the future. These men’s narratives of taking PEP, and their mostly 
negative experiences of it, chime with those that the men who had considered PEP, but 
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not taken it, recounted from their peers: that the side effects of PEP outweigh the 
potential benefits of being on it. 
 
“I’ve heard that the side effects can be really horrendous and you have to do it 
for a month or something. I had a friend who did it and he was sick every day 
and he just felt so ill. And so I thought … well … I’m not willing to put myself 
through that for something that is actually … when I talk about high risk … is 
still hundreds if not thousands to one against that I’ve been infected.” (Duncan) 
 
These findings are illuminating with regard to men’s knowledge of currently accessible 
prevention technologies. Not only does this indicate the source of men’s PEP 
knowledge (other men and peers), it indicates that men’s views of PEP are informed and 
influenced by other men’s PEP experience. That is: men are put-off accessing a 
technology that is almost wholly influenced by a narrative that describes PEP as 
unpleasant, and that side effects seem to have been rarely mitigated or reduced by health 
professionals prescribing PEP. That almost all participants had a reasonable knowledge 
of PEP demonstrates the capacity to promote biomedical interventions to key at-risk 
communities.  
 
4.4.2 The potential impact of PrEP on risk reduction strategies 
Looking across the range of currently available HIV risk reduction strategies, it is 
evident that men chose different strategies, at different periods of time, and during 
different ‘seasons of risk’ (Newman, 2015a); the concept that periods of risk are not 
constant and consistent and may move through ‘seasons’. As will be explored further in 
Chapter 5, different PrEP methods might be used by men during those different seasons 
of risk, thereby expanding and drawing on the strategies that men are already 
employing, As such it is likely that PrEP will build on and develop existing risk 
reduction strategies, rather than create entirely new ways of managing risk. 
 
However, for risk reduction strategies to be utilized, men need to recognize the potential 
risk of HIV exposure. Whilst almost all of the participants in this study recognized that 
they were engaging in some level of HIV exposure risk (even if that risk was 
underestimated), a very small number of men, failed to recognise that the sex they were 
having might be sero-discordant. The challenges of PrEP use, and indeed other risk 
reduction strategies, for naïve risk taking men, is explored in further detail in Chapter 8. 
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Most participants recognised the imperfections of their current risk reduction strategies, 
and that they frequently offered uncertainty – one of the dimensions of men’s post-hoc 
HIV testing. It is worth considering if one of the attractions of PrEP might be the 
increased certainty that PrEP might offer, when used alongside or instead of other 
strategies. 
 
4.5. Chapter summary  
In this chapter I have addressed participant’s narratives about how they manage their 
sex lives: how sex is sought and encountered; how HIV testing is used to manage pre- 
sex decisions and to offer post-sex reassurance; and how a range of risk reduction 
strategies are drawn upon to mitigate HIV risk. The fallibility of these strategies has 
been addressed, including that of HIV testing, and knowledge of status, and have 
highlighted how men need to be cognizant of their HIV risk to most effectively draw on 
these strategies. Whilst most men understand and are cognisant of the risks they are 
taking, albeit if their management of risk is imperfect and offers uncertainties, a small 
number of men – naïve risk takers – do not, or do not want to, recognise the risks they 
are taking and, as such, do not appraise that risk or modify their strategies accordingly. 
Such naïve risk taking offers particular challenges to the uptake and acceptability of 
PrEP. 
 
In the next chapter, the way that PrEP could be positioned in men’s lives is carefully 
examined.  
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Chapter 5: Results - Positioning PrEP in men’s lives 
 
In this second results chapter, participants’ immediate considerations regarding 
willingness to use daily oral PrEP is considered and their understandings of the 
perceived impact and utility of PrEP. This is contexualised through men’s narratives of 
sex and risk, intimacy, opportunity and pleasure. The reporting of this first initial 
discussion of willingness to use PrEP focuses on daily oral PrEP and then moves on to 
address other PrEP methods, including acceptability dimensions that are unique to 
particular PrEP methods. The chapter moves on to examine the centrality of PrEP 
efficacy in how men consider PrEP, before concluding with an exploration of how men 
might navigate or negotiate their own and other men’s PrEP use.  
 
5.1 Knowledge and initial reactions to PrEP 
In this first section, participant’s knowledge of, and their initial reactions to, PrEP are 
examined. While further exploration of concerns, potential challenges and possibilities 
occurred later in the interviews, men’s initial thoughts on (oral) PrEP, including their 
willingness to utilise it were enlightening. In the section that follows participants reflect 
where they are now in relation to their PrEP knowledge and use, as opposed to where 
they might be in the future.  
 
5.1.1 Knowledge of PrEP  
Participants were asked if they had ever heard of PrEP, to recall the source of their PrEP 
knowledge and to describe what they knew. If they had not heard of PrEP, the 
technology was described to them, and they were asked again if this was something they 
had heard of.  
 
The responses obtained demonstrated significant variation in men’s prior knowledge of 
PrEP and the manner in which this knowledge was obtained. While a small proportion 
(around a quarter) had what might be considered an in-depth knowledge of PrEP, in that 
they had deliberately accessed and digested information about it from sexual health 
clinics, journal or media articles, around half of the remainder had only a basic 
understanding. Often this amounted to perceiving PrEP as “like a contraceptive pill” 
(Colin) or a vague understanding that PrEP could allow sex without condoms. Many 
had drawn understanding from global news coverage of the topic (in both gay and 
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mainstream media), while others had discussions with friends or were simply informed 
by their involvement in the Sigma Panel. Only four participants said that they had never 
heard of PrEP and could not recall ever hearing about it when prompted.  
 
Crucially, men’s knowledge of PrEP appeared intrinsically linked to their proximity to 
HIV: men who had a primary partner with HIV, or who had knowingly had condom-
less sex with an HIV positive partner, were more likely to know about PrEP in general, 
and more likely to have a detailed knowledge of PrEP. Such men were more likely to 
have had conversations about PrEP or have sought out further information. Conversely, 
men who considered they had less proximity to HIV (even if an objective assessment of 
their sexual behavior suggested this may not be the reality) were broadly less 
knowledgeable about PrEP.  
 
5.1.2 Potential PrEP use  
The key headline findings of the iPREX trial were presented to participants (see 
Appendix 6), with an opportunity for discussion and questions about the study. They 
were then asked, on the basis of this information, if they would consider taking daily 
oral pill to prevent HIV infection, if such a technology became available in the UK. 
These initial views on potential PrEP use relate only to daily oral PrEP and reflect 
participants’ initial perspectives on potential PrEP use. As will be seen later in this 
chapter, men’s views about PrEP use tended to become richer and more detailed as they 
were presented with details about different PrEP methods and when participants had 
further opportunity to consider a concept that was new to many of them. Participant’s 
perceptions of other PrEP methods are reported below. 
 
One man was already accessing PrEP independently (not through a clinical trial) and 
another had previously sought PrEP through his sexual health clinic and responded 
favourably to taking, or continuing to take, a one-a-day pill. Five further men 
immediately responded that they would want to take PrEP in this format, even if they 
some had reservations about it (see below).  
 
“Would I use it? Um … I personally would personally. Probably. Absolutely!” 
(Francis) 
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Over one quarter of participants said that they would not consider using a daily pill at 
this time, either because they thought that their risk was currently insufficient or 
because they did not want to use a medication that they felt was not needed by them.  
 
“I don’t think I’d want to put a drug into my system that I don’t necessarily 
need. I wouldn’t feel comfortable taking something when it isn’t really 
something I need, I guess.” (Ed) 
 
One man raised an immediate concern that PrEP might be protective against HIV but 
not other STIs and another raised concerns about his potential elevated risk taking on 
PrEP (see below). Most of these men described how they might consider using PrEP in 
the future if either their circumstances, or availability of information or evidence about 
PrEP changed. 
 
However, as many participants felt that a one-a-day pill would be something they would 
currently consider but they would want to weigh up any possible consequences of 
taking the daily pill, or wanted to consider further information about taking daily oral 
PrEP. Especially for men who had little PrEP knowledge, they would want to explore 
the concepts and potential risks of taking PrEP. Two of those men raised initial 
concerns about possible elevated sexual risks that they might take if they were using 
PrEP, either through decreased condom use or by switching the modality of the SWC 
they have. For each of these men, thought was given to how they currently manage 
sexual risk, and their ambiguity towards PrEP was balanced and played out against that 
current risk management.  
 
A decision to take PrEP in the future was also considered circumstantial – depending on 
relationship status; if one increased sexual activity or had more SWC; and if a man 
started to date or have sex with a known HIV positive partner.  
 
Men were also broadly more likely to hold more positive views about PrEP, and its 
potential, and sometimes its downsides, if they had closer proximity to HIV. It is worth 
noting that being proximate to HIV, in and of itself, might not necessarily lead to 
greater acceptability of PrEP. Although this research did not interview men with 
diagnosed HIV, research suggests that some people with HIV raise not insignificant 
concerns and doubts about PrEP use (Saberi et al., 2012; Frankis et al., 2014) that might 
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impact on negative peer and partner views of PrEP. As Chapter 6 will show, HIV 
positive peers and partners of men I interviewed were believed to have broad and 
disparate attitudes to the acceptability of PrEP.  
 
From the accounts in this study, we can surmise that men that have been, or could have 
been, involved in HIV exposure, are broadly willing to consider using a daily pill to 
prevent HIV. One-third of men in the study said that they would currently not consider 
using PrEP, with a further third of men considering PrEP a possibility, and one third 
saying that they would take PrEP now, if it became available. These levels of 
willingness to consider using PrEP are broadly comparable with existing community 
surveys and studies that indicate that around a half of MSM surveyed would consider 
using PrEP (Aghaiz et al., 2012; Frankis et al., 2014; Sigma Research, 2011; Thng et 
al., 2012; Young et al., 2013).  
 
5.2 Perceived impact and utility of PrEP  
Interview participants were asked to describe the perceived potential impact of PrEP on 
their lives (and the actual impact of PrEP use for the one current PrEP user). 
Participant’s narratives can be broadly divided into two (over lapping) themes: the way 
in which PrEP may influence sexual behavior and risk-taking; and the experience of 
intimacy and pleasure within sexual relationships and the opportunities this may afford. 
These are explored in turn below, with further detailed narrative on the interpersonal 
impact of PrEP on sex and risk management in section 5.6 
 
5.2.1 Sex and risk  
Significant lengths of time were spent within the interviews considering how PrEP 
might impact on the type of sex men have. If discourse did not arise naturally then 
participants were directly asked to consider how PrEP might impact on their existing 
risk reduction strategies. Three men articulated that they were fairly confident that PrEP 
use would not have an impact on their condom use. Javi felt that his current level of risk 
would not change because the potential reduction in risk from PrEP was not sufficient 
and Jovan said that he was content with his current risk levels and could see no reason 
for changing it. And Alex thought that although he might be more relaxed about the sex 
he would have, he did not perceive any likely fundamental changes. 
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“No. I don’t think so. No, I don’t think I would. I think I might be slightly more 
relaxed about it but not like ‘great, I’m on PrEP let’s go and get bare backed by 
40 people or whatever”. (Alex) 
 
However, half of participants said that they were certain or fairly confident that PrEP 
would reduce the occasions when condoms were used during anal intercourse. For one 
man, this made PrEP totally unacceptable for him, as it would result in levels of risk 
that he was not happy with. 
 
“I doubt I would do it purely because it would change the risk assessment of 
things I would do. It would make me more inclined to take more risks with 
unprotected sex.” (Jos) 
 
Two thirds of participants raised the potential increase in exposure to other STIs as a 
consideration of PrEP’s acceptability to them personally. Almost all of these 
participants articulated that they thought availability of PrEP would lead to a population 
increase in STIs, although fewer men were so confident that this would be the case for 
them personally. Although only one man felt that potential exposure to other STIs made 
PrEP unacceptable to him, other men weighed up the benefit of PrEP verses the cost of 
potential STI exposure. Three men took a pragmatic approach and acknowledged that, 
for them, HIV was, as described by one man, “the big one”, and although STIs might 
increase, at least PrEP mitigated against HIV. 
 
“It would … at least rule some of the worst case scenarios out. I know I would 
still catch other serious STIs. But everyone you rule out is one you rule out, 
right?” (Francis) 
 
These men viewed the more common STIs as easily treatable with one man articulating 
that, given that PrEP might be most attractive to men who took risks anyway, STIs were 
inevitable whether men used PrEP or not. Other men – especially those who had 
previously experienced an STI – did not want to underplay the issues and were 
concerned that HIV might overshadow the implications of other STIs.  
 
“Um … the other thing is … it would be eminently stupid just to take that tablet 
[without thinking about other STIs] because there are a lot of things you can 
get. You can get pills for almost all the other things but anyone who has ever 
had a shot in the arse for syphilis never wants that again because it’s agony! 
And you know … you forget … HIV is the spectre at the feast but there are little 
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demons hiding under the table and good god I never want to have that again! 
That HURT! Um … I really, really don’t want to have that again.” (Colin) 
 
Others felt that using PrEP might present greater opportunities to reduce or diagnose 
STIs. One man argued that PrEP use would offer an opportunity to discuss PrEP 
generally and an opportunity to discuss if a partner might have other STIs.  For another, 
regular clinic visits for PrEP would help to reduce undiagnosed STIs, as there would be 
increased contact with clinical services. Still further, those men who saw themselves as 
the least risk takers - those who had SWC infrequently and/or only with regular partners 
- saw STIs less of a risk personally because their sexual practice reduced likely 
exposure.  
 
A few men raised concerns that, although their own condom use might not change with 
PrEP, other men’s would and this would lead to a population increase in STIs, therefore 
making him more likely to be exposed to STIs. 
 
“Well, personally I would be concerned. And this is great … you don’t want to 
contract HIV … but you don’t want to contract gonorrhea or syphilis either. But 
… I think those people who are happy to have something like this are not really 
concerned if they pass anything on to others.” (Yan) 
 
Two men raised the issue that increased exposure to STIs may increase their 
susceptibility to HIV transmission, even if on PrEP, or increase the viral load of an HIV 
positive partner. In general, men recognized that there might be a potential play-off 
between an individual or population HIV prevention benefit in prescribing PrEP, at the 
expense of a population increase in other STIs. For Roy, this highlighted the importance 
of ensuring that any PrEP awareness work was embedded within a broader sexual health 
and STI prevention framework. 
 
“That’s the million dollar question isn’t it? You’ve got things like hepatitis [C] 
that you can’t cure … so I think there would have to be an awareness or 
protection programme that says ‘yes, you’re protected against HIV but these are 
all the other things you need to think about.” (Roy) 
 
The risks of STIs that these men refer to highlights the extent to which condomless anal 
intercourse was held by some to be intrinsically risky. Ed articulated that in the context 
of PrEP being available he “probably would be a bit more blasé” about using condoms, 
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whereas Max considered that “the pretty impressive drop” in HIV acquisition on oral 
PrEP would probably result in less condom use for him personally and, therefore, 
greater ‘risk’ taking. For Colin, PrEP would give him more control over his sexual 
health, even if it resulted in using condoms less often. 
 
“This type of tablet enables you to take more control of your own sexual health. 
Would it make me take more risks? Probably. Certainly. Forget probably – 
certainly! If I was on holiday in [name of place] and had been taking this every 
day of the week I’d think ‘fuck it!’ and go in to [name of bar] of a night and … 
um … come find me in the morning with a mop, you know? That’s sort of what 
would happen.” (Colin) 
 
Generally, these men took a considered view that, although SWC might increase, the 
protective nature of PrEP would cancel out that (HIV) risk. However, some were still 
keen to mention their other risk reduction strategies, beyond condom use, and these 
might be incorporated into sex while on PrEP. Duncan felt that, as he had established 
that being a top (being insertive) carried less of a risk than bottoming (being receptive), 
if he went on PrEP he would “probably start doing that with complete gay abandon and 
not feel too guilty about it”. Other men felt that they would continue to discuss HIV 
status or viral load of partners; or would continue to employ other strategies such as 
withdrawal before ejaculation or considering modality of intercourse should they have 
SWC on PrEP. For Mattie, he would continue to employ a strategy of avoiding SWC 
with someone he knew to be HIV positive. In doing so he draws a clear distinction 
between sex with a theoretical risk of HIV exposure and sex where he knew he might be 
exposed to HIV. 
 
“If a guy told you he was HIV positive and you were taking PrEP, do you think 
that would change the kind of sex you have with him?” (WN) 
 
“No. No. I wouldn’t have unsafe sex with anyone if I knew he was positive. Um 
… I wouldn’t do it.” (Mattie) 
 
For two men, their consideration about whether PrEP would diminish condom use was 
tempered by consideration about adherence to PrEP. For Simon, there was a concern 
that he would not be sufficiently protected because of forgetting to take pills.  
 
“I don’t know is the answer. I don’t know how well I’d be at taking it every day 
and so I don’t know how it would impact on my sex life … if I’ve taken it every 
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day and then become paranoid that because you haven’t taken it and catch 
[HIV].” (Simon) 
 
Whereas for Yan, complete adherence and ensuring that he was fully protected by PrEP 
might well be the point when PrEP could have an impact on his sex life. 
 
“What if you were really adherent? Taking it every day and using it 
consistently?” (WN) 
 
“Hmmmm … yeah probably I would risk it … I would.” (Yan) 
 
“You think you would use condoms less often?” (WN) 
 
“Yeah. (But) I’m not going to turn into a complete bare backing slut! No! No!” 
(Yan) 
 
Yan’s response here perhaps sheds light on entrenched anxieties relating to prevention 
techniques that are reliant on a daily regimen, leading some participants to question or 
observe their own fallacies (a point which is re-visited in relation to intermittent PrEP 
dosing). 
 
Despite concerns by some men of the potential to increase their own, or a broader 
community sexual risk, participants also voiced the potential for PrEP to offer 
opportunity and pleasure. It is to this that the chapter now turns.  
 
5.2.2 Intimacy, opportunity and pleasure 
Over one quarter of participants identified that PrEP might have a positive impact on 
their experience of intimacy or pleasure, both highly valued aspects of sex among most 
of those interviewed. PrEP also might allow for the performance of different sexual 
acts, which may have been considered too risky previously. In addition to potentially 
overcoming some of the physiological barriers to sexual health management, men 
identified the potential for PrEP to open up opportunities for the sex they have, or who 
they have sex with. Philip could see the potential to have a relationship with a man with 
HIV if he used PrEP: 
 
“I do tend to like guys who are positive. Um and so … it could open up 
possibilities of having a relationship with somebody … because the whole thing 
is I want to have unprotected sex with my partner and that rules out sex with 
guys who are positive. This would make it an option.” (Philip) 
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Around a third of participants felt that PrEP might reduce anxieties or stress relating to 
sex, which would have a positive impact on their experience of it. For Francis, PrEP 
offered an opportunity for greater intimacy and a reduction in exposure related stress 
during sex with his HIV positive partner, which could have significant benefits for their 
relationship: 
 
“To go without condoms … that would be a pretty amazing thing for our 
relationship. It’s always been a stress that we’ve never been able to do that, that 
we’ll worry about it. And more likely that we’ll consider each other as sexual 
partners. It takes away the fear that he’ll infect me and that’s something we both 
have in the back of our minds. We’ve never been able to get that close in almost 
a decade and a half. [PrEP’s] a very, very significant thing, yeah.” (Francis) 
 
This was a view shared by a number of other participants in a primary relationship with 
an HIV positive partner who felt that at a very holistic level, PrEP could have a positive 
impact on their relationship and how they could feel intimate with others over the long 
term. For other men, PrEP could be seen as reducing anxiety during sex (that is, men 
could better enjoy sex knowing that they were protected) and post-sex, especially in 
circumstances when SWC was unplanned when men might be “less worried about 
having had a slip-up” (Mattie). Those men experiencing regular mental health issues 
that they associated with risky sexual behaviour also saw potential for using PrEP 
during periods of depression. 
 
“If I was in a depressive cycle and I was at risk … having that in my drawer 
would be a peace of mind … knowing it was there.” (Philip) 
 
A striking narrative for participants who felt that PrEP might offer more intimacy or 
pleasure, or that it might reduce stress, was less that PrEP might offer greater HIV 
protection, but that not worrying about HIV – or worrying less – might lead to better sex 
and a more healthy sex life in general. That men view PrEP within a broader context of 
holistic sexual health offers opportunities and challenges for how PrEP might be 
prescribed, and the contexts in which it is available. This is discussed further in Chapter 
8. 
 
In summary, participants gave an initial reaction to the perceived utility of PrEP that 
was carefully considered. For the half of men who considered that using PrEP might 
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increase the occasions when they had SWC, they understood that either within the 
context of the protective nature of PrEP (at least for HIV) or alongside their current risk 
reduction strategies. Others considered the impact of PrEP on sex and risk within the 
context of adherence and PrEP efficacy. Men’s views on PrEP and risk were broadly 
considered, often cautious and framed within their current knowledge of, and analysis of 
risk. As with the risk strategies reported, these considerations were sometimes 
overlapping and imperfect. What is telling is that despite contemporary discourse on the 
(negative) impact of PrEP on sex and risk (Garner, 2012; Stern, 2014b), participants 
articulated the potential opportunities for PrEP to increase opportunity, intimacy and 
pleasure, particularly in circumstances when men had a known HIV positive primary 
relationship. I return to this theme in Chapter 8. 
 
5.3 Perceived practicalities of PrEP use  
This section explores the acceptability of PrEP for this sample across a range of 
dimensions. These relate to practicalities that men often felt could have a significant 
impact on their daily lives. These relate firstly to the implications of repeated and 
regular clinical interaction (a likely requirement of PrEP prescription), and secondly to 
the regimens of pill taking and concerns relating to drug resistance. For each of these, 
men’s acceptability with regard to daily oral PrEP is explored first and, where men gave 
narratives that pertained to other PrEP methods, these follow. Whilst it is apparent that 
some dimensions of PrEP acceptability are shared across all PrEP methods, some 
dimensions are more unique to particular methods. For example, participants raised no 
method-specific acceptability issues regarding taking medications or drug resistance but 
particular acceptability dimensions for daily oral PrEP exist, as they do for methods 
other than daily oral PrEP. This is especially the case for topical PrEP and slow acting 
injectable PrEP and these unique dimensions are addressed below in the section titled 
‘Body, Lifestyle and Routine’.  
 
5.3.1 Considering the clinical interaction  
During discussions on the practicalities of the availability of PrEP, all but one 
participant raised the issue of where PrEP would be available and how it might be 
physically prescribed. Most acknowledged that such medication should be regulated and 
made available through health practitioners. Participants were asked if making regular 
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clinical visits, would be acceptable to them, or if this would be a disincentive to using 
PrEP. 
 
Three-quarters of participants responded that a monthly clinic visit, at least in the initial 
stages of taking PrEP, would be acceptable to them, and, for a quarter of men, this 
would be dependent on the proximity of the clinic, or the ease of access, including 
suitable opening times and swiftness of appointments. Four participants considered that 
monthly clinic appointments would not fit with their work patterns or lifestyles, usually 
due to travel and time away from home, and felt that quarterly visits would be more 
suitable. One man preferred the concept of quarterly clinic visits because he felt that 
more regular visits might increase his condom-less intercourse. 
 
“I think [monthly visits] would make me use condoms less – because if I was 
having an MOT every month and I knew if I was getting Chlamydia or 
gonorrhea or syphilis tests all at the same time then that would increase my 
likelihood of being unsafe. If I was 3 monthly then I think I might still have a 
little voice in my head about the other things. But monthly, I think I would pretty 
much feel invincible!” (Colin) 
 
For four of the men who favored regular clinic visits, there was an added benefit that 
they would get checked (more) regularly for STIs or for possible side effects or toxicity 
of PrEP. For these men, regular clinic visits incentivised PrEP use and made it more 
acceptable and they would be reassured by being seen regularly by a health 
professional. Interestingly, there was no difference in the acceptability of clinic visits by 
different PrEP method: a further quarter of men felt that regular clinic visits to have 
injectable PrEP would be acceptable, especially if such visits might be expected for any 
method of PrEP. 
 
“It’s an easy visit to a clinic. You get an injection and then off you go.” (Marc) 
 
However, one man felt that he would be more likely to miss an appointment for an 
injection, than he would be to miss a pill dose, due to work and travel commitments. 
The impact of travel was raised by two further men with regard to missing injection 
appointments.  
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5.3.2 Regimens and resistance 
Four men raised the issue of taking any pharmaceutical drug and how the overall 
acceptability of PrEP to them was tempered by their general dislike of using any 
medication.  
 
“I avoid taking medicinal drugs … even pain killers. I’ll take that only as a last 
resort”. (Philip) 
 
For two of these men, this was also balanced against the relative risk they were taking. 
That is: if their sexual risk was greater, they would be prepared to consider PrEP and its 
own (from their perspective) associated risks as a pharmaceutical.  
 
While two other men raised concerns about the possible interactivity of PrEP with the 
other daily drugs they were prescribed, more common were concerns about possible 
drug resistance emerging if PrEP was not taken correctly (including by other men on 
PrEP). Some expressed concern that this might limit possible future treatment options 
should they become infected with HIV, and how this might impact on the effectiveness 
of PrEP more generally in the future.  
 
“I’d certainly be worried about some of the long term effects that we don’t know 
about … There’s a worry there will be a massive change in the virus that makes 
this class of drugs useless in the future.  It’s already given to people as a 
treatment isn’t it so it’s possible that this virus can beat it. Um … so that’ a 
worry that the virus goes sideways on it and this particular version of PrEP is 
no longer efficacious.” (Francis) 
 
A few men understood the general principle that drug resistance was more likely to 
develop if people are not adherent to their medication and, indeed, concerns relating to 
regular pill-taking for daily oral PrEP were discussed by the majority of people. Over 
one third of men said that taking a pill every day would not be an imposition for them, 
especially as most were already taking a daily vitamin or supplement pill either or daily 
prescription medication.  
 
“Would I find it difficult to take a pill every day? Well … I would have to show 
you my cupboard. Come, please. You’ll have to describe it later. [Moves to 
cupboard and opens door]. Look at that! It’s ridiculous! I take a daily pill every 
day! If it’s laid out I just take another pill!” (Javi) 
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Other men felt that taking a daily pill would simply be the reality of something like 
PrEP, necessary to receive its benefits, whilst one man was surprised that the regime 
was, to him, so simple. 
 
Alex articulated a somewhat more complex reason for finding daily pill taking 
attractive; the process of taking a pill everyday might not only be protective against the 
sex he was currently having, but would also encourage regular reflection about the risk 
he is taking and how it feels about them. 
 
“By taking a pill everyday it’s kind of reminding you what’s at risk. It might 
actually make me more considerate of it. I think it’s easy to forget HIV 
sometimes … I think if that was a constant reminder every day – I have to take a 
pill, I have to take a pill – something in the back of your head might click in if 
you were getting in to a situation and you’d think ‘hang on a second: there’s a 
reason why I’m taking a pill. There’s a reason why I’m taking this … why this 
behavior might be risky … so let’s do something about it before engaging in it.” 
(Alex) 
 
A number of men found the notion of regularity in daily PrEP use particularly 
appealing. It was, they perceived, more likely that they could successfully integrate a 
once-a-day behavior into their routine – similar to showering or putting in contact 
lenses.   
 
“You know … it’s become something I do automatically. I have an alarm on my 
phone. I have an hour’s window. I have a couple of spare pills in my bag, you 
know. I take them when I get up. It’s completely automatic.” (Louis) 
 
Only one man raised concerns relating to control in relation to daily oral PrEP. Philip 
disliked the concept of PrEP being regulated and available only through medical 
professionals, articulating that the experience might be “degrading” and diminish his 
control over his health. As such, this would lead him to think twice about taking PrEP.  
 
“It kind of fits me into having to go and see someone to get it. It’s kind of like a 
[social security] benefit … the whole experience would be a bit tiresome and it 
can be a bit, you know, degrading as well, so I think that … it’s like some of 
those science fiction shows I’ve watched when the company owns the drug and 
you don’t get you next fix until you get what they say … it’s a bit like being 
controlled … you are reliant on someone else giving you the supply.” (Philip) 
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Further to issues of control, there were those who found other dimensions of a daily 
medication to be problematic including possible side effects as addressed in following 
section and the potential of forgetting to take a daily pill (as addressed above). The 
perceived (un)acceptability of daily pill taking influenced how men considered the 
utility or practicality of other PrEP methods. When men were less favourable towards a 
daily oral pill regime, the reasons were less about its inconveniences and were more to 
do with a man forgetting to dose daily, thereby making the medication less effective.  
 
One-third of participants felt that the reliability of PrEP provided by an injection made 
it attractive when compared with pill taking, even if this was not the preferred method 
for all of them. This was because they understood that they (or others on PrEP) might be 
more likely to forget or miss a pill dose, whereas injections provided longer-term 
coverage.  
 
“That would be awesome actually because I know that taking the pill is 
something that not everyone does. How many pregnant women are wandering 
around thinking they wish they hadn’t forgotten to take the pill? But if you … 
then went to the clinic once a month to get an injection, that would be amazing. 
Yeah it really would. Definitely preferable.” (Francis) 
 
Interestingly, both the man currently taking PrEP and the man who had previously 
sought PrEP, found this method particularly appealing due to the diminished likelihood 
of missing necessary doses. In the following quote, Louis articulates how injectable 
PrEP might actually reduce stress or anxiety more generally.   
 
“Um … yeah … look implants would be awesome … It really appeals to me that 
you can’t miss a dose. You don’t have to think about it … um … you know, you 
get a steady rate of release.” (Louis) 
 
How injectable PrEP might be administered raised acceptability issues for a quarter of 
men, but in diametrically opposing directions. Two men were concerned that there 
might be an eventual expectation that they would have to give themselves the injection. 
 
“I wouldn’t do it myself. I could inject my boyfriend and I could probably let 
him inject me. I went for bloods … the other day and I can’t look. When I had to 
have all the bloods for PEP I passed out. What a wimp! We would probably 
inject each other. He could probably do himself. He’s hard as nails.” (Colin) 
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Whereas a small number of men would want to be further in control by administering 
their own PrEP injections and the administration of PrEP by a medical professional took 
away their sense of control of how to prevent HIV: 
 
“Control is a big issue actually. The control about who is doing the injection is 
quite important actually – whether it’s them or me. I would feel less in control of 
my life if I had to go and get this injection. I would feel more positive about it if I 
could do it at home and looking after my own health. But I don’t like the idea of 
going for an injection with someone else maintaining control. [It is about] 
control over my well-being rather than control as in who is doing the thing, 
having an active part in my health rather than being a patient I suppose.” (Nate) 
 
5.3.3 Concerns relating to side-effects of PrEP medication 
Perhaps the over-arching issue relating to the physical impact of PrEP that influenced 
men’s personal PrEP acceptability surrounded the issue of side effects. Two-thirds of 
men held significant concern about this issue. Although findings from major 
international studies showed few side effects with oral PrEP (Grant, 2014), it still 
played heavily on the minds of many participants as they considered how PrEP could be 
incorporated in their everyday lives and, ultimately, the extent to which they considered 
PrEP acceptable. 
 
Overall, perceptions of PrEP were situated within the types of side effects that men 
might experience – if these were mild or severe; if they were temporary or permanent – 
and whether the side effects would differ between short-term use or long-term use of 
PrEP. Whilst some men acknowledged that, unlike current HIV treatment, PrEP would 
be unlikely to be taken for life, there were questions about evidence on the long- term 
impact of taking Truvada. Men who were more informed about PrEP, or other medical 
issues, highlighted the short-term ness of trials such as iPREX, and that the longer term 
impact and side-effects of PrEP could not yet be known.  
 
“I probably wouldn’t bother until there was more evidence to say that actually, 
going on this for 5 to ten years doesn’t cause any long term problems, and it’s 
fine to keep using it for that period of time.” (Jos) 
 
Some men’s views about side effects of daily HIV drugs were tempered by a friend or 
partner’s experience on HIV treatment, or an experience of being on PEP. 
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“If side effects were like PEP then I wouldn’t go near any of them. I simply 
wouldn’t do it again.” (Colin) 
 
For others men, a play-off would be made between the side effects and other factors. 
For example, one man felt that he could accommodate more side effects if he were sure 
the result was a more efficacious medication, in terms of protecting him from HIV. For 
others, minimal side effects would be worth the benefit of taking PrEP – either through 
sexual pleasure and enjoyment, or, in Marc’s case, a reduction in stress.  
 
“I would want to look in to the toxicity around the drug … just to understand 
that a bit more … you know … it would be nice to have a little bit less stress 
around catching HIV too.” (Marc) 
 
A quarter of men said that taking PrEP intermittently was a preferred routine compared 
to taking a daily pill because of the impact of daily pills on their body, and a perception 
that intermittent PrEP could have fewer side effects.  
 
“For me … the advantage of not taking a daily pill would be, you know, to give 
my body a rest. For me that would be like a, you know, not overdoing my liver 
or kidney. For me, that would be the benefit, that I could pick and choose and, 
you know, ‘I’ve got a party this weekend, I’ll take this’ and then give my body a 
rest rather than taking the drug everyday continually which, you know, although 
it says there are no side effects, you are still taking a drug every day. That would 
be the attraction of that.” (Marc) 
 
Only two men made mention of the potential side-effects of injectable PrEP: one was 
concerned that they might be greater, as an injection would give a greater dose of 
medication than a pill; one felt that the side effects of injected PrEP might be less 
because of how the body would process the drugs. Three men raised acceptability 
concerns regarding the potential side effects of long-acting injectable PrEP and would 
factor these into any future decisions about taking this format of PrEP. For one man, his 
rare episodes of SWC made topical PrEP most attractive, as he would only need to 
apply PrEP on these small occasions, rather than having a drug in his body for longer 
periods of time. 
 
5.4 Body, lifestyle and routine  
As mentioned at the opening of this chapter, while many aspects of PrEP acceptability 
were common across delivery methods, some were more specific and require discussion 
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on an individual basis. In the first sub-section I address: the extent to which sex is pre-
planned and how this influences perceived acceptability of both intermittent PrEP and 
topical PrEP; sections 5.4.2 and 5.4.3 relate to acceptability dimensions that relate to 
topical PrEP only; and sections 5.4.4 and 5.4.5 relate to formats of injectable PrEP. 
 
5.4.1 Pre-planning of sex  
In Chapter 4, the issue of how men plan their sex lives was explored, with men 
reporting that they increasingly have spontaneous, rather than pre-planned sex. Perhaps 
inevitably, this highlighted acceptability issues for those PrEP methods that need to be 
taken or applied in advance of sex. While a few men felt that intermittent PrEP dosing 
might counter their concerns regarding pill taking and resistance, a third were concerned 
that as their sex did not fit around a pre-planned schedule it would be hard to identify 
the right time to take the medication.   
 
“I’m not in a position when I can predict so well. It’s a nice idea if my life had 
that structure to it … it could work if I knew when I was having sex you know 
but … yeah … only if I knew so it’s a bit hit and miss.” (Nate) 
 
Some men actually felt that even if prescribed an intermittent dosing regime may 
actually end up taking PrEP daily to alleviate concerns about the timing of sex.  
 
“If you have such a sex life it makes all the sense in the world. But my sex life is 
essentially the same except that some days I have sex and some days I don’t … 
so I would have to take [PrEP] every day. I never plan that way. It just happens. 
It would be interesting to see a frequency diagram across the week and I think it 
will be a flat line.” (Javi) 
 
However, one quarter of men said that intermittent PrEP offered a greater level of 
acceptability when it was considered situationally. For these men, the concept of being 
able to use intermittent PrEP for a party weekend, a special occasion, or when on 
holiday, was extremely attractive.  
 
“Yeah, I mean, that’s kind of a good idea if you a regular party goer or if you 
knew that you were having a regular party weekend … or a DJ is in town I’d 
like to see and I can probably think that after that I might hook up with someone. 
So in that way you could probably plan for it and that might be better than 
having it every day and worrying about not taking it.” (Alex) 
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With regards to topical PrEP, the issues associated with pre-planning of sex were even 
starker than in relation to intermittent PrEP. Half of participants found that any need to 
pre-plan insertion of topical PrEP made it unacceptable for them. In addition to the 
practical issues explored below with regard to douching and bowel movements, men 
cited concerns about how and where they would practically insert the gel in advance of 
intercourse. 
 
“I would guess that if you were going out that night that would put you at work 
doing it in the toilets. That would be a hassle. Kind of annoying I think.” 
(Martin) 
 
One quarter of men said that the pre-planning of the application of topical PrEP did not 
fit in with how they managed finding sex, or that being so disciplined would not work 
for them. For Mattie, the spontaneity of his sex would make topical PrEP unacceptable 
for him. 
 
“There’s too much preparation and forethought. And one of the things about sex 
is the spontaneity … um … you might be out … in the countryside for a hike or 
whatever and suddenly there’s someone there and the urge takes you and, you 
know, pants down and spitting on your cock.”  (Mattie) 
 
Participants were more likely to find topical PrEP acceptable if usability allowed for 
spontaneous use, such as being used as a lubricant, rather than it having to be pre-
applied.  
 
“The idea is potentially good but I think for me that product would be really 
good if it was something I could apply during the act. If I was going to get 
fucked then I could put it in there and go ahead. Other than that I don’t think it’s 
going to work for me.” (Duncan) 
 
These results suggest that PrEP methods that require pre-planning of application or 
planning of taking pills to account for sex without condoms at specific times may be 
unacceptable for some men. However, also indicated is the potential appeal of 
intermittent PrEP dosing to men who may not engage in HIV risk-behaviours on a 
regular basis, but rather those who think ahead to times or events when they think it 
likely they will be sexually active and would value the protective effect of PrEP on such 
occasions. The timing of application of topical PrEP before sex was seen as particularly 
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problematic, as were the more practical complications of topical PrEP use, as explored 
in the following section.  
 
5.4.2 The practicality of using topical PrEP 
One half of men said that the practicality of preparing for and applying topical PrEP 
would make it unappealing for them personally.  Especially for men who were used to 
preparing for receptive anal intercourse, the need to pre-apply PrEP was incompatible 
with the cleaning and prepping regime they were used to. These men understood how 
such pre-application might be suitable for the vagina, but the rectum posed a set of other 
challenges. 
 
“On no! You take a poo and everything is coming out. You take a poo and then 
you’re going to have to put [the gel] back in. It doesn’t make any sense. It makes 
sense in vaginas because vaginas are all about stuff going in and staying there. 
But here we’re talking about a two-way street!” (Javi) 
 
Other men were concerned that topical PrEP might leak prior to sex, causing issues of 
embarrassment, or having to reapply the gel, or raising concerns that there was 
insufficient gel inside to be protective.  The mess of topical PrEP was a reoccurring 
theme and one that posed a major dis-incentive to PrEP acceptability. 
 
Some men were concerned about how PrEP might be contained, administered and 
carried by men, especially if anal intercourse was not pre-planned and, as such, was 
viewed as less practical than keeping pills in one’s pocket or bag. Such a dilemma were 
illustrated by Colin: 
 
“What a faff! You know, it’s not easy to get something up your ass and for it to 
stay there. It’s not like you can just have a gel packet that you can squirt up your 
ass. You would need an applicator and it doesn’t fold like a packet of lube in 
your pocket. Hmmm … not sure about that one. Gel? No. Not for me.” (Colin) 
 
A small number of other men were concerned about dosage and self-dosing and, rather 
than seeing topical PrEP as giving men more ‘self-control’, the impracticality of topical 
PrEP made it less attractive than a pill. 
 
“I guess I wonder … how long before I am having to [apply] that … how easy is 
it to do … how easy is it to know that I’ve gotten it right? Um, I think my initial 
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thoughts are, I’m wondering, have I done it right? Have I done enough? Have I 
got it in at the right time?” (Jos) 
 
A quarter of men raised concerns about the taste, smell or feel of topical PrEP and the 
impact this would have during sex. Given the necessity of applying topical PrEP prior to 
intercourse, men voiced concerns about the impact on oral sex and analingus and 
questioned if the gel would impose on such sexual activity. One man articulated safety 
concerns about oral ingestion of topical PrEP during oral sex, and if this might be of 
danger. For one man, the sensation of pre-intercourse sex made topical PrEP 
unacceptable. 
 
“The mess! You know, it’s bad enough when you’ve got lube in your arse! 
Someone starts fingering you and you’re full of gel – that’s not going to be an 
attractive look is it? It’s really not! No! It’s going to leak and that. It’s not going 
to be great that. It’s like with being fingered and stuff … No! That is something 
else up there that you don’t really need to be there isn’t it? No. No. That 
wouldn’t work for me.” (Colin) 
 
Mattie raised a further concern about the impact on sex: he felt that the pre-preparation 
of topical PrEP imposed on intercourse, making sex somehow clinical and a deviation 
from sex: 
 
“Yeah … we’re getting too much in to clinical territory … you know if it was 
part of a clinical trial that would all be fine but … when you’re in the bedroom, 
I just wouldn’t do it. Possibly if you could squirt it on the other guy’s glans 
before he enters you, then it’s possible because that’s like … it’s not really 
deviating from normal sex. But any other deviation? No.” (Mattie) 
 
5.4.3 Noticeability and pain 
Of all of the technologies discussed, longer-acting injectable PrEP, when considered as 
an implant, was the PrEP method that elicited particularly negative responses, common 
among a quarter of participants. The concept of longer-acting PrEP was considered 
“scary” (Philip) and “dehumanizing” (Duncan). For these men, having an implant 
inside them was considered a step too far: 
 
“Instant recoil from that. I don’t like the idea of being physically marked. It’s 
almost like being branded in some way and it’s um … it feels like it is 
depersonalizing or dehumanizing me in some way. At some basic level it’s 
making me think ‘urgh!’ ” (Duncan) 
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Two men raised concerns about the impact of implants during work – that the implant 
might get knocked, or, in the case of one participant, having to shower with work-mates 
might make him stand out as having an implant, if it were visible, and that would raise 
uncomfortable discussions at work. This theme of noticeability, or being seen by others, 
emerged as an issue for over a third of all men. Others seeing an implant might mean 
that assumptions are made about you, or about the lifestyle being lead: 
 
“Um … it sounds a bit silly but you don’t want to publicise the fact that you’re 
… although you’re effectively trying to look after your health and protecting 
others, it’s almost like you’re saying ‘I lead a life that is risky and I’m taking an 
anti-HIV medication’ … and even though I’m taking it because I don’t want to 
have HIV … and I don’t want others to have it, it’s almost like saying that I’m 
involving myself in sex that is risky.” (Mattie) 
 
Whereas Nate commented that this might offer an inadvertent benefit: 
 
“I can see almost at some point like it becoming a thing that people could 
identify each other and it would reduce the need for a particular conversation!” 
(Nate) 
 
Different PrEP methods had an impact on participants’ acceptability of PrEP based 
upon the dimensions discussed above. Further consideration of acceptability by PrEP 
method is discussed further in Chapter 8. However, a marked determinant of PrEP 
acceptability pertained to the efficacy of PrEP, to which this chapter now turns. 
 
5.5 PrEP efficacy  
Participants’ considerations of the acceptability of daily oral PrEP were, in part, 
influenced by the compelling efficacy data from the iPREX trial. Given the dearth of 
similar data for other PrEP methods it is perhaps inevitable that participants might have 
viewed these other methods less favourably (although practicality of use concerns 
would likely remain regardless). In this section, the issue of efficacy as an acceptability 
dimension is explored further. 
  
Over one third of men identified that a major acceptability factor for intermittent PrEP 
centered on the efficacy of such a method. That is: would intermittent PrEP offer the 
same protection as daily PrEP? Some men immediately translated the findings of the 
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iPREX trial data into potential efficacy of intermittent dosing, noting that men who had 
been less adherent in iPREX had been less well protected by daily PrEP.  
 
“We already know by that [iPREX data] that it’s not very effective for people 
who took it badly. I think it’s the effectiveness that’s important. I think if the pills 
were only 50% effective then people wouldn’t be that interested in them.” 
(Francis) 
 
For some of these men, intermittent PrEP would be more acceptable than daily PrEP 
(for reason discussed above) but only if efficacy was equal or greater than daily pills. 
 
“I’d want the one that is more likely to offer protection.” (Mattie) 
 
Three men explored the issue of efficacy of an injectable form of PrEP. Medication 
administered by injections were viewed as more efficacious by one man, whilst another 
felt that injections were “like a vaccine” and so it made sense to him that they would be 
perceived to more efficacious. The issue of efficacy played out for Javi who considered 
injectable PrEP only of worth if it was as efficacious as an HIV vaccine. For him, the 
downside of injectable PrEP could only be balanced by a huge increase in the protection 
that an injection would give him. 
 
“Only if the results were to be vaccine-like protection. If you tell me it is zero 
and I can go and become a cum whore then sure! LAUGHS But otherwise it 
would have to be … there’s a much higher level of commitment to go to a clinic 
and get injected than to take a pill. It really boils down to risk. If this reduces the 
risk to zero or close to, then we are talking.” (Javi) 
 
For almost a third of participants, the efficacy of longer-acting PrEP was a significant 
concern. Three men felt that longer-acting PrEP would have to be as efficacious, or 
more so, than other technologies before they would consider using it and, as with 
injectable PrEP, one man felt that effectiveness would need to be higher, due to the 
added inconvenience of having longer-acting PrEP administered or inserted. Two men, 
both of whom were currently taking daily medication for other health conditions, raised 
concerns that dosage might be insufficient if it tailed off towards the end of a three 
month period, or that it might have a peak and a crash. They were also concerned if an 
implant might work differently across individuals due to physiological differences. 
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“I’m not so much one for longer term because I know stuff changes  … if it has a 
more individual thing, like having to get the dose right, then I’m loathed around 
longer lasting in that sense. Like, does it last for the same time in everybody? 
Does it peak and crash? Those sorts of things.” (Nate)  
 
Three men raised the vaccine-like qualities of longer-acting PrEP and Jovan saw the 
strengths of longer-term protection but raised his concerns that this would lead to a 
proliferation of other STIs as men reduced their clinic visits: 
 
“From an HIV perspective chances are the longer the cover the better because 
in essence a drug can replicate the characteristics of a vaccine … so from that 
point of view it’s a strength. The other point of view that this person now thinks 
they are impervious to STIs and they have now have three months when they 
don’t have to get tested. It may solve one problem and exacerbate another one.” 
(Jovan) 
 
However, none of the men raised a personal concern that would increase SWC any 
more than any of the other potential PrEP formats. Indeed, Alex raised an interesting 
parallel about the protective factors and risk taking of other injectable protective 
medical technologies: 
 
“[It’s] like a vaccine in a way … um … so it’s almost like you’re going to 
somewhere to prevent something. With a tetanus shot you don’t go out and start 
licking dirty nails because you know that you’re covered against that … and I 
think that would be like the same thing.” (Alex) 
 
For two men, the issue of the efficacy was the major dis-inhibition to topical PrEP 
acceptability. Whilst most men focused on the use of topical PrEP, these two men 
focused on both the efficacy differences between the studies on oral PrEP and topical 
PrEP and the potential reductions in effectiveness if gel was self-administered 
incorrectly.  For Louis, there was a sense that topical PrEP had more potential for 
failure “just in terms of the mechanics” of how topical PrEP would be applied whilst, 
for Jovan, his concern included the differences due to individual physiology: 
 
“If the pill gave a 60% greater chance of not becoming infected and the gel gave 
a 95% chance then it would warrant more because this gel [would then be] 
almost fool proof. But doing it in advance – I assume there has to be a certain 
amount of absorption – you can’t just suddenly start fucking like with a lube. It 
won’t be in the right place and it depends on the people. You know, some guys 
have greater anal mucus therefore absorption … it’s certainly not cut and dry 
and certainly not as swallowing a pill.” (Jovan) 
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The bottom line for most men was: the benefit of using a method that offers the greatest 
protection outweighs the other costs of that method. Or, put another way: any cost of 
using a particular method needs to be heavily outweighed by the additional protection 
one would get from using it. The second most important issue was: a method with high 
efficacy becomes less acceptable if (one’s) use of it makes it less effective. That is: if a 
man cannot take it, or forgets to take it; if he cannot self-administer an optimal dose (or 
vomits up the medication); then his acceptability of a method with a high efficacy starts 
to reduce. As such, it is important to factor both the efficacy and the effectiveness or 
usability when considering PrEP acceptability. 
 
5.6 Negotiation and navigation 
Having explored a range of PrEP acceptability dimensions for participants, the chapter 
now moves to consider how men might negotiate and navigate PrEP use themselves. 
Dimensions of personal acceptability of PrEP do not purely relate to how acceptable it 
is to put a drug or gel into one’s body, or to be injected: the social and inter-personal 
dimensions of negotiating PrEP use, disclosure of use to sexual partners, and the 
perception of what that negotiation and navigation entails and results in, is also of prime 
importance in understanding PrEP acceptability. In the first sub-section, the manner in 
which men perceived they might negotiate their own PrEP use is explored. The section 
then moves on to explore how men might relate to another man’s PrEP use and what 
this indicates in terms of what is, and is not, acceptable.   
 
5.6.1 Men’s own potential PrEP disclosure to sexual partners 
During the interviews, men were asked to consider if they thought that they would 
disclose their own PrEP use to sexual partners and the circumstances within which that 
disclosure might occur. Over one quarter of men said that PrEP use disclosure would be 
something that they would consider to always or usually take place before or during sex, 
and would become part of their sexual negotiation or discussion – even if their sexual 
practice did not alter as a result of this disclosure. For these men, PrEP disclosure 
offered a level of certainty to a sexual encounter, in the same way that discussion 
around recency of an HIV test or a discussion around HIV status might take place. 
There was a sense of the normalisation of such disclosure: 
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“It would become part of what I already do.” (Duncan) 
 
A further quarter of men were more ambivalent about PrEP disclosure and felt it would 
be dependent upon situation, circumstance and the relationship to the sexual partner. 
Men’s ambiguity lessened if a potential partner was regular or if they already had a 
level of trust established with him: 
 
“I … it would depend on the type of contact it was. If it was a one-off person 
then no. Sometimes you don’t even share your name so you wouldn’t really 
share more details about my personal stuff … If it was someone I was potentially 
dating, or at least had a coffee or beer with or a meal or something with them 
first, then it might come up in conversation.” (Alex) 
 
Some men indicated that PrEP disclosure would only arise in the context of other 
discussions, such as HIV status, or whether a partner with HIV had an undetectable 
viral load, but only in circumstances when that partner offered that information first. 
 
“If someone offered that conversation … someone might say ‘I have HIV and my 
viral load is undetectable’ and I would say ‘it’s OK, I’m also doing this’ … so it 
might come up there in that sense.” (Nate) 
 
A further quarter of men were absolutely adamant that their PrEP use would not be 
disclosed in a sexual context. Their reasons fell into two overlapping areas: how PrEP 
use would be perceived by sexual partners and issues surrounding sexual control. In the 
first area, Yan understood that disclosing PrEP use would indicate that men were 
somehow diseased, and this would put men off having sex, especially if SWC was a 
possibility. Interestingly, it was not unprotected sex that was seen as an issue for him, 
but unprotected sex and PrEP use. 
 
“If you are bottom and you take PrEP … probably your partner, they don’t want 
to have unprotected sex because they are afraid that they could catch something 
…” (Yan) 
 
Of those men who would not consider PrEP use disclosure, the key issue was about 
being in control of their sex. Even with men who said that they were certain to discuss 
PrEP use with regular partners, there may be circumstances when it would not be 
disclosed. Max understood that PrEP use disclosure would give him a level of certainty 
and control in some circumstances: 
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“If … and … yeah. I would say I’m on PrEP and explain it … and I think that 
would give certainty that we’ve thought about it.” (Max) 
 
But he would construct a different strategy in circumstances when men, as he had 
previously discussed, tried to force SWC on him.  
 
“What about the guys you mentioned earlier who are pushing you into having 
unprotected sex? Would you tell them?” (WN) 
 
“No! No! It would give them another reason to push me. I would feel more 
comfortable anyway … and either have unprotected sex with them anyway or 
have protected sex with them … but I wouldn’t tell them.” (Max) 
 
For Javi, non-disclosure of PrEP use would assist in protecting himself against risks that 
he found difficult to avoid: 
 
“No. Most certainly not. Because you will be telling them that effectively I’m 
willing to take more risk … It would almost be a wink and a nod to ‘yeah, yeah, 
you can cum in me’ which is absolutely … no … absolutely not.” (Javi) 
 
Whereas Colin raised concerns that he might get coerced into not using condoms and 
was adamant that his own PrEP use would not be disclosed within casual settings: 
 
“They’d have no idea if you were taking the stuff at all, so there would be no 
bullying you into not using a condom. You’d be much more in control. I 
wouldn’t tell them. No way! Absolutely no way! I would be entirely in control of 
my own arse and there’s no way I’d let anyone try to bully me …  No. No way! 
Because that is asking for trouble! You might as well get your arse in the sling 
at the sauna and have a ticket machine!” (Colin) 
 
Participants’ responses to disclosure of their own PrEP use were varied, often 
situational and context dependent. When men presented cautious narratives about PrEP 
use disclosure they did so to remain in control of their sexual encounters or because of 
fears of how they would be perceived by others. These narratives of others’ perceptions 
of PrEP use are mirrored and magnified in the section that follows regarding 
participants’ perceptions of other men’s use of PrEP. 
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5.6.2 Perceptions of other men’s use of PrEP 
Participants were asked to consider how they would respond to a sexual partner’s 
disclosure that he was using PrEP, if the participant himself was not using PrEP. 
Understanding men’s responses to another man’s use of PrEP assists in understanding 
the inter-personal dimensions of PrEP acceptability, and in building further 
understanding of community attitudes to PrEP use. 
 
For almost all men, this was an issue that they had not previously considered or 
explored and, for some men, their responses were drawn from accounts of encounters 
with men with diagnosed HIV, who had disclosed their HIV medication use (and an 
undetectable viral load) in order to negotiate sex. More broadly, men divided their 
responses into two narratives: one of a man seeking to guard and maintain his health 
and well-being by using PrEP; and one of a man who was reckless, promiscuous and 
not to be trusted. 
 
For men who followed the former narrative, a partner’s PrEP use – and disclosure - 
demonstrated a sense of responsibility and, regardless of the sex that might occur, 
indicated that the man was looking after his health and taking steps to avoid HIV 
infection. In addition, by having regular clinic appointments, such a man might 
therefore be less likely to have other undiagnosed STIs. Rather than being seen to be 
reckless, such a man was viewed as a ‘good’ man: a man to be trusted, and an indication 
that, not only was the man out to protect his own health, but was taking steps to protect 
the health of his sexual partners too. 
 
“He’s being responsible about his decisions. He’s doing something that reduces 
his chance of getting HIV so that makes me safer too. That would make me see 
him as being more responsible, rather than less.” (Max) 
 
“It’s like the guys who quiz you in detail about when you were last tested and 
your status … you know … It would be some evidence that they look after 
themselves and less likely to have HIV and to pass it on to you … so … you know 
… it would be positive to me.” (Marc) 
 
For men who followed the latter narrative, there was a sense that disclosure of PrEP use 
indicated a promiscuous sexual lifestyle, with judgments being made about whether he 
would be a man one would want to have sex with at all. 
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“If you think about it … if you … you can think that the other person is a slut if 
he’s taking it … he must be screwing around … he might not … but that must be 
one of your ideas – that the other person is quite sluttish.” (Yan) 
 
Whilst, for other men, there was a sense of ambivalence about their response, as they 
weighed up a range of considerations. 
 
“I don’t know. I really don’t know. I absolutely have ambivalence on that one. 
On the one hand I’m thinking ‘great, they are people that give a damn and 
protect’ and the other hand I’m thinking ‘they are far more likely to be going out 
and having bare back sex and fucking other people’, right? I’m not sure about 
falling between those two. Both of them … yeah.” (Francis) 
 
A few participants raised more fundamental questions about trust and control over HIV 
prevention.  Philip, based on previous sexual encounters, wondered if men might 
disclose PrEP use, as a way of getting condom-less sex, even if they were not taking 
PrEP, and questioned men’s motivations for such disclosure. 
 
“I’d look them in the eye and think ‘are you just lying to have unprotected sex 
with me because that is what you want? I’ve had experience of that with 
someone. So, I wouldn’t trust them. If they said ‘I’m taking PrEP’ then I’d be 
thinking ‘are they really taking PrEP?’ ” (Philip) 
 
5.6.3 Other men’s PrEP disclosure and sexual risk 
After being asked to describe their response, if any, to another man’s disclosure of PrEP 
use, participants were asked to consider if such disclosure would impact on the type of 
sex they would have with that man. 
 
For all participants, their decisions about sexual activity and sexual risk taking, 
following potential PrEP disclosure from another man, were considered alongside their 
current risk taking and risk reduction strategies. Men were mindful of whom the sex 
might be happening with and where the sex might happen, overlaid with issues of trust 
and control, along with discussion about HIV risk. 
 
Generally, as with the case of Jos, men felt that their sexual risk would not alter. 
 
“Um … I think … I don’t think it would change my opinion … I think it’s nice to 
know that it’s their protection from HIV … I don’t think it would have a major 
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opinion of someone telling me. I’m generally having one off sex with people and 
I’m assuming they are doing the same thing. I guess if they are taking something 
like this then I guess they are saying “I have a higher proportion of sex than 
other men and all of that or some of that involves some kind of risk” and that’s 
nothing different to what I should and do assume now for the people I have sex 
with. My risk would neither increase or decrease, no.” (Jos) 
 
Or, in the case of Javi, any increase in risk, would be tempered by his current risk 
reduction decisions, of not allowing sexual partners to ejaculate in him. 
 
“Hmmmm … interesting. That’s an interesting twist. I think I would be more 
relaxed. I still don’t think I’d let them cum in me … but I would be more willing 
to take a risk if they were to tell me that they are on it.” (Javi) 
 
The responses from men who said that such disclosure would be likely to have an 
impact can be grouped into situational or setting responses; contextual responses; and 
activity responses. 
 
Situational or setting responses – these were responses that were based upon the 
situation or setting where PrEP disclosure took place, or where the sex was occurring. 
That is, for some men, the decision to permit PrEP disclosure to impact upon sexual 
activity was dependent on where the encounter was taking place. For Colin, this meant 
that the setting was crucial to his decision, not only because he could ‘see’ that PrEP 
was being taken, but based on the ‘types’ of men who would go to commercial sex 
venues. 
 
“I think I’d make the same risk assessment that I always have. If it was in a club 
or a sauna then, no. If he was in my hotel room and there’s the tablets by the 
bedside, then maybe.” (Colin) 
 
Contextual responses – these were responses based upon the context of the sex, 
including whether the partner was known or unknown, or if the sex was with a regular 
or casual partner. Generally, men were more likely to be trusting of a man they knew, 
and regular partners, to take PrEP, and to modify their sexual activity with him, than 
with an unknown or casual partner. 
 
“Well, I say I’d be less concerned, it depends on how well I know him … 
because some guys might say they are when in fact they’re not.” (Philip) 
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“I’d feel more comfortable about condoms or not condoms. If I knew a guy was 
taking PrEP and he was someone I knew … then maybe perhaps … I would …” 
(Max) 
 
Activity responses – these were responses based on the type of sexual activity that men 
were describing. For men who had described risk reduction strategies, including 
modality of anal intercourse and ejaculation during anal intercourse, other men’s PrEP 
disclosure tended to sit alongside and complement those strategies. 
 
“I probably wouldn’t bottom with him and have him cum inside me. I don’t think 
that would change. I might not use condoms with him if I was topping him … 
that might happen.” (Alex) 
 
“Probably not any different to how I do normally. I’d still want to use condoms. 
And tops are less likely to pick up HIV anyway so if he always tops then … yeah 
… it’s great he’s on the tablet but actually … I’d still want to be safe.” (Ed) 
 
5.7 Section Summary 
In the section immediately above, participants own personal narratives of how they 
might negotiate and navigate PrEP use disclosure have been situated alongside 
narratives of how they might respond to other men’s PrEP use. It is telling that these 
narratives are often in conflict: although some men articulated that other men might 
perceive a participant’s PrEP use as being a sign of promiscuity (and all of the 
associations that go with that), far more of the participants indicated that they would 
consider another man’s PrEP to be a signal of promiscuity. That is: the social stigma 
and scripts that participants attached to other men’s PrEP use was greater than the social 
stigma attached to PrEP use that participants considered that other men would apply to 
them. This presents an interesting and challenging dynamic pertaining to inter-personal 
acceptability of PrEP: whilst a man might perceive that others will view his PrEP use as 
being broadly responsible (and acceptable), in essence, other men are likely to view that 
PrEP use as a greater sign of promiscuity than that individual man believes.  
 
Overall, this chapter has explored participant’s personal acceptability of PrEP, first by 
exploring their immediate considerations of using daily oral PrEP, before going on to 
consider more nuanced responses to PrEP acceptability by a range of different PrEP 
methods. The chapter examined how efficacy of a particular PrEP method is central to 
men’s personal acceptability of PrEP and how men might navigate and negotiate their 
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own PrEP use, or that of others. The contradictions between men’s perceptions of how 
their own PrEP use might be viewed, and how men view other men’s PrEP use draw on 
community and societal norms around sex and sexual risk taking, to which the next 
chapter turns. 
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Chapter 6: Results - Community and societal acceptability of PrEP  
 
The previous two results chapters focused on dimensions of acceptability that most 
closely align with individual perception, experience and need, or considered those 
dimensions that are most pressing in the context of inter-personal negotiation. This third 
results chapter addresses dimensions that relate to men’s perceptions of broader 
community and societal acceptability of PrEP, and the potential impact of those 
perceptions on men’s own personal acceptability of PrEP. That is: how community and 
social forces influence whether and why they consider PrEP to be acceptable to them 
personally.   
 
Much has been written in the health literature about the role of peers and broader 
community and society on the social impact of health seeking behaviours and on 
attitudes to health. Bronfenbrenner’s (1979) social ecological model situates the 
individual at the centre of the model, being influenced by community level actors and 
attitudes which are themselves mediated by wider social influences, all of which are 
interdependent. Greens and Tones (2010) further suggest that those with the most 
proximal relationship to an individual, including significant others and peers, have the 
greatest influence on that individual’s health actions. Although it has been argued that 
more distal community or national norms (including those norms set by the media) have 
less impact on individual health actions, those distal norms contribute to the norms of 
the peer group themselves. As such, it is feasible that norms established by community 
peers, or by societal actors, may contribute to whether and how men consider PrEP to 
be acceptable. The next chapter reports on men’s perceptions of broader community and 
societal PrEP acceptability and how both distal and proximal attitudes to PrEP might 
impact on men’s thinking, potential use and disclosure of PrEP use. 
 
The chapter starts with participants’ perceptions of more direct or proximal influences 
of PrEP use, before moving on to more distal influences that might impact on PrEP 
acceptability.  Notions of both HIV-related and gay-related stigma, and stigma 
surrounding sex more generally, are woven through these findings.  
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6.1 Discussion and disclosure of PrEP among social peers 
Participants were asked to consider the circumstances in which PrEP might be discussed 
within social networks, and the views that social peers might have about PrEP. 
Participant narratives are reported below in two overarching themes: social divisions 
and permissive discourse, and disclosure of PrEP use with social peers.  
 
6.1.1 Social divisions and permissive discourse 
Participants’ responses to whether PrEP would be discussed with social peers were 
contextual and dependent upon their social circles and the extent to which they 
overlapped with other men’s social networks. A common narrative was for men to 
identify a ‘PrEP positive’ social network and a ‘PrEP averse’ circle of friends. In the 
former group, men identified peers who they thought might personally benefit from 
PrEP, or would actively encourage those in their peer group to use it. These men 
generally tended to already include discussions about sex (and risk) in their 
conversations, and for these men PrEP use and discussion about PrEP would be 
supportive and affirming. 
 
“I think they probably would [talk about it] yeah. I mean we’re all pretty open 
about what we get up to and sex generally. Friends … you know … friends are 
open about their HIV status generally so … you know. Yeah.” (Marc) 
 
These interactions tended to include men who were open about their sero-discordant 
relationships within certain social networks. There was a sense that men in mixed HIV 
status couples would openly discuss the benefits of PrEP. 
 
“I think that most of the mixed HIV couples I know would be very enthusiastic. 
This is an alternative that there is to a vaccine. I think anyone in the same 
situation would be very enthusiastic.” (Francis) 
 
Men who identified peers who would be ‘PrEP averse’ talked about the potential 
judgment or stigma, not necessarily of taking PrEP, but for that attached to the reasons 
behind seeking PrEP. For these men, there was a perceived taboo about talking about 
unprotected sex and sexual risk with their social peers, including those peers who Alex 
describes as being “old fashioned” about sex. Max describes his sense of silencing 
about being able to discuss potential PrEP use, and the risks he takes, with some of his 
closest peers: 
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“I also have a couple of really good friends who are [HIV] positive who are 
slightly … bitter is not the right word … sort of … really down on anyone who is 
unsafe. Like, if they know about the risks I have taken … then they would be 
furious.” (Max) 
 
Many of the men could identify different groups of peers who would be PrEP positive 
or PrEP averse and any discussion about PrEP use would be situational, depending on 
the peers and their perceived attitudes. It was acknowledged that, because of the relative 
rarity of PrEP use, peer responses to PrEP may initially be cautious, or not evidence 
based and that, as more men used PrEP, attitudes to disclosure of PrEP use might 
change. 
 
“I would be hesitant about starting a discussion because I would just, you know, 
it’s like me admitting to irresponsible behaviour to friends and that would be 
something you are cautious about. So it would depend on the context … but it’s 
possible and I can imagine that once people become familiar with it, it becomes 
really quite common for people to talk about it and talk about taking their PrEP 
pills.” (Duncan) 
 
This notion of sex on PrEP being ‘responsible’ or ‘irresponsible’ has been a dominant 
feature of PrEP discourse, particularly in online environments, originating in the United 
States. Some stakeholders and community leaders have referred to this as ‘slut-
shaming’ (Grindley, 2014): a judgment of those who openly acknowledge having a 
higher number of sexual partners and who take steps to protect themselves (perceived in 
both a positive and negative light). Louis, the only participant with experience of PrEP 
use, had found that some of the attitudes to sex and PrEP he had encountered online 
were surprising, not least because they were not views he had heard expressed within 
his own social networks. 
 
“There was some judgmental comments about casual sex … um … which quite 
surprised me actually. Some conservative views on casual sex. That’s quite 
different from the views of people I know and mix with in London.” (Louis) 
 
A common theme that emerged in relation to discussions amongst social peers was that 
failure to discuss PrEP use (and sexual risk behaviour more broadly) amongst peer 
networks was not seen as peculiar to PrEP, but that men (in some social circles) would 
not discuss any issues around sex or risk. As such, the thought of discussing PrEP was 
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as unimaginable as discussing HIV status, erectile dysfunction or any other issues 
concerning men’s sexual health and, in some circumstances, would be seen as a 
discussion that was “going too far” (Mattie) 
 
“Um … I don’t think there’s a lot of talking about any medical issues. People 
are very wary of it. [The bear community] is one where there’s a lot of sex 
happening and not a lot of talking about it, which is very bad.” (Francis) 
 
Javi went even further in describing his peer groups’ discussions about sex. For him, it 
was not that his peers do not talk about sex at all, but that a taboo existed around 
discussing unprotected sex. 
 
“I have never discussed anything like this and I don’t think we would because 
we only tell to each other that we have safe sex.” (Javi) 
 
6.1.2 Disclosure of PrEP use with social peers 
It follows, therefore, that disclosure of PrEP use within social networks is likely to be a 
function of the response to attitudes and discussion of PrEP or the broader sexual risk 
environments within those networks. As such, the signs and signals that men pick up 
from their peers may influence men’s disclosure of PrEP use. 
 
Participants were asked to consider the circumstances in which they might disclose or 
discuss PrEP use with social peers. This is an additional hypothetical scenario, but one 
which helps to identify how social factors may influence the manner in which 
conversations and decisions about PrEP may be encouraged by health professionals in 
the statutory and charitable sectors. Just over half of men provided a response as to 
whether such disclosure or discussion of PrEP would take place. Participants’ responses 
fell broadly into three categories, and these draw parallels with the narratives men 
presented with regard to how they might view sexual peers’ use of PrEP, as previously 
discussed. The first narrative presents participants as making positive health choices if 
they were using PrEP. Half of the men felt that they would be strong advocates of PrEP 
use disclosure and would actively discuss PrEP use with their social circles. For these 
men, they expected their friends to see PrEP use as being rational and sensible in the 
context of living in a high HIV prevalence city, such as London: 
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“My first impression is that if I was to tell my friends that I’m taking this pill 
and it’s halving my risk of getting infected then everyone would understand … If 
I even think of my straight friends they will think that it’s a rational thing to do 
but then again I do tell them I’m a cum whore!” (Javi) 
 
Here Javi highlights a key socially permissible context of PrEP use. He believes his 
friends recognize the extent of his risk exposure (a ‘cum whore’) and this would 
convince his friends to consider his decision to use PrEP as a rational one. Indeed, in 
some instances there was a sense that friends would be relieved to know that a man was 
using PrEP: 
 
“ … the friends I talk to about the types of sex I have, they might recommend it 
to me, you know ‘that weekend that’s coming up … you know what you get like, 
you know, maybe you should think about that!’. Ha, ha!” (Alex) 
 
The second narrative concerned a sense that PrEP use disclosure was not an issue for 
discussion, or one that would be dealt with cautiously because of the other implications 
of PrEP use disclosure. Two participants identified instances when men would not have 
a concern with PrEP use per se, but discussion would involve disclosure of a partner’s 
HIV status, or information a man’s partner would not want shared peers to know about, 
such as non-monogamy within a relationship.  
 
The third narrative centered round an articulation that participants had a tendency not to 
discuss issues of any sexual nature with social peers. Of the participants who did not 
consider that PrEP disclosure would take place the reasons this that “it is not their 
business” (Yan) or that issues of a sexual nature – or a sexual risk taking nature – were 
never discussed with peers. As such, men could not imagine a circumstance when PrEP 
would be discussed. This issue is discussed further in the next section. 
 
These findings illuminate how any discussion of PrEP cannot occur without an honest 
discussion of risk and risk-taking among gay men more broadly. Although efforts have 
been made to facilitate such dialogues (including by community based organisations), 
these efforts have rarely shown evidence of widespread success. 
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6.2 Societal and community influences on PrEP acceptability 
Participants were given the opportunity to explore the potential social dimensions of 
PrEP and how existing community norms and disclosure relating to sex and risks might 
shape its acceptability. There are various social actors who can shape or inform the 
acceptability of PrEP and whose views participants took into account. These actors 
included social peers and broader community members; the gay media, including the 
more focused gay media and online media; the mainstream general media; and health 
professionals. 
 
Two dominant themes emerged in men’s assessments of social dimensions of PrEP 
acceptability: stigmatization of ‘risk’; and (mis) information, norm-setting and agenda-
setting.  
 
6.2.1 Stigmatisation of risk and risk-taking  
Given societal stigma attached to HIV, to sex in general and to homo-sex in particular 
(Fish and Karban, 2015; Pachankis et al., 2015), it is perhaps not surprising that the 
issue of stigma and PrEP was raised by over three-quarters of men in this study.  
 
While few participants had encountered PrEP specific stigma, some had experienced, 
and made reference to, other HIV or sex based stigma. This included Roy who 
remarked. 
 
“The reason my partner hasn’t told anyone [about his HIV status] is because of 
social stigma” (Roy). 
 
However, one quarter of men felt that there would be a strong stigma attached to PrEP 
use although, as has been seen with regard to men’s concerns about PrEP use disclosure 
to social peers, these concerns around stigma were more attached to having unprotected 
sex, rather than PrEP use per se, or of being promiscuous.  
 
“I’m worried … if I was to tell someone I’d want something a bit more serious 
and long-term with … it’s almost like saying ‘I’m slutty, whatever, I’m always 
having unprotected sex’ and I’d worry it might be putting that person off.” 
(Mattie) 
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A larger number of men felt that stigma would not play a significant part in PrEP use, 
and that someone using PrEP would be regarded as sensible and, although there might 
be some light hearted joking or teasing, these men felt that PrEP use would not be 
stigmatised. A number of these men gave a caveat that this was also a reflection on their 
friendship networks and accepted that there might be broader PrEP stigma in other parts 
of society. 
 
Simon felt that the potential for PrEP being stigmatised lay, in part, with the early 
adopters of PrEP and how these men conducted themselves, including any 
consequences of PrEP use – such as a population increase in annual STI incidence. 
 
“You don’t know if these stigmas are going to develop until they do because they 
depend on the activities of [early PrEP users] or the people that are prominent 
within it and how wide flung those activities really are.” (Simon) 
 
Mattie felt that stigma existed because, unlike being vaccinated against something that 
was more than 99% effective, using an HIV preventative technology that was not as 
effective as a vaccine might somehow carry a degree of recklessness. However, 
Francis’s perspective serves as a counter argument, also utilising a vaccine comparison, 
to make a point that he thought it irrational for PrEP use to be stigmatised: 
 
“I don’t think in the community there would be a stigma. I don’t think I’ve ever 
heard someone say ‘you’ve taken the hepatitis vaccine? How horrible is that? 
Can you believe it? You’re such a slag!’ So no, I don’t think there would.” 
(Francis) 
 
More common was a fear of PrEP stigma that might prevent men from discussing it. 
 
“I know some guys wouldn’t want to talk about it. I know one guy who will be at 
[name of club] with things up his arse and he won’t even talk about anything to 
do with his arse. And I’m thinking ‘but last week I saw you with a fist up your 
arse and now you’re being all coquettish when someone mentions anything to do 
with an arse’.” (Jovan) 
 
In addition to social contacts, a small number of participants voiced concerns about 
potential stigmatisation of PrEP use by medics or other health professionals. For some, 
such concerns were based upon their own recent experience with a sexual health 
professional, including Philip who had recently changed sexual health clinics because 
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firstly he considered he would be viewed as ‘bad’ by the clinic staff, and secondly 
because he had been pressured into attending counseling services that he considered he 
did not require and did not desire. This, coupled with an unwillingness to have his HIV 
prevention ‘controlled’ by health professionals, led him to conclude that his own 
experience of medical professionals would make PrEP less acceptable. 
 
Jovan also raised a concern that men’s internalised views of what it was to have an STI 
or to have SWC would make it hard to honestly convey personal sexual behavior to 
medical staff, and thus be in a position to access PrEP. 
 
“I think a lot of men when they get tested are afraid to be honest and tell they 
have been a dirty whore because a lot of people internalize that and they think ‘I 
am a bad person, I really am a whore. I am not in the hetero normative, you 
know, finding a partner and settling down’. And they won’t want to admit that to 
their friends, let alone a clinician.” (Jovan) 
 
In reality, concerns about PrEP acceptability from medical staff were raised by only a 
small number of men. With one exception, articulated concerns were based on men’s 
perceptions of how they might be treated or judged, rather than prior experience of an 
unsympathetic service. That said, such perspectives highlight an important concern that 
future PrEP providers articulate clearly and publically their non-judgmental and 
supportive PrEP based services.  
 
6.2.2 Mis-information, norm setting and agenda setting  
Two men reported that they had seen comments about PrEP on web-based gay media 
forums and raised concerns that misinformation about PrEP, and attitudes or opinion 
about it, rather than facts or evidence would influence whether other men consider PrEP 
to be acceptable. Louis voiced a concern that the gay media gave a correct and 
evidence-informed analysis and reporting about PrEP and its potential to reduce HIV. 
 
“In terms of the gay media, rather than the mainstream media, who will have a 
field day whatever, I find it really hard to imagine them as not recognizing 
[PrEP] as the third way. I don’t really care what people think … I don’t really 
care if [name of magazine] says ‘PrEP’s not effective enough’ [but] I care that 
people will make decisions based on that.” (Louis) 
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However, as was seen in Chapter 4, although some participants had heard about PrEP 
through community internet channels, none of the participants demonstrated that their 
views on PrEP had been shaped by misinformation. 
 
A similar view was articulated by a small number of men with regard to how the 
broader (mainstream) media might view and report on PrEP. This was especially the 
case given the media’s potential role in societal norm setting and in setting public health 
policy agendas. Of those men who raised concerns about how the media might impact 
on PrEP acceptability, concerns were far less about potential PrEP stigmatisation and 
much more about how (mis) reporting of PrEP might impact upon a policy setting 
agenda, and therefore PrEP availability on the NHS. 
 
“I’m really concerned about negative spin in the press.  In my head I have a 
transmission curve … and it just becomes exponential. As a scientist you can see 
the value of that. And as someone reading the Daily Mail you can’t. These 
things really concern me because we need … a third option. Whether PrEP is a 
little bit effective or a lot effective we still need it … and that worries me.” 
(Louis) 
 
Despite participant’s narratives that broader media coverage of PrEP would be unlikely 
to have an impact on personal acceptability of PrEP, it is worth emphasizing how media 
can shape norms more broadly. As such, negative media portrayals or narratives of 
MSM using PrEP to enable or facilitate doing ‘risky’ activities has the potential to have 
a significant consequence for how information about PrEP is disseminated at a 
population level.  
 
6.3 Summary 
Few men felt that societal or community attitudes to PrEP would personally impact or 
influence the acceptability of PrEP for them. Most men felt they had a strong element of 
personal resilience and that PrEP acceptability was largely influenced by other factors 
(including those explored in Chapters 4 and 5) and, if they had made a decision to 
access PrEP, the attitude of others – especially ‘others’ who they did not know – would 
have little impact or influence. 
 
There was a broader concern about misinformation or the influence of the media in 
shifting the landscape of PrEP – especially for men who had not heard about PrEP 
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through other sources. Although community or societal views of PrEP were seen to be 
unlikely to impact on men’s personal use of PrEP, those norms were seen – for some 
men - to impact upon if and how men discussed PrEP use with their sexual peers. The 
implications of this are considered in the discussion. 
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Chapter 7: Naivety, certainty and ambivalence: four case studies 
 of PrEP acceptability 
 
The aim of the following brief case studies is to provide a holistic sense of the 
acceptability and potential for PrEP use among four of the study’s participants. Each 
case study builds on the data previously presented in the results section. They highlight 
the dynamic nature of individual’s PrEP beliefs, including their own inconsistencies in 
how PrEP might be used or considered. These case studies are presented as data from 
individual participants and are not composite narratives from several men. The process 
of qualitative analysis can fragment the nature of human perception and experience. In 
breaking down the speech of individual’s line-by-line and re-constructing as themes, 
alongside other people, something of the gestalt is lost. These case studies are presented 
as a way of counter-balancing that and present, in a more holistic way, individual 
thoughts and feelings relating to PrEP and its acceptability. 
 
As discussed in Chapter 3, given the nature of applied research within a DrPH, that 
embeds the transferability of research into practice and policy, these case studies are 
also intended to provide an over-arching summary of the broad perspectives of 
participants in a way that is more relevant and accessible for non-academic audiences. 
 
These four men were selected as case studies as they provided the most distinct 
characterisations of PrEP acceptability and potential use: the naïve risk taker, for whom 
PrEP would not be deemed acceptable as the man could not recognise his HIV risk; the 
man who definitely would seek PrEP; the ambivalent man, for whom PrEP would be 
acceptable in certain circumstances but had a considered approach to determining PrEP 
use; and the man who would not use PrEP, broadly for whom HIV risk was deemed 
insufficient to warrant PrEP. 
 
Although all other sixteen participants fell somewhere into these categories, most fell 
somewhere across one or more, with sometimes more complex narratives surrounding 
risk, sex and potential PrEP use than those more easily categorised above.  
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7.1 Simon: the naïve risk taker 
Simon, one of the youngest participants in the study was the most obvious naïve risk 
taker within the study. It might be tempting to ascribe his naïve risk taking to his youth, 
yet elements of naïve risk taking can be found in other participants, including men 
almost twice Simon’s age.  
 
Simon described how he regularly attended bars in one of London’s gay 
neighbourhoods where, after a few drinks with friends, he would start to look for men 
nearby on his phone. Almost all of Simon’s sex was unplanned, with the majority of 
encounters occurring using phone apps and to meet an immediate sexual need, rather 
than to pre-plan ahead for sex. HIV testing occurred periodically, based on the numbers 
of men sex had occurred with, rather than the types of sex that have taken place. 
Although some unprotected sex was pre-planned with someone he knew or had already 
had an encounter with, most of the “immediate quick fix” sex was without condoms. He 
rarely talked to men about HIV status before or after those quick encounters and rarely 
employed other risk reduction strategies, although sometimes considered not letting a 
man cum inside him but as he said, “Yeah, I might. It’s that key word – might!”. Simon 
believed that it was unlikely that he had had unprotected sex with someone with HIV: 
 
“Yeah, as far as I’m aware … conclusively … I have not had sex with someone 
who is positive”. 
 
He said that if a man told him he was HIV positive then sex would be unlikely to 
happen or continue: 
 
“I think … god … I suppose if someone says that they are positive … it will … 
not bring your back up … but bring things to your forefront. Being brutally 
honest I don’t know, especially on a one-night stand, that I would sleep with 
someone if they were positive. Um … which probably sounds very harsh … My 
shut-down mechanism would be just to shut it down”.  
 
Whilst Simon’s sexual risk taking might make him an apparent candidate for PrEP, he 
held strong ambivalence about considering PrEP. For him, the issues of remembering to 
take a pill on a daily basis would be challenging, and he would need more consideration 
of longer-term side effects. Intermittent oral PrEP and topical PrEP sat less well with 
the more spontaneous nature of his sex planning and although injectable PrEP offered 
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some level of acceptability, Simon wanted to know more about those technologies and 
their use in the real world before better determining their acceptability. Although he 
raised a potential concern about his own sexual risk taking increasing as a result of 
using PrEP, he remained fairly adamant that he would still not have sex with a known 
HIV positive partner whilst using PrEP.  
 
7.2 Martin: the definitely wants to use PrEP 
Simon’s understanding and conceptualisation of risk contrasted sharply with that of 
Martin, whose risk taking was far more cognisant. Martin was in a non-monogamous 
relationship with a partner with HIV and an undetectable viral load. They had 
unprotected sex together, with Martin being the receptive partner and with ejaculation 
often occurring. As such, Martin considered that “it is responsible for me to test 
regularly”. Martin went through a lengthy and informed process with his partner to 
decide not to use condoms, seeking advice from HIV positive peers and health 
professionals. Martin had other regular partners with whom unprotected sex was almost 
always planned and negotiated. Condoms were used during anonymous intercourse, 
such as in a sex venue, and Martin concluded that his sex was “not some sort of a 
reckless stab in the dark mistaken behaviour … it’s pretty well informed”. 
 
On hearing about the results of the iPREX study when they were first released, Martin 
attempted to access PrEP but was told that NHS guidelines prohibited his doctor from 
prescribing them. As such, if a daily PrEP pill became available in England, Martin 
would want to start using them. Minor and manageable side effects and clinic visits 
would be an expected part of taking such a medicine.  
 
Other forms of oral PrEP and topical PrEP were seen as less acceptable as they required 
pre-planning of sex. Although a rectal gel was seen as a possible option for the future, 
issues around application and messiness made it far less acceptable. When considering 
injectable formulations of PrEP, injections made it less likely that a pill would be 
forgotten to be taken, but the biggest factor of acceptability was the effectiveness of any 
method: 
 
“You know … if a certain format of medication is more effective than one 
another, then that is the one that should be used. I don’t particularly think that 
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the way that it’s given is not necessarily … I mean it wouldn’t be the deciding 
factor for me. I would take the most effective … I’d prefer the most effective 
format rather than the one that gave me the most comfort, if you like”.  
 
Martin saw that taking PrEP would broadly be seen as acceptable within a large part of 
his social circle, particularly those in which sex was already discussed and that PrEP use 
would not be something he would be ashamed of. Rather he would see it as “a 
mechanism for on-going health”. 
 
Given Martin’s consideration of how he managed sexual risk, it is no surprise that his 
response to the possible impact of PrEP use on sexual risk was as equally considered. In 
some circumstances, PrEP use might change the type of sex that would be negotiated 
and take place; for example if a man with HIV had a detectable viral load. In these 
circumstances, Martin clarified that: 
 
“I would be more comfortable having condom less sex with him … It doesn’t 
mean I’d definitely have condom less sex with him but I’d feel more comfortable 
if that was the case”.  
 
7.3 Alex: the ambivalent 
Alex provided a much more ambivalent narrative to PrEP use. He reported that his 
patterns of seeking sex had changed over recent years, with far less focus on quick sex. 
With a previous partner where condom use was stopped during the duration of the 
relationship, Alex usually otherwise used condoms during sex. During recent 
encounters he had had a number of unsafe experiences to which he accounted as being 
due to being drunk, having used recreational drugs and having low self-esteem. He 
reported: 
 
“The combination of those three things kind of made me more careless. I was 
going to say carefree but that has the wrong connotations. Yes … more careless 
… to not paying enough attention to what I was doing, as to what I should be 
…”. 
 
One of his risk reduction strategies was to attempt to ensure that those three risk factors 
did not collide: something that he accepted is a challenge given that one way of 
escaping from low self-esteem or depression is to self-medicate with drink or drugs. 
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Having read about PrEP briefly in a news article, Alex was keen to understand more, 
including about possible side effects and the impact of not remembering to take pills 
regularly. If he were in a sero-discordant relationship then Alex’s acceptability of 
personal PrEP use was clear: it would be something that he would be very interested in 
taking.  
 
“If there was a reason to take it because your partner is HIV positive and you’re 
not, then I think that would be more of … more of an impulse … you know. More 
of a driving factor to make sure you take it as you should.” 
 
But as a single man, even one having occasional and irregular SWC with men whose 
HIV status was unknown or not discussed, Alex’s PrEP use became more ambivalent. 
He raised a concern that PrEP use might potentially increase his sexual risk taking and 
then articulated that taking a daily pill might serve as a reminder to why he would be 
taking the medication in the first place, and that might further modify his (safe) 
behavior: 
 
“Actually, probably strangely … by taking a daily pill it’s kind of a reminding 
you of what’s at risk. I think if that was a constant reminder every day – I have 
to take the pill, I have to take the pill – it might click in if you were getting in to 
a situation and you’d think ‘hang on a second, there’s a reason why I’m taking 
this … there’s a reason why this behavior might be risky so let’s do something 
about it.” 
 
Both intermittent oral PrEP and injectable PrEP were viewed as being more acceptable 
than a daily oral pill – not only because Alex could see the former better fitting his 
lifestyle but because he associated pill taking with being ill. Yet, he saw an injection as 
being more like an inoculation: 
 
“It’s something to do with the psychology behind it: it’s less worrisome but still 
providing the same benefit maybe.” 
 
For Alex, injectable PrEP provided a different analysis of sexual risk compared with 
oral PrEP in that he articulated that injections, which he saw as being similar to 
vaccines, would be less likely to lead to sexual risk. 
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7.4 Ed: the would not use PrEP 
Ed, another of the younger participants in the study, typified the view of the quarter of 
the men in the study who would not find PrEP use personally acceptable. As has been 
discussed, the two primary reasons for not considering PrEP personally was a concern 
about putting drugs in to one’s body and not considering one’s HIV risk to be sufficient 
to take PrEP. Ed straddled both of those reasons. 
 
Ed used clubs and bars and other social venues as a setting for meeting men for sex and 
although Ed was also a user of smart phone apps, he rarely met men for instant sex, 
preferring rather to pre-plan and arrange to meet a potential sexual partner in a venue.  
 
He was a regular tester, regardless of the type of sex he has had, and had few encounters 
that involve unprotected sex. His most recent one was with a man “and basically we 
were just playing around and he sat on me and it was sort of not for very long because 
after a moment I kind of was … right … like no … actually.” Other encounters had 
almost exclusively been with condoms apart from an occasion of condom failure and 
non-condom use during monogamous relationships. 
 
Ed raised a personal conflict concerning PrEP in that he could see the benefits of it in 
preventing HIV but felt that it was fraught with potential danger if “it’s encouraging 
risky behaviour”. The friends he had discussed PrEP with shared this view.  
 
If Ed were hypothetically using PrEP it would not alter the sex he was having. He 
would disclose his PrEP use to sexual partners but would not let this be seen as 
permission to them not to use condoms. If another man disclosed his own PrEP use then 
sex would “probably not be any different to how I do normally. I’d still want him to use 
condoms.” 
 
Ed’s unambiguous statement of a desire not to use PrEP was based primarily on his 
perceptions of his lack of HIV exposure risk: 
 
“I guess there’s always an element of chance but I wouldn’t really feel 
comfortable taking something when it isn’t really something I need … I like to 
try to be safe … I know it’s preventing something but I can use these other 
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methods, although they aren’t completely [reliable] then I’d rather stick to them 
I think.” 
 
This was enhanced by a consideration of the possible side effects and toxicity of PrEP 
and seeing himself as “not really a big drug person and I don’t really like to take drugs 
unless I need to”.  
 
If Ed, again hypothetically, took PrEP, intermittent oral PrEP would be preferable to 
daily oral PrEP: not only did he consider the toxicity and side effects to be less, but he 
understood that such a PrEP method might fit more neatly with how he pre-plans sex. 
 
7.5 Summary 
As outlined in Chapter 3, these case studies serve to provide a more holistic concept of 
PrEP acceptability, sitting alongside the more thematic results section in the preceding 
three chapters. They further serve as more easily digestible overviews of four key 
accounts of PrEP use, especially accessible for non-academic readers, policy makers 
and health promoters.  
 
In the following chapter, the results from the preceding four chapters are synthesized 
and discussed. 
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Chapter 8: Discussion 
 
Introduction 
This research set out to explore the acceptability of HIV PrEP among MSM in London. 
It adopted a holistic approach to the consideration of acceptability, recognising the 
personal, inter-personal, social and community dimensions that influence or inform 
whether or not something is acceptable. A qualitative methodology, that employed in-
depth interviews with twenty MSM in London, was considered the most appropriate 
approach, given the multiple and discursive elements of acceptability and the need to 
understand individual perceptions and consideration of PrEP. 
 
In the preceding results chapters, data were presented from these interviews with men 
who, given their self-reported prior risk behaviour, potentially stood to benefit from 
greater availability and use of PrEP. Those chapters explored the acceptability of PrEP 
from the positions of the personal, inter-personal, community and societal, 
acknowledging that each dimension has a role in uptake and efficient use by the 
individual. In this discussion chapter, I draw together these strands to consider the 
acceptability of PrEP among this sample of MSM, and contrast these findings with 
other contemporary evidence relating to PrEP. The chapter establishes the key findings 
of the research before moving on to explore in further detail how this thesis adds a 
unique contribution to the evidence base on PrEP and its acceptability. The discussion 
focuses on major findings from the research and the chapter concludes with discussion 
on a proposed model for improving our understanding of how PrEP acceptability 
amongst MSM might be better articulated and understood in future research and health 
promotion practice. 
 
As is acknowledged throughout this thesis, the evidence relating to PrEP uptake and 
use, as well as the policy environment of provision is developing apace and, as such, 
this discussion chapter discusses emerging evidence that was only in development when 
field work for this thesis was being undertaken. The discussion chapter places particular 
emphasis on areas where emerging evidence is compounding and where recent 
published evidence serves to further develop the findings described in this thesis.  
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8.1 Key findings of the research 
In this first section the key findings from the thesis are outlined and summarised. These 
key findings form the basis for the discussion in the following sections of this chapter 
and for the conclusions that follow in chapter 9. The key findings of the research are: 
 
 Daily oral PrEP was broadly personally acceptable to this sample of MSM living 
in London who are exposed or potentially exposed to HIV. When PrEP is 
personally unacceptable, it is generally so because men consider their HIV risks 
to be too insignificant to justify using a daily pill, because they were concerned 
about the possible side effects, or because they are uncomfortable using a 
pharmaceutical medicine to prevent HIV. 
 
 PrEP was most acceptable to those men who knew they were taking the greatest 
risks of contracting HIV, and when men have a close proximity to HIV. Men 
who were less cognisant of the risks they were taking that might lead to HIV 
transmission, or did not consider themselves to have a close proximity to HIV, 
were least likely to consider PrEP use personally. 
 
 Participants positioned PrEP as having benefits that move beyond HIV 
prevention. These benefits included the ability to increase intimacy, pleasure and 
opportunity during sex, and to reduce the stress that surrounds sex. This was 
particularly the case for men who had a primary HIV positive partner or sero-
discordant relationship. 
 
 The extent to which different methods of PrEP delivery were considered 
acceptable varied. Intermittent oral PrEP was attractive to men who felt their 
risks did not justify taking a daily pill. However, methods that require pre-
planning of sex were felt to pose particular challenges in a world when sex is 
increasingly spontaneous.  
 
 PrEP became more acceptable when viewed as a range of technologies and 
methods that include, but are not restricted to only, daily oral PrEP. Participants 
who were taking, or who had sought PrEP, found methods other than daily oral 
PrEP to be more acceptable than men who had never taken or sought PrEP, 
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suggesting a continuum of acceptability and the role of prior personal experience 
in informing this. 
 
 Although there were some dimensions of acceptability that differ according to 
different PrEP method, the biggest determining factor was efficacy of the 
method. Men felt they might be willing to experience more inconvenience, or 
greater discomfort, for example, if a particular PrEP method offered them 
greater protection than another method. 
 
 Participants broadly viewed PrEP as an HIV prevention method that could be 
incorporated with and used alongside their existing HIV risk reduction 
strategies. Whilst some men considered that the sex they have without condoms 
would increase if they used PrEP, most men’s narratives on PrEP and sexual risk 
were considered and cautious. 
 
 Broadly, men’s decisions to discuss and disclose their own PrEP use, should 
they decide to use it, mirrored the discussions and disclosure that surrounds their 
current sexual activity. Control was central to men’s considerations of PrEP 
discussion and disclosure and participants could identify occasions and 
situations when PrEP use disclosure could diminish and strengthen control over 
their sex. 
 
 Despite participant’s own views on PrEP use and PrEP use disclosure, 
participants’ views on other men’s PrEP use cast challenges and contradictions 
about how men might view PrEP use by others. Although some participants 
viewed other men’s PrEP use as being rational and a signal that a man looks 
after his health, another strong narrative emerged that positions other PrEP users 
as being promiscuous and therefore men to be avoided. 
 
 Decisions to discuss PrEP, and its use, with social peers, also mirrored the 
discussions that took place regarding sexual activity. When participants said 
they do not discuss other sexual issues with social peers, then they also said that 
PrEP would also be unlikely to be discussed. Conversely, when men had 
122 
 
relationships with social peers where HIV, sex or sexual risk is discussed, then 
discussion about PrEP and its use was seen to be more amenable. 
 
 Participants recognised the role that community and social actors have in 
influencing the discourse on, and attitudes to, PrEP. Whilst stigma about PrEP 
featured as a major theme in men’s narratives of PrEP use, the overwhelming 
majority of participants determined that stigma about PrEP would not deter them 
from seeking or using PrEP. However, stigma or perceptions of a negative 
response from social peers, or other social actors, would contribute to how and 
whether men would discuss or disclose their PrEP use, including in sexual 
situations. 
 
 Participants’ major concern relating to community and social actors was the 
ability of such actors to dictate or wrongly influence public agenda setting on 
PrEP, including publishing misinformation about PrEP that might deter other 
men from seeking it. 
 
8.2 Willingness to use PrEP: contributors and barriers 
The second objective of this thesis focuses on understanding men’s willingness to use 
PrEP and the contributors and barriers to that potential use. This section examines a 
number of key themes, drawn together from across the preceding chapters that relate to 
willingness to use, and overarching acceptability of PrEP. I begin with a discussion of 
perceptions of risk and the notion of naïve risk taking, which is central to discourse 
regarding PrEP among this sample. This is followed by a consideration of the wider, 
holistic health benefits of using PrEP, and the level of health systems engagement that 
would be required. As has been the case throughout the history of the HIV global 
pandemic, Chapter 6 illustrated how perceived or felt stigma plays a role in how men 
consider PrEP (and how they may discuss it) and this is further reflected in this section. 
Finally, I examine men’s perception of how PrEP could be integrated into their sexual 
lives alongside their existing HIV risk reduction strategies. The ease of use, or of 
integration, was central to some in how they considered PrEP acceptable, or otherwise.  
 
123 
 
8.2.1 Risk perception and naïve risk taking  
Whether or not men considered themselves at personal risk of contracting HIV, or other 
STIs, significantly influenced their perception of PrEP and whether or not they 
considered it acceptable. In short, those who did not perceive a high risk of HIV 
acquisition were less likely to be personally willing to use it, and found the concept in 
general less acceptable. However, as described in detail in Chapter 5 (as well as in case 
study 7.1), a small number of men in the study presented a risk analysis that was flawed 
or naïve. As with the case of Simon, his unwillingness to consider using PrEP was 
based on his assumption that the SWC he was having was primarily HIV sero-
concordant and he struggled to conceive of a scenario in which he had had sex with 
someone who had HIV, now or in the future. In the context of an active sexual life in 
central London, with a HIV prevalence of nearly 1 in 8 MSM (Yin et al., 2014), this is – 
on a subjective level – somewhat naïve. Other men presented scenarios where a 
justification or rationalisation was made about the sero-status of partners (such as based 
on the setting in which sex occurred), and failed to take account of the challenges that 
some men with diagnosed HIV experience in disclosing their status. As reported in 
Bourne et al (2015), some gay men with HIV rely on behavioral indicators of their 
status (such as the sexual position they adopt or the type of sex they have), which can 
stand in conflict to the assumptions that HIV negative gay men can hold about the 
likelihood of a HIV positive man actively disclosing (i.e. the assumptions that positive 
and negative men make about the nature of disclosure are not always in sync).   
 
Such naïve risk taking has presented challenges for HIV health promotion for decades 
(Henderson et al., 2001; Keogh, 2007; Reid et al., 2002; Williamson et al., 2008) and 
the advent of PrEP illuminates these challenges, and the contradictions of naïve risk 
takers, further. For, not only might a naïve risk taker be unwittingly exposing himself to 
HIV, he might (based on the assumption that the men he has previously had sex with 
must also be uninfected) pass on HIV to other sexual partners at an early stage of 
infection and when most infectious, based on his own assumption that he is uninfected.  
 
This is the first research that attempts to draw out the implications of such naïve risk 
taking within the context of PrEP provision and access. If PrEP is going to realise a 
significant public health (rather than solely an individual) impact, such naïve risk takers 
need to be at the centre of frameworks that engage MSM about PrEP. It is likely to take 
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a significant number of men cognisant of their exposure to risk to be using PrEP to 
provide a notion of “herd-immunity” to HIV for men such as Simon. Indeed, 
understanding that some of the men who shun those who disclose a HIV positive status 
are also likely to reject men who disclose their PrEP use (as discussed further below), it 
is conceivable that men who base their risk reduction strategies by seeking “neg for neg 
only” will be taking even greater, not fewer, naïve risks. In this scenario, men will be 
rejecting those with undetectable viral loads or those whose PrEP use means they 
cannot have undiagnosed HIV. 
 
However, it is important to also consider the broader consequences of risk perception 
and how this could impact PrEP access or uptake. The fact that men who perceive only 
a limited likelihood of HIV exposure consider PrEP to be less acceptable has an obvious 
impact on the cost-efficiency of this intervention (i.e. at a general level, those less at risk 
are less likely to want to use PrEP). This finding is in line with those reported in the 
iPREX OLE study (Grant, 2014) where participants most willing to continue to 
participate in the study were those taking the greatest HIV related risk. Those who 
considered their risk to be insufficient to justify taking PrEP were more likely to stop 
taking it in this open label trial. However, I return to the notion that self-assessment of 
risk exposure is problematic, and these potential outcomes have to be considered 
accordingly.  
 
8.2.2 Holistic dimensions of health and well-being 
Although PrEP is broadly conceived and conceptualised as a technology that would be 
most beneficial to those taking the greatest HIV risk, this study establishes that there 
may be additional, more holistic health benefits afforded by PrEP that influence 
perceived acceptability. In a bid to capitalise on the public health impact of PrEP, 
discussions on who should be offered PrEP, and in what circumstances, have focused on 
those most likely to acquire HIV within certain prescribing guidelines (NHS England, 
2015). For example, suggestions have been made that HIV negative partners of men 
with HIV who have an undetectable viral load (and are therefore unlikely to pass on 
HIV), would not additionally benefit from using PrEP (as the ‘extra’ protection that 
PrEP would offer would be negligible) (Pebody, 2015).  
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However, findings articulated in this thesis demonstrate that men understand the 
benefits of PrEP to be more complex and holistic than purely an HIV prevention 
benefit. This study highlights that some men in sero-discordant relationships consider 
that PrEP offers the opportunity to share the responsibility of HIV prevention with their 
HIV positive partners, and that potential could be seen for a greater level of intimacy 
and pleasure within such relationships. Other participants recounted that PrEP might 
offer the opportunity to have intimate, longer-term relationships with men with HIV, or 
that using PrEP might lead to a reduction in stress or anxiety during or after sex, even if 
SWC occurred infrequently. 
 
These more holistic dimensions of PrEP acceptability identified in this research offer 
challenges and opportunities for future PrEP provision and broader sexual health 
promotion amongst MSM in England. The most obvious challenge will be to situate 
these dimensions within NHS prescribing criteria: criteria that currently seek to 
demonstrate that the broad prescribing of PrEP will be cost-effective or cost saving to 
the NHS (Cambiano, 2015; Ong et al., 2015). A further challenge is that men who do 
not fit any future prescribing criteria but who might benefit from PrEP more 
holistically, might be those who can either most afford to purchase PrEP privately, or 
who have sufficient social capital to access PrEP in other ways (including knowing how 
to navigate, albeit dishonestly, an NHS prescribing system), further exacerbating sexual 
health inequalities (EMIS, 2013).  
 
The most obvious opportunity might be to diminish fear and anxiety and to increase 
intimacy and pleasure during sex by prescribing PrEP. However, those presenting to 
NHS services with a low HIV exposure risk but with other anxieties and concerns about 
sexual health or HIV offer the biggest additional opportunity of PrEP (other than 
preventing HIV): by situating PrEP services within a broader (sexual) health service 
that offers a range of interventions and services that address a broad range of (sexual) 
health needs, even when a desire to access PrEP is a man’s presenting issue. So, for 
example, a man attempting to access PrEP because of concerns about maintaining 
erections when condoms are used, might better benefit from an erectile dysfunction 
service, and be referred to such a service – a service he might otherwise have been 
unwilling to access independently. Just as men in the study saw the STI and sexual 
health opportunities of having a regular PrEP clinic visit, attempting to access PrEP – 
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even if the underlying (sexual) health issue might be better resolved by an intervention 
other than PrEP – offers huge opportunities for improving MSM’s more holistic health 
and well-being. 
 
Despite the fact that there were clear perceived benefits of using PrEP, these were 
sometimes counter-balanced by other concerns that had the potential to negatively 
influence health and wellbeing. As was reported in Chapter 4, men who were not keen 
on taking PrEP can be broadly divided into two groups: men who fundamentally 
disagree or object to taking medication (for preventing HIV), and men who do not 
believe that their risk taking justifies taking PrEP. For this first group, reasons include 
concerns about side effects or of following a pill-taking regime.  Two-thirds of 
participants expressed a concern about potential side effects of PrEP (sometimes 
associating side effects with experience of using PEP), although many men understood 
that the potential time-limited nature of side effects would not negatively impact on 
their actual use of PrEP. This finding mirrors much international evidence that concerns 
about side effects may serve as a barrier to PrEP uptake, yet these concerns have 
broadly shown to be misplaced (Grant, 2014; McCormack et al., 2015) and points to the 
need for UK health promotion on PrEP to address this potential barrier to uptake.  
 
8.2.3 PrEP use and stigma 
One quarter of men felt that there would be a strong stigma attached to using PrEP – 
although these concerns about stigma were more attached to PrEP’s associations with 
unprotected sex, or of promiscuity, rather than PrEP per se. However, more than half of 
men felt that stigma from friends and their wider community would not play a 
significant part in any decision to use PrEP – although men accepted that this might be a 
reflection on their peer networks and accepted that stigma might exist, and play a part, 
for other men. 
 
Given the discourse on stigma around PrEP use, much of it appearing from within the 
USA (Garner, 2012; Glavek, 2013; Stangl et al., 2012; Highleyman, 2014; Stern, 
2014b), it could be considered surprising that men in this study did not consider 
potential stigma around PrEP use as a more prominent factor influencing their 
overarching perception. It could be that, as PrEP use becomes more prevalent in 
England and Europe, the playing-out of more stigmatising discourse will grow. Whilst 
127 
 
men broadly reported that they did not expect stigma or anti-PrEP attitudes of peers, 
health service providers or the media to have an impact on their PrEP seeking behavior, 
there was a clear indication that stigma or fear of judgment (either about using PrEP or 
about what might be associated with PrEP use) might prevent men from discussing 
PrEP with peers or health service providers, or from disclosing PrEP use with sexual 
partners. As such, the potential stigma associated with PrEP stands to have an impact on 
one of the most powerful ways that gay men have traditionally sought information and 
support about sex, sexual health and HIV prevention: directly from their social and 
sexual peers. The potential silencing of discussion and disclosure of PrEP use due to 
stigma carries parallels with the silencing of those with diagnosed HIV (Bourne et al., 
2012).  
 
It is useful to situate these concepts of PrEP related stigma within broader theories of 
HIV related stigma. Stangl et al (2012) provide a framework for conceptualising HIV 
stigma and discrimination in which these data can be positioned. Stangl’s framework 
provides conceptual domains for understanding (and measuring) stigma that might also 
be applied to PrEP stigma that include: anticipated stigma (fear of consequences of 
PrEP use and its disclosure); perceived stigma (such as perceptions of how others will 
view PrEP users); internalised stigma (acceptance of negative feelings associated with 
PrEP use or SWC); and experienced stigma (actual experience of discrimination 
associated with PrEP use, for example). The strength of positioning PrEP related stigma 
within Stangl’s framework is that the framework identifies the drivers of stigma and 
where to intervene. By indicating how stigma functions, it is possible to identify where 
to intervene: providing a framework for action for HIV (and PrEP) health promoters 
(see related recommendations in Chapter 9). 
 
8.2.4 Incorporating PrEP into current risk reduction strategies 
In some respects, one of the key factors that influenced the extent to which participants 
considered PrEP to be acceptable was that most perceived it easy to integrate alongside 
their existing HIV risk reduction strategies. One of the most commonly voiced concerns 
about PrEP has been that PrEP use will lead to population wide reductions in condom 
use (Evans and van Gorder, 2013; Heywood, 2014; Highleyman, 2013). Despite 
findings from a range of international research that consider this not to be the case, 
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recent high profile media commentary has fuelled these concerns further (Peterson, 
2014; Stern, 2014). 
 
However, despite participants being asked about their hypothetical sexual activity in the 
future, should they use PrEP, nearly all men felt that PrEP would be used in conjunction 
with and alongside their current risk reduction strategies. It was perceived as an 
additional strategy that could complement their current strategies including decisions 
about internal ejaculation, modality of anal intercourse, discussions around HIV status 
and recent HIV testing history, and condom use, rather than replacing these strategies 
altogether.  
 
How men would respond to PrEP use reported by sexual partners was felt to be 
dependent on where the encounter was taking place, the context of the sex, including if 
the man was a casual or regular partner; and the type of sexual activity that was taking 
place. These considerations were overlaid with issues around trust, and being in control 
of sex and sexual risks, which it was felt personal PrEP use could help to develop. In 
turn, men’s considerations about disclosure of their own PrEP use fell into three areas 
(with equal numbers of men in each group): the first said that disclosure of their own 
PrEP use would be something that would always or usually take place as part of sexual 
negotiation and discussion – even if sexual practice did not alter as a result of this 
discussion; the second group of men were more ambivalent about PrEP disclosure and it 
would be dependent upon situation, circumstance and relationship to a partner; and the 
third group were adamant that PrEP use disclosure would not take place – either 
because of how they thought they would be perceived by sexual partners or because of 
issues of sexual control.  
 
These accounts have obvious implications for how PrEP educational and awareness 
interventions may be implemented, given that men’s risk reduction strategies may 
already be complex. Accordingly, if and how men disclose or negotiate sex when using 
PrEP has implications for non-PrEP users, including those with diagnosed HIV. Men’s 
accounts of other men’s PrEP use also gives us some (albeit limited) insight into how 
HIV negative men who have regular or occasional sex might negotiate sex with other 
men who are using PrEP. Central to these narratives are issues of trust, honesty and who 
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is in control of men’s HIV prevention: narratives that resonate with negative men’s 
accounts of ‘trusting’ another man’s recent negative HIV test results, or that a man with 
HIV really has an undetectable viral load when he reports that he has. 
 
8.3 The relative acceptability of different PrEP methods 
In Chapter 6 the differences in participants’ acceptability of PrEP were distinguished 
according to different PrEP methods. Although PrEP efficacy was generally constructed 
as the central component of personal PrEP acceptability, the differences of acceptability 
by method are worthy of further discussion. As such, this section addresses the third 
objective of this research – the relative acceptability of different PrEP methods.   
  
8.3.1 Daily oral PrEP 
When fieldwork commenced for this research, daily oral PrEP was the only PrEP 
method for which efficacy data for MSM existed. As such, it might be expected that 
daily oral PrEP would be viewed more favourably than any other PrEP method, and 
broadly, it was seen by participants to be the PrEP method they would most likely to 
consider. Since field work, further evidence has galvanised the case for daily PrEP 
(Grant, 2014; McCormack et al., 2015) evidence on the efficacy of daily oral PrEP 
remains the most compelling aspect of its acceptability to MSM in London. In addition, 
far more MSM are now using daily oral PrEP than when fieldwork commenced through 
clinical trials (anecdotal estimates suggest that around 400 of the PROUD participants 
continue on the trial since the closure of the deferred arm) and through self-purchase or 
private prescription. As such, more men will be now more familiar with concepts of 
daily oral PrEP and it makes sense that this familiarity might lead to a greater level of 
acceptability, as more men start to experience using PrEP, or discussing its use. 
 
8.3.2 Intermittent oral PrEP  
At the point of fieldwork for this research, intermittent oral PrEP remained a concept for 
which evidence was lacking. Since completion of fieldwork, and as highlighted in 
Chapter 2, a broad range of evidence, not least from Ipergay, exists on the feasibility of 
non-daily PrEP. This includes event-based dosing (taking PrEP before, and then after 
intercourse) and time-based dosing (taking PrEP a certain number of times a week – but 
not daily – and then a short time after intercourse). 
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A key finding from this study was that participants saw three key benefits of 
intermittent PrEP, compared with daily oral PrEP: first, that they might experience 
fewer side effects; second, if PrEP had to be purchased it would cost less to take a pill 
intermittently rather than daily; and third, it was viewed as a more suitable option for 
men whose sexual risk taking occurs only occasionally. These findings are consistent 
with other recent studies into intermittent PrEP dosing (Molina, 2015) and help to build 
a picture of PrEP being used in two, possibly overlapping, ways: first, daily oral PrEP 
being used by MSM who take on-going and regular risks; and second, intermittent PrEP 
being used by men whose (risky) sex is less frequent, occasional and planned (and when 
men do not find the possible side effects of daily PrEP acceptable). The study identified 
situations when participants could see the benefits of following one regime and then 
switching to another: an approach that reflects what is commonly being referred to as 
men’s ‘seasons of risk’ (Newman, 2015a). The ability to switch between different types 
of PrEP dosing regimens will offer potential challenges to PrEP educational activity and 
again underlines the possible complexities of the prescription and administration of 
PrEP. 
 
As was explored in section 5.5, efficacy of PrEP was the biggest issue of acceptability 
by different PrEP method and over one-third of men stated that this would be of similar 
concern to them with regard to intermittent PrEP. It is worth reflecting back to the data 
from the iPREX study that suggested that non-daily dosing of PrEP offered significantly 
less protection in that trial. These concerns are partially compounded by more recently 
published research. Despite the findings from Ipergay, and evidence from iPREX OLE, 
that four or more pills a week are sufficient to be protective (Grant, 2014; Molina, 
2015), efficacy evidence on non-daily oral PrEP still remains less compelling than that 
for daily oral PrEP. Indeed, the authors of the ADAPT study (a phase II open label 
study of Truvada based in Bangkok, Cape Town and Harlem, New York) note that 
“non-daily dosing is feasible …  if someday it is proven to be effective” (my emphasis) 
(Amico, 2015; Chemnasiri, 2015; Franks, 2015) and other commentators (Collins, 
2015) have called into question the evidence base of some recent prescribing decisions 
concerning non-daily PrEP. As such, further evidence on the efficacy of non-daily PrEP 
compared with daily oral PrEP is necessary if it is to become a compelling alternative. 
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Even if efficacy data for non-daily PrEP could be better demonstrated, intermittent PrEP 
dosing would still remain unacceptable for some men because of a central issue relating 
to effectiveness: remembering to take a pill that is not taken on a daily basis. This 
finding is further illuminated by the recent release of the Phase 2 HPTN 067 ADAPT 
trial (Amico, 2015; Chemnasiri, 2015; Franks, 2015), a three-country study exploring 
the feasibility and acceptability of daily; event-based; and time-based PrEP. ADAPT 
found that those following a non-daily dosing regimen had significantly lower 
adherence than those following a daily dosing regime in young Black women in Cape 
Town, South Africa. The same study found that daily dosing provided the best coverage 
in MSM and transgender women in Harlem, New York. In the Harlem group, 
participants were most likely to miss the post-sex does of PrEP. These findings, along 
with this thesis, contribute to the further knowledge about the pros and cons of different 
PrEP based regimes.  
 
This research, coupled with my own findings, demonstrates that intermittent PrEP may 
become far more compelling for men whose risk is occasional or episodic. For such 
men, taking a short course of PrEP prior to a holiday, or a particular occasion, is likely 
to be more acceptable and justifiable. However, questions remain about how 
intermittent PrEP might be used and managed by infrequent risk takers. These questions 
include: the extent to which side effects, if and when they occur, might (re)appear at 
each dosing period, and if side effects experienced on a first dosing period might inhibit 
later intermittent dosing; the optimal days prior to sex that PrEP should be taken; and 
how long PrEP remains protective following sex. Once again, this indicates how PrEP 
health promotion needs to be nuanced, specific and tailored to different sex patterns, 
whilst acknowledging that men’s sex patterns do not remain static.  
 
Whilst non-daily PrEP offers further attraction to men who have regular sex patterns, 
data described in Chapter 4 illustrate how men are not always good at predicting when 
sex will occur (Parsons et al., 2014). As highlighted in the results section, increased use 
of GPS-based sexual networking apps make finding and getting sex on-demand, rather 
than pre-planned, more common. As such, PrEP methods that require pre-planning are 
less amenable to those who have spontaneous encounters. 
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In summary, non-daily PrEP is likely to be less useful, and less acceptable, to men who 
have higher numbers of sexual risky encounters, and for men who have spontaneous, 
rather than pre-planned sex. As long as efficacy evidence on non-daily PrEP, especially 
for more regular risk takers, is less compelling than it is for daily PrEP, it will remain 
less acceptable. Non-daily PrEP offers more attraction to men whose risk is not seen to 
be sufficient to warrant daily PrEP but who have infrequent episodes of sex that might 
merit considering event-based use. Regardless of the evidence on efficacy of non-daily 
PrEP, there will be some men who will hold a preference to daily dosing – as this better 
fits the way they would prefer to take pills. 
 
8.3.3 Topical PrEP  
Again, since the initiation of fieldwork for this thesis, increasing evidence on the use of 
topical PrEP has emerged (Carballo-Dieguez et al., 2014). However, this global 
research has offered fewer opportunities to address men’s acceptability of topical PrEP, 
compared with other PrEP formats. This research described in this thesis is significant 
in that it represents the only UK based study that addresses topical PrEP acceptability in 
MSM. As described in Chapter 5, topical PrEP was by far the least acceptable method 
of PrEP for men in this study, for a number of reasons.  
 
The fact that a significant number of men said that they tended not to pre-plan their sex, 
meant that topical PrEP was unappealing. The need for pre-application of topical PrEP 
(at least based on current efficacy studies of vaginal microbicides) was one of the most 
significant barriers to rectal microbicide acceptability, although, as with other methods, 
greater efficacy could influence the extent it is considered acceptable in the future. 
Having a formulation of rectal PrEP that could be used instantaneously, such as with a 
lubricant, would further increase the acceptability of rectal microbicides. However, a 
significant number of men still found topical PrEP less acceptable because of other 
factors including concerns about dosing, application and the potential impact on sex.  
 
This study’s findings support Kinsler et al’s (2011) findings on the acceptability of 
rectal microbicides in four South American cities. This study used conjoint analysis to 
predict hypothetical products. As with my research, efficacy and effectiveness of rectal 
microbicides had the greatest impact on men’s acceptability of hypothetical products, 
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although Kinsler also found that the impact of other product characteristics, such as 
cost, formulation and side effects, varied by city, even within the same regions.  
 
Given the current evidence and stage of product development of rectal microbicides, the 
study found that rectal microbicide acceptability is unlikely to improve, despite 
considerable international advocacy for its further development, until significant 
research breakthrough of product developments occurs. Developing formulations of 
rectal microbicide that can either be used alongside preparation for sex (such as rectal 
douches) or during sex (such as lubricants) will greatly improve such acceptability for 
some men. 
 
8.3.4 Injectable PrEP  
Given the similarities and overlaps between all types of injectable PrEP, monthly and 
slow-release injectable methods are discussed in this section together. As with rectal 
microbicides, this is the only UK research that addresses acceptability of injectable 
PrEP amongst MSM. As was seen in Chapter 5, men who held concerns about 
forgetting to take daily doses of PrEP viewed injectable PrEP favourably. It was also 
seen to be more acceptable, in ways similar to daily oral PrEP, by men whose sexual 
activity was not pre-planned and who could see the benefits of on-going PrEP use.  
 
It is perhaps telling that the one participant who was using PrEP during the time of field 
work, as well as the other participant who had sought PrEP, found slow-release 
injectable methods to be more acceptable than most of the other men in the study. This 
might suggest that there could be a PrEP acceptability continuum: that once men have 
considered PrEP acceptable enough to take, and have taken or deeply contemplated one 
method, the opportunities to explore and consider (more convenient) methods might 
become more acceptable. The acceptability of developing new PrEP methods with 
current users, in addition to non-users of PrEP, and as such, merits further research and 
investigation. 
 
Whilst some men viewed injectable PrEP as being “vaccine like” and therefore 
considered it more effective, others identified concerns that injectable PrEP would 
become less efficacious towards the end of an injection cycle. That further recent 
evidence now strongly indicates that injectable PrEP offers more ‘forgiveness’ (Spreen 
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et al., 2013) towards the end of an injection cycle offers a more compelling case for its 
acceptability in the future.  
 
8.3.5 Summary   
This discussion sub-section has addressed the relative acceptability of different PrEP 
methods. Whilst efficacy remains central to notions of acceptability, other dimensions 
hold importance. How men pre-plan their sex is a key determinant of acceptability by 
method, as is the frequency of sex, and the frequency of SWC in particular. This 
research highlights not only that different men have different ways of planning and 
having sex but the patterns of how individual men plan and have sex changes over time. 
As such, PrEP researchers and policy makers should be considering the benefits of a 
mixed market of PrEP methods, where different methods will be suited to men’s 
different needs. As importantly, researchers, policy makers and educators should 
understand that men will move from method to method (and sometimes back again) 
according to how men plan their sex, the type of sex they have, their relationship status, 
and any changes or developments to different PrEP methods (including efficacy of 
method). Just as contraceptive methods have evolved to a mixed market, according to 
individual need, this research highlights the potential of a mixed market of PrEP 
availability.  
 
8.4 Developing a PrEP acceptability framework 
In Chapter 2 of this thesis I suggested that current notions of how to understand 
acceptability of PrEP were insufficient. I highlighted existing concepts of how 
acceptability has traditionally been framed, not least those drawn up in the literature of 
contraceptive methods that have focused on measures of efficacy and effectiveness, and 
on physical user-acceptability, such as leakage.  
  
As explored above, by far the biggest issue pertaining to acceptability raised by men in 
this study is that of efficacy of PrEP method. Although other acceptability issues were 
important and common, the extent to which a PrEP method works holds the greatest 
level of protection against HIV infection outweighs other acceptability measures. 
However, this does not mean that other factors in acceptability should be disregarded – 
not least when research is suggesting that different PrEP methods are emerging with 
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very similar efficacy rates (as was seen in the PROUD trial compared with the Ipergay 
trial – with both formats of PrEP offering 86% efficacy). 
  
This thesis research adds further to the discourse on notions of good citizenship and of 
carefree (or careless) risk takers (Highleyman, 2013; King, 2014; McNeil, 2014; Tuller, 
2013). Whilst being obviously simplistic opposites, how men frame other men’s 
behaviours (or other men who have condom-less sex) verses how they frame their own 
behaviours is not unique to PrEP. The emergence of PrEP offers further dimensions in 
the good verses bad gay: it is not uncommon for PrEP users online to voice stigmatising 
discourse towards non-PrEP users, whilst in the same forum, PrEP users display the 
stigmatising examples they have received from non-PrEP using men. The recent 
emergence of (albeit a very small number of) PrEP users who have sero-converted stand 
to offer a further dimension of stigmatisation: the PrEP user who did not adhere to his 
PrEP regime, or who otherwise ‘failed’ on PrEP. Such narratives feed into the discourse 
and the challenges of what we see as, and how we view PrEP ‘users’ (Holt, 2014). 
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As such, it can be determined that dimensions of acceptability are far more complex 
than presented in much of the existing literature on new prevention technologies. I have 
outlined the multiple dimensions of personal acceptability in Chapter 5, ranging from 
those dimensions most commonly raised in existing literature (such as side effects and 
physical impacts) and those infrequently addressed in the literature (such as the 
possibilities of PrEP – such as pleasure, intimacy and reductions in stress). These are 
 
 Dimensions of interpersonal 
acceptability 
Dimensions of 
community/social acceptability 
Sex and risk 
STIs 
Clinical interaction 
Intimacy, opportunity, pleasure 
Practicalities  
                  Efficacy 
Impact on sex 
Medicines + Medicalisation 
Pain 
Noticability 
Side effects 
Impact on lifestyle + routine 
Pre-planning + regimes 
 
Negotiation + navigation 
Trust  
Control 
How I will be perceived 
How I will perceive others 
Good gay vs bad gay 
 
Stigma  
Good gay vs bad gay 
Disclosure  
Agenda setting + misinformation  
 
 
Dimensions of personal 
acceptability 
Figure 1: Dimensions of acceptability 
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presented in Figure 1 with efficacy being presented as the central and most over-riding 
dimension of personal PrEP acceptability. The complex interaction between inter-
personal and community or societal dimensions of acceptability, and their impact on the 
personal dimensions should not be under-played. They are presented in Figure 1 as 
multi-directional and over-lapping processes – with community or societal dimensions 
impacting on inter-personal dimensions (which in themselves will impact on personal 
acceptability), and community or societal dimensions impacting directly on personal 
acceptability (which then impacts on inter-personal dimensions). This raises 
implications of the complexities of understanding concepts of acceptability (and even 
more so of how a health promoter might seek to influence acceptability, at any level). 
Those seeking to undertake future research or practice into PrEP acceptability should 
understand that ‘acceptability’ means far more than whether a technology will work, 
whether people will be willing to use it, or whether it will cause side effects. 
Acceptability models need to capture social dimensions, and understand that personal 
considerations are shaped – and in themselves shape and influence – inter-personal and 
community or societal dimensions. 
 
8.5 Contributing to the evidence-base on PrEP and its acceptability 
The acceptability of using PrEP to prevent HIV infection has been an under-researched 
area and since fieldwork for this research has been undertaken further research on PrEP 
acceptability has been more broadly undertaken (Aghaizu et al., 2012; Frankis et al., 
2014; Thng et al., 2012; Young et al., 2013). In general, these studies have focused on 
the views of groups with highest incidence and prevalence, and people with HIV and 
their partners, but not necessarily those who have recently been exposed to HIV (Young 
et al., 2013). However, this research study is the first to focus on MSM in London who 
do not have HIV but are within a population, both geographically and 
epidemiologically, with a high prevalence of HIV.  
 
Although international research has been conducted into the acceptability of topical 
PrEP, this has largely focused on vaginal microbicide use amongst women. Almost the 
entire published research on topical PrEP and MSM has focused on low or middle-
income countries or, when research has been undertaken in a high-income setting, North 
America has predominated. This is the first UK research to address the acceptability of 
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topical PrEP in MSM, and the first to explore potential barriers to using a rectal 
microbicide in the UK. 
 
And, although the England PROUD study has now started exploration of PrEP 
acceptability and feasibility in MSM who are using PrEP (albeit in a clinical trial), this 
doctoral research is the only available research from England to explore potential PrEP 
acceptability in men who are not using it (with the exception of one participant) during 
a period when public and social discourse on PrEP was relatively minimal. As such, this 
study enhances the research agenda on the potential acceptability and use of PrEP in 
men who were relatively PrEP-naïve, and assists in evidencing future PrEP education 
and service needs. In addition, this research is unique in that it is the only UK research 
that explores comparative acceptability of PrEP by different methods including those 
methods that, at the time, were broadly still in concept or pipeline development phase. 
 
Finally, whilst other social research has started to evidence how community and social 
actors might influence potential PrEP uses, including the impact of stigma, this is the 
only existing UK research that explores how men might respond to another man’s use 
of PrEP, thereby exposing the contradictions in men’s own narratives between concepts 
of self, and concepts of other. 
 
With these novel findings in mind, the final chapter of this thesis considers 
recommendations relating to PrEP provision, future research and lobbying or advocacy.  
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Chapter 9: Conclusion 
 
In this concluding chapter, I return to the final objective of this thesis and establish 
recommendations for potential PrEP providers, for PrEP health promotion interventions, 
and those responsible for the commissioning and funding of these. These 
recommendations are based on this study’s research findings, supported by other current 
and emerging evidence on PrEP.  
 
In the course of researching and writing this thesis, our collective knowledge of, and 
access to PrEP has increased. In the first wave of interviews for this study, the England 
PROUD study was not recruiting, yet by the final set of interviews, men had the 
opportunity to enroll into and access PrEP, albeit on a trial basis, in the UK’s first 
clinical PrEP trial. In addition, a number of gay community media (Azad, 2015a) and 
mainstream media publications (Cairns, 2014a; Holpuch, 2014; Tuller, 2013) featured 
news stories about PrEP, including individual men’s accounts of using this new HIV 
prevention technology. By the point of completion of this thesis, developments in 
Europe, and England in particular, further fast-tracked a collective dialogue about PrEP 
availability. Those dialogues have included the free availability of PrEP on the NHS, 
including how PrEP might be resourced (by NHS England, through local authority 
public health budgets, through Clinical Commissioning Groups, or a combination of 
all); who PrEP might or should be available to and the decisions about how availability 
might be decided; and the moral and ethical dilemmas of if and how a cohort of men on 
existing PrEP clinical trials, many of whom have integrated PrEP centrally into their 
HIV risk reduction practices, should have PrEP available to them once clinical trials 
have ceased. The early closure of PROUD’s deferred arm and the cessation of Ipergay’s 
placebo arm that followed have further added to an emerging urgency to resolve PrEP 
prescribing policy and availability (Nutland, 2014). 
 
With this in mind, it is likely that knowledge about and use of PrEP is growing. Given 
the coverage described above, it is reasonable to assume that MSM in London – 
particularly those connected with particular social and sexual networks – know more 
about PrEP than they did at the start of data collection for this research. Indeed, there 
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have been suggestions that some men are starting to use PrEP outside of clinical trials, 
in some cases through online purchase or by using friend’s supplies, and not always 
with the support of medical interventions to monitor and support their use (Azad, 
2015b). As such, the recommendations that follow focus not only on assumptions of 
future population based use of PrEP, but also acknowledge that a small but growing 
number of men would benefit from PrEP interventions now, rather than waiting to see if 
and when PrEP is available on the NHS. 
 
It should be acknowledged that, although these recommendations are based on the 
study’s research findings, they are additionally shaped by my former experience and 
career as an HIV health promoter. As is appropriate within the scope of an applied 
research doctorate, these recommendations are intended to shape and influence health 
promotion policy and practice, based upon and embedded within my professional 
experience. 
 
9.1 Recommendations for future research 
Recommendation 1: Research should be conducted into the efficacy, efficiency and 
acceptability of topical, injectable and other (non-oral) emerging PrEP application 
methods. 
As this research found, no single method of PrEP was ideally suited to every man. 
Whilst daily oral PrEP was the most acceptable method – in part because it was the only 
available and therefore the most tangible technology – other PrEP technologies need to 
be developed that offer at risk populations a range of technologies that meet the 
complex and differing needs of MSM. Such technologies need to account for the 
different use and differences in physiology in key HIV at-risk target groups and to take 
into account people’s ‘seasons’ of risks, and how PrEP users might jump between 
different PrEP methods, according to their risk taking at any point in time. 
 
Recommendation 2: Further research should examine the longer-term impact of daily or 
regular Truvada use and, in tandem, PrEP methods using alternative drugs, which might 
be less toxic, should be developed. 
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This research highlights men’s concerns about the side effects – especially the longer-
term side effects - of PrEP, and the impact of side effects on PrEP acceptability. It is 
important that longer-term cohort studies are undertaken that examine the toxicity 
effects of PrEP over the longer term so that men are able to make informed choices as to 
its use.  
 
Recommendation 3: Further research should be undertaken to pilot and up-scale 
interventions that increase knowledge and awareness of PrEP, and build skills and 
abilities in accessing and using PrEP. 
This research should be undertaken along PrEP health promoters and service providers 
(see Recommendation 7 below). 
 
9.2 Recommendations for development of policy and lobbying 
Recommendation 4: Community-based organisations and national partnerships should 
make clear and unambiguous statements on PrEP and build further consensus and 
collaboration on PrEP policy and practice.  
It is telling that none of the men in this study had heard about PrEP from community-
based organisations. In some instances a perceived silence about PrEP from such 
organisations made men suspicious about PrEP. Despite recent PrEP community 
statements (PrEP Access, 2014), community-based leadership on PrEP has been 
cautious, and on some occasions ambiguous (Mundasad, 2014). In doing so, 
community-based organisations can build social capital and empower key at-risk 
communities to take action on PrEP and to develop better peer-led and community-led 
education interventions. 
 
Recommendation 5: HIV organisations should position PrEP alongside other forms of HIV 
risk reduction  - all of which have benefits and costs - and should recognise that PrEP use 
and availability is a valid method that may be used in conjunction with condoms and, on 
occasion, instead of condoms.  
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Stigma and taboo around PrEP use and/or sex without condoms has been identified as a 
major barrier to PrEP use and discussion about its use. As such, HIV organisations and 
policy makers should continue to work to de-stigmatise HIV and sex, including through 
developing policies and programmes that promote the best sex with the least harm. 
 
9.3 Recommendations for commissioning of PrEP services 
Recommendation 6: PrEP services should be embedded within a broad range of 
educational, psychological and behavioural services, that attempt to address a man’s 
wider (HIV related) (sexual) health needs, rather than a ‘stand-alone’ service.   
For PrEP clinical providers, opportunities exist to offer ‘wrap-around’ services, or 
alternatives to PrEP, that may better meet those men’s needs other than PrEP provision. 
As such, as PrEP provision develops, PrEP should be offered and made available within 
a holistic health service that offers services around sexual health, drug and alcohol 
support, and mental health support. For some men, their health needs may be better met 
by interventions other than PrEP provision, even if a desire for PrEP was the reason for 
presenting at a service. 
 
Recommendation 7: Health promoters should, in conjunction with researchers, plan, pilot 
and up-scale interventions that increase knowledge and awareness of PrEP, and build 
skills and abilities in accessing and using PrEP.  
These should over-serve those with greatest HIV prevention and PrEP need (see 
Recommendation 11 below). Education and awareness interventions around PrEP 
should recognise how PrEP will be used alongside other risk reduction strategies 
including condom use, decisions about whether to top or bottom, and discussions 
around HIV testing or viral load detectability in HIV positive partners. PrEP does not 
replace or make these strategies irrelevant or unnecessary. Those providing PrEP health 
promotion should review educational frameworks, strategies and interventions so that 
potential PrEP use is accounted for and incorporated, including sex negotiation 
strategies and options. 
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Recommendation 8: A well-planned and well-resourced knowledge transfer and training 
programme for policy makers and health professionals and community based health 
promoters – especially front line staff – should be developed. 
Research from the USA and a range of developing countries has demonstrated that the 
capacity and ability of policymakers and health professionals to respond to PrEP can be 
a barrier to PrEP access (Arnold, 2012; Wheelock et al., 2012). This is likely to be the 
case for policy makers, health practitioners and health promoters in the UK too, 
especially given the fast changing evidence about PrEP. Such a programme should 
frame PrEP alongside other HIV prevention and sexual health tools and interventions, 
and enables those seeking information about PrEP, or those seeking access to PrEP to 
have the best control over their own PrEP based health needs. 
 
9.4 Recommendations for PrEP service delivery 
Recommendation 9: Consideration should be given to the merits of prescribing guidelines 
based only on a sexual risk-taking algorithm. 
Whilst acknowledging the importance of cost-effectiveness considerations in 
prescribing PrEP primarily to men at highest risk of HIV acquisition, consideration 
should be given to the broader (sexual) health benefits of PrEP prescription to those 
taking fewer HIV risks but who may additionally benefit from PrEP. These may include 
the negative partners of men with HIV who have undetectable viral loads; men whose 
occasional SWC causes anxiety, stress or depression; and those men who experience 
sexual dysfunction during condom use. Whilst some of these needs might be met by 
having ‘wrap-around’ services for those presenting for PrEP (see below), PrEP 
prescribing guidelines need to allow for individual clinician flexibility in making PrEP 
prescribing decisions on a case-by-case basis. 
 
Recommendation 10: Providers of PrEP health promotion services (and the 
commissioners of them) should research, plan, pilot and upscale interventions, drawing 
on a broad range of methods that support, enable and facilitate access to PrEP and its 
use. 
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Both providers of clinical PrEP services and those providing a broad range of PrEP 
health promotion services have the potential to enhance PrEP effectiveness – such as 
supporting adherence or assisting in managing side effects. Evidence from PrEP 
implementation demonstrates the importance – especially for more marginalised or 
vulnerable populations – of PrEP support. Such interventions might include developing 
skills on PrEP disclose and sexual negotiation; adherence support; and skills building 
for those starting and stopping PrEP. 
 
Recommendation 11: Further service development should be undertaken, driven by 
research and evidence based practice, which enhances service access for those most in 
need of HIV prevention and PrEP related services. 
From the perspective of NHS sexual health service provision, there stands a danger that 
PrEP delivery may lead to a two-tier system. That is: that those prescribed PrEP may 
get (or expect) a ‘gold-standard’ sexual health clinic service (such as regular 
appointments, fast-tracked services, dedicated staff members) and those (who may have 
the same or greater need) who may not benefit from the additional benefits of being on 
PrEP. This might include, but not be restricted to, provision of targeted and tailored 
services, accessible only to those most at-risk groups (e.g. MSM only services). 
 
Recommendation 12: Those planning PrEP clinical services and those providing PrEP 
educational interventions should account for how they intend to reduce inequalities and 
how they intend to over-serve those in greatest HIV need. 
Given the research evidence that exists around health inequalities and access to health 
technologies, the introduction of a new HIV prevention technology provides 
opportunities to plan and build strategies around reducing those health inequalities, not 
least regarding access to and awareness of it. Evidence from PrEP implementation pilots 
and other research (Holpuch, 2014; Hosek, 2013; Rodriguez, 2014) continue to 
highlight how key communities – such as young Black MSM – are underserved or 
neglected by PrEP interventions. Over two decades of HIV prevention research in the 
UK has highlighted how Black gay men, migrant men, younger men, and men with 
lower educational qualifications should be over-served by HIV prevention, yet most 
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existing prevention programmes have failed, or have been unable to re-configure their 
services to over-serve such men. The introduction of PrEP provides an opportunity for 
prevention programmes, and how they fail to over-serve such men, to be reviewed and 
revised. This might include providing enhanced PrEP support, including adherence 
support, or focused outreach interventions, to key groups. 
 
Recommendation 13: HIV prevention interventions should continue to challenge naïve 
risk takers’ beliefs that they are not taking HIV related risks. 
As discussed in the preceding chapter, those men who are at risk of HIV acquisition, but 
who fail to recognise their risk-taking, are those who will least benefit from PrEP 
availability. Such strategies should include: raising awareness of the prevalence of HIV 
in MSM communities; increasing awareness that a significant proportion of men with 
HIV do not know that they have it; undermining men’s beliefs that all men with HIV 
know they have it, always disclose their HIV status, always use condoms during anal 
intercourse, or would not have SWC without discussing their own, or their partner’s, 
HIV status. Such approaches should be undertaken in a way that challenges naïve risk 
takers’ world beliefs, without undermining the human rights or dignity of people with 
HIV, nor stigmatising those living with HIV. 
 
Recommendation 14: Health promoters should embed PrEP health promotion 
interventions within established ethical frameworks, including those described in Making 
it Count (CHAPS Partnership, 2011) 
For those developing PrEP educational interventions, it is important that those should be 
done within the context of how men might and do use PrEP. These should recognise the 
varying and complex ways that men negotiate sex and risk and how, for many men, 
PrEP might make this more complex. Further, such interventions should recognise how 
PrEP is being used or will be used, rather than how ‘we’ (health promoters, 
commissioners, public health professionals) might desire PrEP to be used. PrEP offers 
an opportunity for those delivering HIV health promotion to (re)engage and interact 
with key target groups in the reality of how sex and risk happens. Being seen to enforce 
a set of PrEP ‘rules’ or judgments relating to its use will be a missed opportunity for 
HIV health organisations to build engagement and dialogue with those most in need of 
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PrEP interventions. As such, PrEP health promotion cannot (and should not) be diluted 
in to a set of “messages”. Sex and risk are already complex and the introduction of PrEP 
makes it more so. Thoughtful, well-developed and evidence informed interventions that 
assist men in navigating and negotiating sex in an ever-complex era need to be 
developed. They need to take into account men’s current risk-reduction strategies, and 
that many men will use PrEP in conjunction with their existing strategies. They also 
need to accept (and not demonise) that some men, on some occasions, will use PrEP 
instead of their prevalent risk reduction strategies. 
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Appendix 1  
 
Dear Sigma Research mailing-list member - 
  
 
My name is Will Nutland and I'm working with the Sigma Research group at the 
London School of Hygiene & Tropical Medicine. I am contacting you because 
you are a member of the Sigma Research mailing list and previously indicated 
you might like to hear about new research that we're doing. 
  
 
I am currently recruiting men in London to take part in one-to-one discussions or 
focus groups on a research project exploring the acceptability of using HIV 
medication to prevent HIV. 
 
  
It would be great to speak to you if: 
  
 
YOU are a man between the ages of 18-45 who lives in London 
AND You have had an HIV negative test in the last 12 months 
AND You have had anal sex with another man without a condom since that last 
HIV test 
AND that sex was with someone you either KNEW was HIV positive or whose 
HIV status you weren't sure of 
  
 
If you meet these criteria it would be great to hear from you. Please follow this 
link for more details: 
 
https://www.surveymonkey.com/s/prepacceptability 
  
 
There's a short survey to complete and you can let me know the best way of 
getting in touch if you decide you'd like to take part. The survey is confidential 
and will not collect your I-P address. 
  
Thank you in advance for your help. 
  
Will Nutland 
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Appendix 2 
 
 
ONLINE QUESTIONNAIRE COPY  
 
Please give your contact details and answer a few questions about yourself.  This will 
help to determine if you meet the criteria to participate in the research and to ensure 
we have a wide cross section of men involved. 
 
If you choose not to give your real name, please give a name you will recognize. Please 
also give a contact telephone number and an email address. The researcher will 
contact you shortly if you are selected to participate. We will NOT leave any message 
on your answering service unless you tick 'yes'. These details will never be used for any 
other purpose. 
 
How old are you? 
How old are you? 
Under 18 (End) 
Over 45 (End) 
 
Are you ...? 
Female (End) 
Male 
 
Which of the options below best describes how you think of yourself? 
 Heterosexual (straight) 
 Gay 
 Bisexual 
 Other 
 
Are you a Trans-man? (Transexual / Transgender – someone who has changed or 
intends to change their biological sex) 
 No 
 Yes 
 
Do you currently live in London? 
Yes 
No (End) 
 
What is your ethnic group? 
 WHITE: British 
 WHITE: Irish 
 WHITE: Any other white background 
 BLACK: African 
 BLACK: Caribbean 
 BLACK: Any other Black background 
 MIXED: White and Black Caribbean 
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 MIXED: White and Black African 
 MIXED: White and Asian 
 MIXED: Any other background 
 ASIAN: Indian 
 ASIAN: Pakistani 
 ASIAN: Bangladeshi 
 ASIAN: Chinese 
 ASIAN: Any other Asian background 
 OTHER: Arab 
 OTHER: Any other ethnic group 
 
What is your highest educational qualification? 
 I have no educational qualifications 
 Primary education only (left school at 11 or 12) 
 O-levels/ GCSEs/ CSEs or equivalent (left school at age 16) 
 A-levels or equivalent (left school at age 18) 
 University degree or higher 
 Other, such as vocational or professional qualifications 
 
In the last 12 months have you: 
Had NO sex at all (End) 
Had sex ONLY with women (End) 
Had sex with men AND women (Go to Question X) 
Had sex ONLY with men (Go to Question X) 
 
Have you EVER received an HIV test result? 
Yes (go to Question X) 
No (End) 
 
Have you: 
Received an HIV test result that was POSITIVE (End) 
Tested for HIV but don’t know/remember the results (End) 
Received an HIV test result that was NEGATIVE (go to Question X) 
 
Have you: 
Received an HIV test that was NEGATIVE more than 12 months ago (End) 
Received an HIV test that was NEGATIVE in the last 12 months (go to Question X) 
 
When did you receive those test results? 
INSERT DATE 
 
The following questions relate to the types of sex you have had. We’re interested in 
the ANAL intercourse you’ve had. By this we mean fucking - top or bottom or both – 
with a penis in to an anus. Please do NOT count anal sex using fingers, fists, dildos or 
sex-toys. 
 
Since receiving that last NEGATIVE HIV test result have you had: 
159 
 
NO sex (End) 
No ANAL intercourse (End) 
Anal intercourse ONLY with condoms (End) 
Anal intercourse WITHOUT condoms (even if only once) (go to Question X) 
 
Tick as many as apply: 
Anal intercourse WITHOUT condoms with a man I KNEW to be HIV negative 
Anal intercourse WITHOUT condoms with a man I KNEW to be HIV positive 
Anal intercourse WITHOUT condoms with a man whose HIV status I did not know or 
whose HIV status was NOT discussed  
 
 
Your First name: 
Your First name: 
 
Would you like to give your email, telephone number or both? 
Tick as many as apply 
 Email address 
 Telephone number 
 
<Are you happy for a message to be left on this telephone number?> 
 
 
<End> Thank you for taking part in the questionnaire. One or more of your responses 
means that you do not fit the criteria for participation in this study. 
 
Thank you for completing the questionnaire. The researcher will be in touch with you 
to discuss what happens next. 
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Appendix 3 
 
 
PRE-INTERVIEW PARTICIPANT INFORMATION SHEET 
 
The acceptability of pre-exposure prophylaxis as an HIV prevention technology 
among men who have sex with men in London 
 
Will Nutland 
London School of Hygiene and Tropical Medicine 
 
Thank you for considering taking part in this study. Before agreeing to take part it is 
important that you read and understand the information on this sheet. If any parts of 
it are unclear or you have any further questions, please ask the researcher. Once you 
have read the sheet, you will be asked to sign a CONSENT FORM if you decide to 
participate. 
 
Why are we doing this study?  
This study is part of a research project exploring the acceptability of using HIV 
medication to prevent new HIV infections in men who have sex with men in London. 
The findings will be used to help inform future HIV prevention services in London. The 
experiences of the kind of sex you have and your thoughts on taking HIV medication to 
prevent HIV are important for the research. The study has been given ethics approval 
from the Ethics Committee of the London School of Hygiene and Tropical Medicine. 
 
What will participation involve?  
 
 One-to-one interviews with men. During the interviews men will be asked 
about the types of sex they have had recently and what they think about using 
HIV medication to prevent HIV. The interviews will take up to 90 minutes. The 
interview will be audio-recorded (see below about confidentiality). 
 
Is my participation confidential? 
Yes. Everything that is said in the interview remains confidential. The researcher will 
not reveal your name, or any other information that might identify you to any other 
person. We will keep your first name, contact telephone number and email address on 
file until after the interview or focus-group and this will be destroyed after 
participation.  
 
What happens after the interview? 
All interviews will be audio-recorded to make sure everything that you say is captured. 
The recordings will be kept in secure, password protected files. Afterwards, the 
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researcher will listen to the recordings and type up everything that was said. We will 
not type up any details that might identify you (such as names or place names) and the 
audio-files will be destroyed once they have been typed-up.  
 
At a later stage the researcher will look at what is interesting or important from the 
interviews and groups and will write up a report about it. The report will be available 
for anyone to read but there will be nothing in it that could identify you and there will 
be no mention that you took part in the study. Any direct quotations from participants 
will be used anonymously. Findings from the report might also be reported at 
conferences, in academic papers and in the media. 
 
Can I change my mind about taking part? 
Yes. If at any time before the date of an interview you decide you do not want to take 
part then you can let the researcher know. At any time during an interview you can ask 
for the interview to stop without having to give a reason. Your participation is entirely 
voluntary and you can withdraw at any time from the study. 
 
 
What happens next? 
If you agree to participate in the study, please read and sign the CONSENT FORM 
provided by the researcher. At the end of the interview the researcher will provide you 
with further information about using HIV medications to prevent HIV. The information 
sheet will also provide you with details of where to get support and information about 
HIV prevention and sexual health. 
  
Will Nutland 
Will.nutland@lshtm.ac.uk 
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Appendix 4 
 
 
Consent form  
 
I understand that participation in the interview is voluntary 
 
I can withdraw from the interview at any time and do not have to give a reason 
 
I agree to the interview being audio-recorded. I understand that these digital 
recordings will be stored securely and not shared without anyone outside the research 
team (the research and his supervisor). All recordings will be safely destroyed once 
they have been transcribed (typed up). 
 
I understand that the results of this interview will be used as part of a research study. 
Although the research report may contain quotes from this interview (along with 
quotes from other individual interviews being undertaken as part of this study), no-one 
will be able to identify me from these quotes. 
 
I understand that the results of this research may also be published in academic 
papers, presented at conferences or discussed in the media and they may contain 
quotes as above. No-one will be able to identify me or any other members of the 
group from these quotes. 
 
I confirm that I have had the opportunity to ask any further questions about this 
research study and any questions have been answered. 
 
I confirm that I am aged 18 or over, I have read and understood the information above 
and DO want to take part in this interview. 
 
Signature 
Date 
 
OR I have read and understood the above information and DO NOT want to take part 
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Appendix 5 
 
PrEP acceptability topic guide  
 
I’m Will – I study at LSHTM, which is part of the University of London. As you know, I’m 
doing research at the moment to find out views about the acceptability of using HIV 
drugs to prevent HIV infection. 
 
Men who have sex with men who live in London have been invited to take part in this 
research. I’m interested in the views of men who do not have HIV and who have had 
unprotected anal sex with a man who either has HIV or whose HIV status he or you do 
not know. I’m interested in interviewing men who have had this kind of sex in the last 
year and since their last negative HIV test. 
 
The interview will be very informal and will take between an hour to ninety minutes. 
I’d like to record the interview to make sure I don’t miss anything. After the interview, 
the recording will be given a code and will be transcribed.  After the research is 
complete, the recording will be destroyed. Everything we talk about will be 
confidential and anonymous.  If there are any questions you would prefer not to 
answer that is no problem. If you want to stop the interview at any time please let me 
know – you do not have to give a reason. 
 
Before we start, is there anything you’d like to ask about the research? 
 
Answer any questions, go through the consent form. 
 
Could you start by telling me a bit about where you socialise? 
Do you use the gay scene? 
What types of places? 
Where do you meet other men (for sex?) 
 
You said in your response to the online survey that your last HIV test was X months 
ago. Is that right? Can you tell me about the type of sex you’ve had since your last 
HIV test? 
I’m interested in the unprotected anal intercourse you have had.  
Was it a one off? With a regular partner? Planned? Did it ‘just happen?’.  Did 
you talk with the other man/men about it before or after? 
When you’ve had UAI how have you managed or thought about managing any 
risk? 
Modality? Withdrawal? PEP? TasP? 
 
In this research, I’m interested in finding out more about if and how men might use 
PrEP. 
- Can you tell me what you have heard about PrEP? 
- Where did you get this information from? 
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International trials of have shown that when someone who doesn’t have HIV takes a 
DAILY oral pill of PrEP it can reduce the chance of HIV transmission by over 90%, 
when the pills are taken properly. 
- What do you think about all of this? 
- Is this something you had heard about? 
- Is this something you think you would take if it became available here? 
- What kind of issues would you consider before making that choice? 
Cost? Effectiveness? Clinic visits? Side effects? 
- In what kind of situations might you consider using it? 
 
What about if the pill could be taken before sex, rather than every day? 
- Would that change things for you? 
Adherence? Convenience? Fewer side-effects? Cheaper? 
 
Research is also being done that looks into providing the drug in a monthly or 3 
monthly injection and in a gel or foam that is inserted in the rectum before sex. 
- Would these be more acceptable for you? 
Usability? Side-effects? Effectiveness? Adherence. Discretion of use. 
 
What about other men you know? What do you think they would make of PrEP? 
- Do you think men you know might use it? 
- In what kind of circumstances? 
- Do you think men you know would talk about using PrEP if they took it? 
Stigma? Discrimination? Taboo? 
 
If you were taking PrEP, how do you think other men would respond? 
-  What would it mean for negotiating the kind of sex you have with these men? 
- Do you think you’d tell them? 
 
And if you weren’t using PrEP, how would you feel about having sex with another 
man who was using it? 
 
How do you think PrEP might be viewed more broadly? 
- By ‘community’ 
- Wider society – media, medical profession 
 
For PrEP to be used by men, it needs to be acceptable to men.  
- What would make PrEP acceptable to you?  
- What does being ‘acceptable’ mean for you with regards to PrEP? 
 
Is there anything else you want to say about everything we’ve talked about today? 
 
 
Clarifying questions. Provide information sheet. 
 
165 
 
Appendix 6 
 
 
 
iPREX study 
 
 
2,500 men who have sex with men 
 
 
Peru, Ecador, Brasil, USA, South Africa and Thailand 
 
 
Half of the men given a placebo 
 
 
Half of the men given a daily oral pill of Truvada 
 
 
In the drug arm – 44% lower rate of HIV infection than in the 
placebo arm 
 
 
In men in the drug arm who were most treatment adherent – 
92% lower rate of HIV infection than in those without a 
detectable level of drugs 
 
 
No major side effects 
 
 
None of participants developed resistance to drugs 
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CAPRISA study 
 
 
889 sexually active women in South Africa 
 
 
Half of the women received a placebo gel 
 
 
Half of the women received a gel with 1% tenofovir  
 
 
All women were asked to apply the gel vaginally within 12 hours 
before sex and within 12 hours after 
 
 
In the trial arm – HIV infection fell by about a half compared with 
women in the placebo arm 
 
 
Women who used the gel consistently and as required were less 
likely to get HIV than women who used it less consistently 
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SSAT 040 trial 
 
 
27 women, 6 men – all HIV negative 
 
 
Injectable once a month formulation of rilpivirine 
 
 
Maintained high enough drug levels to provide sufficient 
protection against HIV infection 
 
 
Few side effects – localised swelling and tenderness 
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Appendix 7 
 
Post interview participant Information Sheet  
 
Thank you for being part of this study, being undertaken as a research project at the 
London School of Hygiene and Tropical Medicine. 
 
The HIV prevention medication we discussed today is called pre-exposure prophylaxis 
or PrEP. There has been a great deal of research undertaken about PrEP in recent 
years, with many new studies in development. 
 
Although PrEP is currently about to be licensed in the USA, it is NOT licensed for HIV 
prevention in the UK at this time. In the USA it will be available as a one-a-day pill. It is 
currently not available – outside of clinical trials – in the other formats we discussed 
today (such as injectable PrEP or as a rectal gel or foam). More clinical research into 
these methods of PrEP is needed.  
 
If PrEP becomes more widely available across the world, it will need to be prescribed 
correctly and regular medical check-ups will be likely. In some parts of the world, 
people who want PrEP might have to pay for it themselves. 
 
Anyone being prescribed PrEP will need to take it as directed by a medical expert and 
will need to have regular HIV tests to ensure they have not become infected.  
 
There are still many things we do not know about PrEP. For example, the long-term 
health effects of taking PrEP are unclear. In addition, PrEP will not prevent other 
sexually transmitted infections, including more serious ones such as syphilis and 
hepatitis B or C. 
 
If you are in a relationship with, or having sex with someone who has HIV, it is 
important that you DO NOT share their HIV medications to try to prevent getting HIV. 
The doses of medication given in PrEP need to be right, and not all HIV medications 
have been tested for use to prevent HIV.  Sharing someone else’s HIV medication could 
be dangerous for you, and the other people you have sex with. 
 
PrEP is different from PEP (post-exposure prophylaxis). PEP is used as an emergency 
HIV prevention course of medication when someone who doesn’t have HIV knows they 
have been exposed to HIV (for example, if a condom broke or if condoms weren’t 
used). PEP has been available for several years and is widely available for FREE from 
sexual health clinics or Accident and Emergency centres. It must be taken as soon after 
exposure to HIV as possible and is a month-long course of tablets. For more 
information on PEP visit - http://www.tht.org.uk/sexual-health/HIV-STIs/HIV-
AIDS/Post-exposure-prophylaxis 
 
If you are worried or concerned about your sexual health or risk taking you can discuss 
this with a doctor or health advisor at a free sexual health clinic. They can discuss the 
options of help and support available to you. You can visit any NHS sexual health clinic 
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you want to for free. To find a clinic close to you visit – http://www.tht.org.uk/sexual-
health/Clinics-and-Services/Local-services-and-clinics 
 
You can also find out more about HIV prevention and sexual health by visiting the 
website of Terrence Higgins Trust – www.tht.org.uk or by calling THT Direct on 0808 
802 1221 
 
If you want to find out more about developments in PrEP research, you can visit, or 
subscribe to Aids Map for free (search for ‘PrEP’ in their search engine) - 
www.aidsmap.com 
 
If you would like to be sent a summary of the final findings of the research you took 
part in today, please email will.nutland@lshtm.ac.uk and ask for a copy to emailed to 
you.  
 
 
 
 
  
 
 
 
 
 
